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ABSTRACT 
In the pharmaceutical industry, pooled human liver microsomes (HLM) and pooled 
cryopreserved human hepatocytes (CHH) are the most commonly used test systems to 
measure the in vitro metabolic intrinsic clearance (CLint) of investigational new drugs in 
order to identify drug candidates with favorable pharmacokinetic properties such as once-
a-day dosing and low oral dose. However, both HLM and CHH have been shown to 
underpredict the in vivo clearance of drugs. For drugs whose clearance is predominantly 
determined by P450 enzymes, metabolic clearance in CHH would be expected to equal 
that in HLM even if both test systems underpredicted (or overpredicted) in vivo clearance. 
Curiously, in the case of drugs with high intrinsic clearance (CLint), CHH underpredict in 
vivo clearance to a greater extent than HLM. Such system-dependent clearance has been 
reported for midazolam, a high CLint drug that is the most widely used CYP3A4/5 
substrate for both the in vitro and in vivo assessment of drug-drug interactions (DDIs). 
Previous investigators have proposed that the system-dependent clearance of 
midazolam is due to permeability- or cofactor-restricted clearance in CHH (i.e., clearance 
in hepatocytes is limited by membrane permeability or the availability of NADPH). The 
objective of this dissertation research was to determine the mechanism underlying the 
system-dependent clearance of midazolam. Studies of midazolam clearance in HLM and 
CHH confirmed previous reports that midazolam clearance is almost an order of 
magnitude lower in CHH than HLM, a system-dependent difference that was much more 
pronounced than with other CYP3A4/5 substrates (namely alfentanil, nifedipine and 
verapamil). In vitro to in vivo extrapolation (IVIVE) of clearance established that HLM 
accurately predicted the in vivo clearance of midazolam whereas CHH underpredicted 
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midazolam clearance by a factor of 5. Permeabilizing CHH by sonication or treatment 
with the pore-forming agent saponin did not increase the rate of midazolam metabolism, 
even in the presence of excess NADPH. Furthermore, the rate of midazolam uptake by 
CHH was found to greatly exceed the rate of midazolam metabolism, and microsomes 
isolated from pooled CHH had comparable CYP3A4/5 activity towards midazolam as 
microsomes prepared directly from human liver. These results suggested that neither 
membrane permeability nor intracellular cofactor availability were likely explanations for 
the system-dependent clearance of midazolam.  
The impact of in vitro incubation conditions on P450 activity, namely the ionic strength of 
the incubation buffer and the effect of cell culture media, was evaluated as a possible 
explanation for the system-dependent clearance of midazolam. As part of this 
investigation, a cell culture medium was sought that was capable of increasing midazolam 
clearance in CHH. Compared with KHB (the medium used in the initial experiment), 
Williams’ E medium supported similar rates of midazolam metabolism but the other three 
media examined, namely Waymouth’s, MCM+ and DMEM, supported lower rates of 
midazolam metabolism. In other words, none of the media examined corrected the 
system-dependent clearance of midazolam (and three of them made matters worse). In 
general, P450 activities in HLM were maximal at 50 mM phosphate buffer, with the 
exception of CYP3A4/5 and CYP2E1, where the enzymatic activities increased with 
increasing buffer ionic strength. The activity of these two enzymes was markedly 
decreased when HLM were incubated in Waymouth’s, MCM+ or DMEM (the same three 
media that decreased the rate of midazolam metabolism in CHH). The effect of certain 
cell culture media on reducing midazolam clearance in both HLM and CHH was not 
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observed with other CYP3A4/5 substrates (namely alfentanil, nifedipine, verapamil, 
testosterone and atorvastatin). The kinetics of midazolam metabolism in HLM in the 
presence of various cell culture media suggested that both MCM+ and Williams’ E 
medium contained an inhibitory substance as evidenced by a marked increase in Km 
compared with 50 mM phosphate buffer. Studies with complete versions or salt-only 
versions of each medium on CYP3A4/5 activity in HLM further suggested the presence 
of an inhibitory component in certain cell culture media. Although, this dissertation 
research was unsuccessful in identifying a the cell culture medium that corrected the 
system-dependent clearance of midazolam, it disproved two previous explanations for 
this phenomenon and formed the basis for recommending valuable improvements for the 
conduct of in vitro metabolism studies, such as ideal buffering conditions for HLM and the 
use of Williams’ E media for studies in CHH. 
In an effort to identify a CYP3A4/5 substrate with the same system-dependent clearance 
characteristics as midazolam, the CYP3A4/5 substrate loratadine was examined in CHH. 
The rate of conversion of loratadine to desloratadine by CHH varied depending on the 
culture medium in a manner similar to that observed with all other CYP3A4/5 substrates 
except midazolam. In these studies of loratadine metabolism in hepatocytes, 
3-hydroxydesloratadine was detected, which was unexpected because no prior in vitro 
test system (such as HLM or recombinant CYP enzymes) or non-clinical species in vivo 
had been previously shown to support its formation. 3-Hydroxydesloratadine is the major 
human metabolite of desloratadine, and the enzyme responsible for its formation had not 
been identified despite this being a postmarketing requirement imposed by the FDA on 
the manufacturer Schering-Plough. Capitalizing on the detection of 
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3-hydroxydesloratadine in incubations with CHH, studies were conducted to elucidate the 
enzymology of 3-hydroxydesloratadine formation and to evaluate the potential of 
desloratadine to be the victim or perpetrator of drug interactions. These studies 
established that the conversion of desloratadine to 3-hydroxydesloratadine is catalyzed 
by CYP2C8 but only after desloratadine is converted to an N-glucuronide by UGT2B10. 
Formation of 3-hydroxydesloratadine could be blocked with inhibitors of either CYP2C8 
or UGT2B10. Recombinant CYP2C8 formed 3-hydroxydesloratadine only when co-
incubated with recombinant UGT2B10 and HLM formed 3-hydroxydesloratadine only 
when supplemented with both NADPH and UDP-GlcUA (the cofactors to support CYP 
and UGT enzymes). The formation of 3-hydroxydesloratadine was proposed to follow a 
three step process: N-glucuronidation of desloratadine by UGT2B10, followed by 
3-hydroxylation by CYP2C8 and a de-conjugation event to form 3-hydroxydesloratadine. 
Desloratadine was found to be a weak inhibitor of CYP2B6, CYP2D6 and CYP3A4/5, but 
a potent and selective inhibitor of UGT2B10. Further studies with inhibitors of UGT2B10 
and UGT1A4 established that UGT2B10 is the sole UGT responsible for supporting the 
CYP2C8-dependent formation of 3-hydroxydesloratadine. In addition to solving a long-
standing mystery surrounding the enzymology of 3-hydroxydesloratadine formation, the 
results of this dissertation have implications on the labeling of desloratadine and, more 
importantly, provide a pathway for investigating the genetic basis of the impaired 
metabolism of desloratadine (the so-called poor metabolizer phenotype) observed in a 
small percentage of patients taking desloratadine. Furthermore, the identification of 
desloratadine as a UGT2B10 selective inhibitor advances the field of UGT research 
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towards the goal of identifying a selective inhibitor of each UGT enzyme for use in in vitro 
metabolism studies.  
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1.1. Cytochrome P450 enzymes and drug-drug interactions 
Cytochrome P450 enzymes (P450 enzymes) are a superfamily of heme-containing 
proteins that catalyze the biotransformation of many endobiotics and xenobiotics (foreign 
chemicals such as drugs). P450 enzymes are expressed throughout the body; however 
they are most prominently expressed in the hepatic endoplasmic reticulum, which serves 
as the primary site of drug metabolism (the next most important site being the intestinal 
epithelium) (Paine et al., 2006; Parkinson et al., 2013). The P450 enzymes are the most 
actively studied drug-metabolizing enzymes because they are responsible for the 
biotransformation of the vast majority of therapeutic drugs. Roughly 80% of the oxidative 
metabolism of all drugs involves xenobiotic-metabolizing P450 enzymes (the major ones 
are CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4 and 3A5), with 
CYP2D6 and CYP3A4/5 accounting for the metabolism of over half of all small-molecule 
drugs (Wilkinson, 2005; Gonzalez et al., 2011; Parkinson et al., 2013). The fact that a 
limited number of xenobiotic-metabolizing enzymes catalyze the vast majority of oxidative 
drug metabolism underscores their broad substrate specificity. In contrast, P450 enzymes 
that specialize in the synthesis and degradation of endobiotics (such as steroid hormones, 
and bile acids) have highly restricted substrate specificity, such as CYP19 (aromatase) 
which can metabolize testosterone or androstenedione to estrogens but is generally not 
involved in xenobiotic metabolism (Gonzalez et al., 2011). Biotransformation by drug-
metabolizing enzymes with broad substrate specificities is important for converting drugs 
and the large number of lipophilic xenobiotics in the diet (such as alkaloids and flavonoids) 
into hydrophilic compounds (metabolites) than can be readily eliminated in urine or bile. 
P450 enzymes accomplish this primarily through the oxidation of xenobiotics in the 
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following basic reaction: RH + O2 + NADPH + H+ → ROH + H2O + NADP+. At the 
endoplasmic reticulum, P450 enzymes receive electrons for the above basic reaction 
from the cofactor reduced nicotinamide adenine dinucleotide phosphate (NADPH) via the 
flavoprotein NADPH-cytochrome P450 reductase (Parkinson et al., 2013). The 
biotransformation of xenobiotics by enzymes that catalyze hydrolysis (e.g. 
carboxylesterases), reduction (e.g. carbonyl reductases), and oxidation (e.g. P450 
enzymes) reactions is known as Phase I metabolism. Phase II metabolism refers to 
conjugation reactions, such as the addition of a glucuronic acid moiety by UDP-
glucuronosyltransferases (UGT), or sulfation by sulfotransferases. The terms Phase I and 
Phase II should not be interpreted as one reaction preceding the other, as there are 
instances in the literature where Phase II reactions precede Phase I reactions and the 
classification system has been the subject of criticism (Josephy et al., 2005; Ogilvie et al., 
2006; Parkinson et al., 2013).  
The ability of a drug to cause clinically relevant drug-drug interactions (DDIs) involves the 
evaluation of that drug’s perpetrator and victim potential. Victim drugs are those whose 
clearance is predominantly through a single route of elimination, an example of which is 
metabolism by a single P450 enzyme. Partial or complete elimination of that pathway of 
clearance, either by genetic polymorphism of that particular P450 or due to inhibition by 
a concomitantly administered drug, can result in a marked decrease in clearance of the 
victim drug. This in turn leads to an increase in systemic exposure to the victim drug (as 
measured by the area under plasma-time concentration curve [AUC]) and can result in 
exaggerated pharmacological effects or toxicity. Terfenadine, cisapride and astemizole 
are all examples of drugs that have been withdrawn from the market due to their high 
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victim potential because they are extensively metabolized by CYP3A4 and interactions 
with inhibitors of CYP3A4, such as the antimycotic ketoconazole and the antibiotic 
erythromycin, has led to serious (even lethal) ventricular arrhythmias (characterized by 
QT prolongation and torsade de pointes) (Huang et al., 2008; Ogilvie et al., 2008). 
Perpetrators are drugs or factors that alter the clearance of a victim drug, such as genetic 
polymorphisms, inhibitory drugs, inducing drugs and agents involved in transporter 
interactions. The calcium channel blocker mibefradil is the only drug withdrawn from the 
U.S. market due to its perpetrator potential; it causes prolonged inactivation of CYP3A4 
because it is a mechanism-based inhibitor (Huang et al., 2008; Ogilvie et al., 2008). 
Genetic polymorphisms can be viewed as perpetrators of DDIs because deficiency in a 
given metabolic pathway, such as those individuals that have a poor metabolizer (PM) or 
intermediate (IM) metabolizer genotype, can result in a decrease in clearance and 
consequently an increase in systemic exposure to victim drugs. Polymorphisms that result 
in the over-expression of a metabolic pathway of clearance, such as those individuals 
that have an ultra-rapid metabolizer (UM) genotype, can also act as perpetrators of DDIs 
because this can result in an increase in clearance leading to a decrease in exposure to 
victim drugs. Both of the aforementioned genetic polymorphisms (PMs & UMs) are 
analogous to the use of inhibitory and inducing drugs respectively as perpetrators of DDIs. 
Of the P450 enzymes, polymorphisms in CYP2C8, CYP2C9, CYP2C19 and CYP2D6  are 
common and have a clinically significant impact (Muszkat et al., 2007; Zhou, 2009b; Zhou, 
2009a; Zi et al., 2010; Aquilante et al., 2013; Parkinson et al., 2013). 
DDIs can be classified as either pharmacodynamic (PD) or pharmacokinetic (PK), where 
the former involves altered pharmacological effects, an example of which is the interaction 
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between non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid 
(aspirin). The administration of an NSAID such as ibuprofen can lead to specific reversible 
inhibition of COX1 which prevents acetylation and irreversible inhibition of COX1 by 
acetylsalicylic acid, which in turn leads to an increased risk of cardiovascular disease due 
to the continued production of COX1-mediated thromboxane A2 (Catella-Lawson et al., 
2001; Cascorbi, 2012). Another example is the increased risk of serotonin syndrome that 
has been reported to result from interactions between MAO inhibitors (Beasley et al., 
1993). Pharmacokinetic DDIs involve alterations in the absorption, distribution, 
metabolism and elimination of drugs, particularly through inhibition or induction of 
xenobiotic-metabolizing enzymes or transporters. Inhibition of drug-metabolizing 
enzymes such as P450 enzymes by perpetrator drugs can lead to supra-pharmacological 
concentrations of a victim drug, which may result in an exaggerated pharmacological 
response or toxicity, whereas induction can lead to sub-pharmacological concentrations 
of a victim drug, which may result in loss of therapeutic efficacy (the opposite 
pharmacological outcome occurs when a metabolite of the drug is the pharmacologically 
active component). Victim drugs that have a narrow therapeutic index (the dosage range 
spanning the minimum threshold dose for efficacy to maximum tolerated dose without 
adverse effect), such as phenytoin, digoxin, and warfarin, are particularly susceptible to 
pharmacokinetic DDIs as slight alterations in drug clearance by perpetrator inhibitors or 
inducers can lead to adverse effects or changes in efficacy. 
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1.2. Uridine diphosphate glucuronosyltransferase (UGT) enzymes 
and their interplay with P450 metabolism 
Uridine diphosphate glucuronosyltransferase (UGT) enzymes catalyze the conjugation of 
glucuronic acid to xenobiotics. This particular reaction requires the cofactor UDP-
glucuronic acid (UDP-GlcUA), but conjugation has been shown to occur with UDP-
glucose, UDP-xylose and UDP-galactose (Mackenzie et al., 2005). UGTs are located in 
the endoplasmic reticulum of liver and other tissues such as kidney, gastrointestinal tract, 
lungs, prostate, mammary glands, skin, brain, spleen, and nasal mucosa (Parkinson et 
al., 2013). Contrary to the cytoplasm-facing P450 enzymes, UGT enzymes are located 
on the luminal side of the endoplasmic reticulum and are the second most actively studied 
drug-metabolizing enzymes, next to P450. The luminal orientation of UGTs suggests that 
a nucleotide transporter may be involved in shuttling the cofactor UDP-GlcUA to the site 
metabolism, and removing the byproduct UDP (because UDP-GlcUA is synthesized in 
the cytosol). In support of a such a transport mechanism, it was recently reported that a 
transporter (possibly the same as in vivo) may be involved in the uptake of UDP-GlcUA 
by inside-out microsomes (Rowland et al., 2015). The spatial differences between P450 
and UGT suggest that metabolites produced by P450 diffuse across the ER membrane 
to access UGT enzymes on the luminal side (in the case of sequential Phase I to Phase 
II metabolism). This spatial difference may also contribute to the consistent in vitro 
underprediction of in vivo UGT-mediated clearance (Miners et al., 2010a). There are 
several factors that may affect UGT-mediated clearance in test systems such as liver 
microsomes and hepatocytes: 1) the permeability of microsomal membranes to allow free 
access of the cofactor UDP-GlcUA as well as the aglycone substrate, 2) the effect of long-
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chain unsaturated fatty acids present in in vitro incubations, and 3) the homo- or 
heterodimerization of UGT proteins in the ER. Other factors may also affect the 
glucuronidation clearance such as UDP-GlcUA concentration, membrane composition, 
microsomal membrane partitioning of a substrate, buffer composition, ionic strength, pH, 
organic solvents (used to dissolve substrates), β-glucuronidase activity and glucuronide 
stability (Miners et al., 2010a). The impact of many of these factors can be minimized with 
controlled in vitro experimental conditions, for example the limitation of cofactor 
availability is bypassed by adding saturating concentrations of UDP-GlcUA (2-5 mM). 
However the byproduct of glucuronidation reactions, namely UDP, has been reported to 
competitively inhibit of the binding of UDP-GlcUA to UGT enzymes and very high 
concentrations of UDP-GlcUA  (8-20 mM) are required to overcome this effect (Fujiwara 
et al., 2008). The in vitro CLint for zidovidine glucuronidation in HLM were shown to vary 
6–fold depending on the incubation conditions, leading to a 3-4 fold underprediction to 
the in vivo clearance rate (Miners et al., 2006). The prediction of in vivo UGT-mediated 
drug clearance is generally more accurate with hepatocytes than with microsomes, 
although both test systems underpredict the in vivo rate of clearance, with the exception 
of zidovidine, whose clearance is accurately predicted with hepatocytes (Miners et al., 
2006). The glucuronidation of xenobiotics by HLM is latent, meaning that it can be 
stimulated by detergents, such as CHAPS and Brij-58, and the pore-forming peptide 
alamethicin. These reagents are thought to permeabilize inside-out microsomes and 
thereby increase access of UGT enzymes to UDP-GlcUA (Parkinson et al., 2013). 
However treatment of HLM with detergents abolishes P450 activity, a property that is not 
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shared by alamethicin, leading to the wide use of this pore-forming peptide in studies of 
drug glucuronidation by microsomes. 
The mammalian UGT gene superfamily contains four families and to date at least 22 
human UGT enzymes have been identified, of which the major xenobiotic metabolizing 
UGTs are UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B11, 2B15, 
2B17, and 2B28 (Parkinson et al., 2013). Several of these enzymes have also been 
identified as being polymorphic, such as UGT1A1 where the UGT1A1*28 allele (a loss-
of-function variant) is an important risk factor for irinotecan toxicity (Parkinson et al., 
2013). Glucuronidation of xenobiotics typically occurs at nucleophilic oxygen, nitrogen 
and sulfur sites, leading to O-, N-, and S-glucuronides, respectively, although the C-
glucuronidation of phenylbutazone by UGT1A9 has been reported (Nishimura and Naito, 
2006). The most common reactions are O- and N-glucuronidation. Kaivosaari and 
colleagues (2011) reviewed the N-glucuronidation of drugs, which occurs to a much 
greater extent than was first appreciated. Historically, UGT1A4 was thought to be the only 
human UGT capable of forming N-glucuronides; however, it is now known that several 
UGT enzymes including UGT1A3, 1A9, 2B4, 2B7 and 2B10 can also form N-glucuronides 
(Zhou et al., 2010; Kaivosaari et al., 2011). Nevertheless, UGT1A4 and UGT2B10 
catalyze the majority of N-glucuronidation reactions. UGT1A4 generally catalyzes the N-
glucuronidation of drugs with low affinity, high capacity whereas UGT2B10 is considered 
a high affinity, low capacity enzyme. Accordingly, under clinical conditions, UGT2B10 – 
the high affinity enzyme – may play an important role in the N-glucuronidation of drugs, 
which are present at relatively low concentrations. In contrast to rodents, humans, 
monkeys, rabbits and, to a lesser extent dogs, can catalyze the N-glucuronidation of 
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tertiary amines. Consequently, the formation of quaternary ammonium glucuronides 
occurs in humans and some nonclinical species but not in rats or mice (Zhou et al., 2010; 
Parkinson et al., 2013). 
There several examples of interplay between P450 and UGT enzymes, where some 
glucuronide conjugates have been found to be substrates for Phase I oxidation or further 
Phase II metabolism. For example, estradiol 17β-glucuronide has been shown to be 
sulfonated by sulfotransferases in Wag/Rij rats (Sun et al., 2006). Furthermore, the 
secondary metabolite 4-hydroxydiclofenac acyl glucuronide can be formed either by 
glucuronidation followed by P450 metabolism or vice versa. This can confound the 
analysis of the CYP2C9 marker substrate diclofenac in test systems that support both 
P450 and UGT metabolism (such as hepatocytes) or in vivo, because the 4ʹ-hydroxylation 
of diclofenac can be catalyzed by CYP2C9 (acting on the parent drug) or CYP2C8 (acting 
on the acyl glucuronide). When the conjugate is hydrolyzed (which can occur by β-
glucuronidase in the lumen of the endoplasmic reticulum or in the gastrointestinal tract), 
it is not possible to discern whether 4ʹ-hydroxydiclofenac was formed by CYP2C9 or 
CYP2C8 (Kumar et al., 2002) as shown in Figure 1.1. There are several other examples 
where glucuronidation effectively converts a CYP2C9 substrate into a CYP2C8 substrate 
or inhibitor. CYP2C8 has been shown to metabolize several glucuronides (the aglycones 
of which are typically CYP2C9 substrates), including naproxen acyl glucuronide, estradiol 
17β-glucuronide and gemfibrozil glucuronide (Delaforge et al., 2005; Kochansky et al., 
2005; Ogilvie et al., 2006). The example of gemfibrozil glucuronide is particularly 
interesting because the CYP2C8-mediated hydroxylation of gemfibrozil-1-O-β-
glucuronide leads to the formation of a reactive metabolite, a benzylic radical, that causes 
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irreversible inhibition of this enzyme (Ogilvie et al., 2006; Baer et al., 2009). Gemfibrozil 
and its glucuronide are also substrates and inhibitors of OATP1B1 (Shitara et al., 2004) 
and this, in combination with CYP2C8 inactivation, accounts for the pharmacokinetic 
interaction between gemfibrozil and several statin drugs, particularly the OATP1B1 and 
CYP2C8 substrate cerivastatin (Tornio et al., 2008). Clopidogrel is another example of a 
clinically used drug whose glucuronide is a mechanism-based inhibitor of CYP2C8 
(Tornio et al., 2014). Like gemfibrozil, clopidogrel also increases the incidence of fatal 
cases of rhabdomyolysis when coadministered with cerivastatin. Kazmi et al. (2010) also 
identified an N-carbamoyl-glucuronide of a drug candidate that caused mechanism-based 
inhibition of CYP2C8 in vitro, although its clinical significance is unknown. 
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Figure 1.1. Role of CYP2C9 and CYP2C8 in the formation of 4ʹ-hydroxydiclofenac 
The schematic depicts the two pathways for the production of 4ʹ-hydroxydiclofenac, the 
in vitro metabolite typically used to assess CYP2C9 activity in human liver microsomes. 
The first pathway involves direct oxidation by CYP2C9, whereas the second pathway 
involves oxidation of diclofenac acyl glucuronide by CYP2C8, followed by hydrolysis (de-
conjugation) of the glucuronide moiety. 
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1.3. Types of in vitro drug metabolism studies and test systems 
In vitro studies of drug metabolism are conducted for the following purposes: 
1. To compare species differences in metabolite profile to examine the potential for 
the formation of human-predominant or human-specific metabolites; 
2. To measure intrinsic metabolic clearance (CLint) to identify drug candidates with 
desirable pharmacokinetic properties (those consistent with once-a-day dosing 
and low oral dose); 
3. To identify the individual enzyme or enzymes responsible for drug metabolism (by 
the process of reaction phenotyping or enzyme mapping) to assess the victim 
potential of a drug (i.e., its potential to be the object of drug-drug interactions or 
genetic polymorphisms in the expression of drug-metabolizing enzymes); 
4. To establish the sample-to-sample variation in the activity of cytochrome P450 
(P450) and UDP-glucuronosyltransferase (UGT) enzymes in a bank of human liver 
microsomes to support reaction phenotyping studies (correlation analysis); 
5. To identify which enzymes can be reversibly or irreversibly inhibited by a drug to 
assess its perpetrator potential (i.e., its potential to be the precipitant of drug-drug 
interactions); 
6. To identify which enzymes can be induced by a drug to assess its perpetrator 
potential (information that can also be obtained by measuring changes in mRNA 
levels). 
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The first three studies involve measurements of the metabolism of the drug or drug 
candidate under investigation. The latter three studies involve measurements of the 
metabolism of marker substrates (substrates specifically metabolized by a single 
enzyme). The latter two studies focus largely on the ability of a drug to inhibit or induce 
P450 enzymes because changes in P450 activity can be large, prolonged and they can 
affect the disposition of a large number of other drugs (Parkinson et al., 2013). However, 
an evaluation of the ability of drugs to inhibit (or possibly induce) UGT and, on a case-by-
case basis, other drug-metabolizing enzymes is becoming more common. The 
metabolism of drugs can be studied in vitro with various test systems including subcellular 
fractions, such as microsomes and post-mitochondrial (S9) fraction from liver, small 
intestine, kidney and other tissues, hepatocytes and recombinant or purified enzymes. 
Such studies can serve a number of purposes, as described below. One application 
involves the use of in vitro systems to determine metabolic intrinsic clearance (CLint) 
based on measurements of Vmax/Km, v/[S] or in vitro half-life (discussed in the next section 
and Chapter 2). In vitro CLint values are widely used to predict the in vivo hepatic 
clearance of drugs, which is used prospectively to select for further development those 
drug candidates that are expected to possess commercially desirable pharmacokinetic 
properties, such as a half-life consistent with once-a-day administration and a low oral 
clearance to reduce dose. 
Studies with recombinant enzymes, microsomes, S9 fraction and hepatocytes provide 
information on rates of drug metabolism. Studies in suspended hepatocytes can also 
provide information on the rate of cellular uptake of the drug by passive diffusion and 
transporters whereas studies in cultured hepatocytes (confluent monolayers) can provide 
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information on rates of uptake and biliary excretion. In the case of acidic and zwitterionic 
drugs, the rate of transporter-mediated uptake into hepatocytes can provide important 
information on the rate-determining step in hepatic clearance. In the case of neutral and 
basic drugs, uptake into hepatocytes and ion partitioning into lysosomes can provide 
valuable information on the potential for a large volume of distribution, which is a particular 
characteristic of lipophilic amines (cationic amphiphilic drugs with a logP > 1 and pKa > 
6) (Kazmi et al., 2013). Studies with microsomes and hepatocytes have also been 
conducted in the presence of plasma to achieve the same concentration of unbound drug 
in vitro that is present in plasma in vivo (Skaggs et al., 2006; Lu et al., 2007; Kazmi et al., 
2009; Mao et al., 2012).  
Measurements of in vitro metabolic CLint with human liver microsomes and hepatocytes 
systematically underpredict in vivo hepatic clearance. The underprediction stems in part 
from attributing the rate-determining step in the clearance of acidic and zwitterionic drug 
to metabolism rather than transporter-mediated uptake; an underprediction that is evident 
with both human and rat in vitro test systems. In the case of neutral and basic drugs, 
however, a systematic underprediction of in vivo metabolic clearance is observed with 
human but not rat test systems, which suggests human liver microsomes and hepatocytes 
have low in vitro enzyme activities relative to those in vivo. This issue is discussed in the 
next sections. 
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1.4. In vitro intrinsic clearance (CLint) and its relationship to Km and 
Vmax, and in vivo clearance 
In pharmacokinetic terms, clearance (CL), the volume of plasma or blood cleared of drug 
per unit time (e.g., L/h), has many mathematical definitions including that shown in 
Equation 1.1, in which clearance is the term relating the rate of elimination of a drug from 
plasma (in units of mg/h) to the concentration of drug in plasma (in units of mg/L): 
 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑟𝑟𝐸𝐸𝐸𝐸𝑟𝑟 = 𝑐𝑐𝐸𝐸𝑟𝑟𝐸𝐸𝑟𝑟𝐸𝐸𝐸𝐸𝑐𝑐𝑟𝑟 ∙ 𝑑𝑑𝑟𝑟𝑑𝑑𝑑𝑑 𝑐𝑐𝐸𝐸𝐸𝐸𝑐𝑐𝑟𝑟𝐸𝐸𝐸𝐸𝑟𝑟𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 Equation 1.1 
The same relationship can be applied to enzymatic rates where the elimination rate is 
represented by reaction velocity (v) and drug concentration is represented by substrate 
concentration (S); in this case clearance is termed intrinsic clearance (CLint): 
 𝑣𝑣 = 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 ∙ [𝑆𝑆] Equation 1.2 
Hence, 
 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 =
𝑣𝑣
[𝑆𝑆]
 Equation 1.3 
The relationship between v and [S] is also given by the Michaelis-Menten equation: 
 𝑣𝑣 =  
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚 ∙ [𝑆𝑆]
𝐾𝐾𝑚𝑚 + [𝑆𝑆]
 Equation 1.4 
Equation 1.4 and Equation 1.5 can be combined so that CLint can be related to the terms 
Vmax and Km, which is accomplished by dividing each side of the Michaelis-Menten 
equation by [S], which gives Equation 1.5: 
 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖  =
𝑣𝑣
[𝑆𝑆]
=  
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
𝐾𝐾𝑚𝑚 + [𝑆𝑆]
 Equation 1.5 
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which, by multiplying by Km/Km, can be expressed as follows: 
 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖  =
𝑣𝑣
[𝑆𝑆]
=  
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
𝐾𝐾𝑚𝑚
∙
𝐾𝐾𝑚𝑚
𝐾𝐾𝑚𝑚 + [𝑆𝑆]
 Equation 1.6 
Alternatively, 
 
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
𝐾𝐾𝑚𝑚
=
𝑣𝑣
[𝑆𝑆]
∙  
𝐾𝐾𝑚𝑚 + [𝑆𝑆]
𝐾𝐾𝑚𝑚
 Equation 1.7 
The terms Km+[S]/Km and Km/Km+[S] are correction factors to convert CLint values 
determined by v/[S] to CLint values determined by Vmax/Km and vice versa, respectively. 
There are two basic in vitro procedures to measure metabolic CLint of drugs by liver 
microsomes, recombinant enzymes, and hepatocytes: one involves measuring Vmax and 
Km, and the other involves measuring the rate of reaction at a single substrate 
concentration. In the former case, CLint is based on Vmax/Km; in the latter case it is based 
on v/[S]. However, from Equation 1.5 it is apparent that these two terms are not identical 
and, furthermore, in accordance with Equation 1.6 and Equation 1.7, they will differ 
depending on the value of [S] relative to Km (which determines the values of the correction 
factors Km/Km+[S] in Equation 1.6 and Km+[S]/Km in Equation 1.7). For example, if [S] = 
Km then the value of CLint based on v/[S] will be half of that based on Vmax/Km (because 
the term Km/Km+[S] is 0.5). If [S] = 1/10 Km then CLint based on v/[S] will be 0.909 of that 
based on Vmax/Km (i.e., it’s within 10%), which is why CLint based on v/[S] should be 
conducted with [S] equal to 1/10 Km or less. The lower the concentration of [S] relative to 
Km the closer values of CLint based on v/[S] equal those based on Vmax/Km.  Strictly 
speaking, a CLint value exactly equal to Vmax/Km could not be achieved experimentally 
because, from Equation 1.5, we see that CLint = Vmax/Km only when [S] = 0, which is 
meaningless from an experimental perspective but it illustrates that values of Vmax/Km 
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represent an upper limit of CLint. Although this upper limit cannot be achieved based on 
measurements of v/[S], it is important to note that, when [S] is 1/10 Km or less, CLint values 
based on v/[S] are within 10% of Vmax/Km, the maximum value of CLint for any given 
reaction. 
There are physiologically based scaling factors (PBSFs; shown in Table 1.3) to 
extrapolate the in vitro value of metabolic CLint to CLH,int, the in vivo hepatic intrinsic 
clearance of drug from whole blood (by the process known as in vitro to in vivo 
extrapolation or IVIVE). In vitro metabolic CLint and its in vivo counterpart CLH,int are 
measures of the ability of the liver to clear a drug by metabolism in the absence of any 
restrictions on delivery of the drug to the intracellular hepatic drug-metabolizing enzymes 
imposed by blood flow, permeability, binding of the drug to plasma proteins or cellular 
components such as proteins, lipids, and organelles (such as lysosomes) or cofactor 
availability. These restrictions cannot be ignored during the process of IVIVE to estimate 
the actual hepatic clearance in vivo (CLH). There are two major restrictions on the in vivo 
hepatic clearance of a drug, namely hepatic blood flow and binding of the drug to plasma 
proteins and erythrocytes. Hepatic blood flow (abbreviated QH) imposes an upper limit on 
the hepatic clearance of drugs (QH = 90L/h in humans); drugs cannot be eliminated by 
the liver any faster than blood flow can deliver them to the liver. The binding of some – 
but not all – drugs to plasma proteins impedes their hepatic uptake and, hence, their 
metabolic and biliary clearance by the liver. These restrictions on hepatic clearance are 
discussed in connection with IVIVE in the next section. 
The uptake of some drugs into liver is mediated by transporters, such as OATPs. For 
drugs with low passive permeability, transporter-mediated uptake can be a rate-
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determining step in hepatic clearance. The predictive value of in vitro metabolic CLint data 
also depends on the importance of hepatic metabolic clearance relative to other routes of 
clearance, such as renal and biliary clearance (renal, biliary and metabolic clearance are 
the three major clearance pathways). The predictive value of in vitro CLint data determined 
with NADPH-fortified liver microsomes or recombinant/purified cytochrome P450 
enzymes further depends on the importance of P450-dependent metabolism relative to 
other routes of metabolism. Obach (1999) summarized the assumptions inherent in the 
use of NADPH-fortified microsomes to the measurement of CLint (all of which can also be 
extended to recombinant/purified P450 enzymes) as follows: 
1. Metabolic clearance is the major mechanism of clearance (i.e., CLmetabolism >> 
CLrenal + CLbiliary + CLother);  
2. The liver is the major organ of clearance (i.e., CLhepatic >> ΣCLall other organs);  
3. Oxidative metabolism predominates over other metabolic routes such as direct 
conjugation, reduction, hydrolysis, etc.;  
4. Rates of metabolism and enzyme activities in vitro are truly reflective of those that 
exist in vivo. 
5. The concentration of drug used to measure CLint based on in vitro half-life is well 
below Km; 
6. There is no significant product inhibition or irreversible enzyme inactivation during 
prolonged incubations to measure in vitro half-life. 
Obach also pointed out that a tenet of the well-stirred and parallel-tube models of hepatic 
extraction is that the unbound concentration of drug in plasma is equal to the unbound 
concentration in hepatocytes. Therefore, facilitated transport processes that could 
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possibly be responsible for drug uptake or drug efflux from hepatocytes are not accounted 
for in in vitro studies with microsomes or recombinant enzymes (or with hepatocytes 
depending on the experimental design).  
In vitro CLint is usually determined from Vmax/Km or in vitro half-life. Both methods are 
widely used to measure in vitro CLint with liver microsomes and recombinant/purified 
enzymes. In contrast, the measurement of CLint in hepatocytes is usually based on in vitro 
half-life (substrate disappearance) because measuring the rate of formation of primary 
metabolites in hepatocytes can be complicated by a lag in their formation and their further 
metabolism (e.g., conjugation) to secondary metabolites. Each method has its 
advantages and disadvantages. The first method (Vmax/Km) generally involves the 
measurement of metabolite formation at multiple substrate concentrations under initial-
rate conditions (a single, short incubation time). The second method (in vitro half-life) 
usually involves the measurement of substrate disappearance at a single, low 
concentration of drug at multiple time points (typically with much longer incubation times 
than those used to determine Vmax and Km). Some investigators use abbreviated 
procedures to estimate CLint in which in vitro half-life is measured with only two time points 
(e.g., zero and 30 min) or in which the rate of metabolite formation (v) is measured at a 
single substrate concentration (ideally one that is well below Km) and CLint is based on 
v/[S]. Estimates of CLint based on in vitro half-life or v/[S] give slightly lower values of CLint 
than that based on Vmax/Km, the magnitude of which depends on the concentration of 
substrate relative to Km. 
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1.5. The importance of membrane partitioning and enzyme inhibition 
in determining in vitro CLint 
The degree of membrane partitioning of drugs to microsomes is dependent on the 
concentration of microsomal protein (the fraction of unbound drug, fumic, decreases with 
increasing protein concentration) and the drug’s lipophilicity and charge at pH 7.4 (Obach, 
1996; Obach, 1997; Obach, 1999; Austin et al., 2002; Hallifax and Houston, 2006; Gertz 
et al., 2008; Nagar and Korzekwa, 2012). Basic (cationic) drugs tend to partition into 
microsomes more extensively than acidic (anionic) drugs; the former, being positively 
charged, are attracted to the negatively charged phospholipids in the membrane whereas 
the latter, being negatively charged, are repelled. Several endpoints, such as the kinetic 
constants Km, Ki and KI, are affected by microsomal partitioning, but others are not. For 
example, if in vitro experiments are performed at 0.1 and 1.0 mg microsomal protein/mL 
with a drug that is 20% bound at the lower protein concentration (fumic = 0.8) and 80% 
bound at the 10-fold higher protein concentration (fumic = 0.2), the four-fold difference in 
fumic would cause a four-fold increase in Km (in studies of the drug’s metabolism) and a 
four-fold increase in Ki or KI for P450 enzymes inhibited reversibly or irreversibly by the 
drug. These concentration-dependent effects on Km, Ki and KI can be corrected by taking 
fumic into account and expressing these constants on the basis of the unbound drug 
concentration (Obach, 1996; Obach, 1997; Obach, 1999; McLure et al., 2000; Austin et 
al., 2002; Di Marco et al., 2003; Margolis and Obach, 2003; Hallifax and Houston, 2006; 
Howgate et al., 2006; Brown et al., 2007a; Brown et al., 2007b). 
Microsomal partitioning (often all microsomal binding) affects in vitro clearance but it does 
not affect in vitro half-life, which seems counterintuitive. How is this possible? Microsomal 
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partitioning affects CLint by changing the apparent volume of the incubation (Vd,app), which 
is the in vitro equivalent of Vd, the in vivo volume of distribution. This is illustrated in Figure 
1.2, which depicts the in vitro metabolism (disappearance) of a drug (1 µM) under the 
conditions noted above: incubations are performed at two concentrations of microsomal 
protein, namely 0.1 mg protein/mL (with fumic = 0.8) and 1.0 mg protein/mL (with fumic = 
0.2). The upper panel in Figure 1.2 depicts substrate disappearance based on the total 
concentration of drug (starting with 1 µM for both protein concentrations); the lower panel 
depicts substrate disappearance based on the unbound concentration (starting with 0.8 
µM at 0.1 mg protein/mL and 0.2 µM at 1.0 mg/mL). Both graphs are semi-log plots and 
substrate disappearance conforms to a first-order elimination process (which gives a 
straight line). In both cases, increasing the concentration of microsomes tenfold 
shortened the in vitro half-life from 25 min (at 0.1 mg/mL) to 10 min (at 1.0 mg/mL). When 
CLint is determined based on total drug concentration (1 µM), Vinc is 1 mL for both 
concentrations of microsomes; hence, the 2.5-fold difference in half-life translates to a 
2.5-fold difference in CLint (Figure 1.2, upper panel). In contrast, when CLint is determined 
based on the unbound drug concentration (0.8 µM at 0.1 mg/mL and 0.2 µM at 1.0 
mg/mL), the apparent incubation volume (Vinc,app) increases fourfold (from 1.25 mL at 0.1 
mg/mL to 5.0 mL at 1.0 mg/mL); now the 2.5-fold difference in half-life combined with the 
four-fold difference in the apparent incubation volume translates into a 10-fold difference 
in CLint (Figure 1.2, lower panel). The important point illustrated in Figure 1.2 is that a 10-
fold increase in the concentration of microsomes results in a 10-fold increase in clearance 
only when the fraction of unbound drug is taken into account. When such clearance 
values are expressed on a per-mg-protein basis, the same result is obtained regardless 
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of the concentration of microsomes. Without correcting for such partitioning, values of 
CLint will decrease with increasing microsomal protein concentration.  
Figure 1.3 shows the elimination of tienilic acid (0.5 µM) and paroxetine (0.2 µM) when 
incubated with human liver microsomes at 0.1 and 1.0 mg/mL (Parkinson et al., 2011). 
Tienilic acid is a substrate and metabolism-dependent inhibitor of CYP2C9 whereas 
paroxetine is a substrate and metabolism-dependent inhibitor of CYP2D6. The key 
parameters for this experiment are summarized in Table 1.1. A visual inspection of Figure 
1.3 reveals that increasing the concentration of human liver microsomes 10-fold markedly 
increased the rate of elimination of tienilic acid but only marginally increased the rate of 
elimination of paroxetine. Table 1.1 shows that increasing the concentration of human 
liver microsomes 10-fold increased the rate of elimination of paroxetine only 2.6 fold (kel 
increased from 0.028 min-1 to 0.073 min-1 and half-life decreased by the same factor from 
25 to 9.5 min). This difference can largely be attributed to membrane partitioning of 
paroxetine, a lipophilic amine that is predominantly positively charged at pH 7.4, to 
microsomal protein and the negatively charged phospholipids. Partitioning of paroxetine 
into microsomes was determined experimentally (discussed later in this section); the 
unbound fraction (fumic) was 0.45 and 0.14 at 0.1 and 1.0 mg microsomal protein/mL, 
respectively (Table 1.1). These values were used to calculate the in vitro clearance of 
unbound paroxetine as follows: 
 𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖 =  
𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
𝑓𝑓𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚
 Equation 1.8 
Without correction for microsomal partitioning, CLint of paroxetine at the lower 
concentration of HLM (280 µL/min/mg microsomal protein) was 3x greater than CLint at 
the higher concentration of HLM (83 µL/min/mg microsomal protein). However, when 
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corrected for membrane partitioning, paroxetine clearance was roughly the same at both 
microsomal concentrations (CLuint = ~600 µL/min/mg microsomal protein). 
Table 1.1 shows that increasing the concentration of HLM 10-fold actually increased the 
rate of elimination of tienilic acid 24 fold (kel increased from 0.014 min-1 to 0.033 min-1 and 
half-life decreased from 50 to 2.1 min). CLint at the higher protein concentration was more 
than twice that at the lower protein concentration (330 versus 140 µL/min/mg microsomal 
protein). This 2.4-fold difference cannot be attributed to microsomal partitioning. No 
membrane partitioning of tienilic acid was measurable at 0.1 mg microsomal protein/mL 
and only 12% partitioning was evident at 1.0 mg microsomal protein/mL; such low 
microsomal  partitioning is characteristic of acidic drugs. In contrast to the situation with 
paroxetine, correcting CLint values for microsomal partitioning in the case of tienilic acid 
made the discrepancy worse (but only slightly): CLuint at the lower and higher protein 
concentration were 140 and 375 µL/min/mg microsomal protein (compared with 
uncorrected values of 140 and 330) (Table 1.1). The 2.7 fold discrepancy in CLuint is likely 
due to the partial inactivation of CYP2C9 by tienilic acid, the extent of which increases 
with decreasing concentration of microsomes (Parkinson et al., 2011). 
The in vitro half-life studies with tienilic acid and paroxetine shown in Figure 1.3 
underscore some important principles: 
1. If fumic is not taken into account then estimates of in vitro CLint will often depend on 
the concentration of liver microsomes (i.e., they will decrease with increasing 
protein concentration). This will be particularly apparent with basic drugs (like 
paroxetine), which tend to partition into microsomes to a greater extent than acidic 
drug (like tienilic acid). The importance of correcting for membrane partitioning 
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applies also to studies with recombinant enzymes and hepatocytes. Correcting in 
vitro CLint values for fumic (according to Equation 1.8) is important regardless of 
whether they are based on in vitro half-life, v/[S] or Vmax/Km.   
2. When an increase in microsomal protein concentration does not cause a 
corresponding increase in metabolic rate based on the total (nominal) 
concentration of substrate, as in the case of paroxetine, this is a good indication 
that microsomal partitioning is lowering the free (unbound) concentration of 
substrate and thereby restricting the enzyme’s access to substrate.   
3. When an increase in microsomal protein concentration causes a supra-
proportional increase in metabolic rate, as in the case of tienilic acid, this is a good 
indication that the substrate inactivates the enzyme, the extent of which decreases 
with increasing concentration of microsomal protein (for reasons detailed in 
Parkinson et al. (2011)). 
4. To avoid a departure from first-order elimination kinetics, measurements of in vitro 
half-life should be based on initial rates of substrate disappearance. A departure 
from first-order elimination kinetics (as indicated by deviation from a straight line 
on a semi-log plot of [Drug] versus time) can occur for three main reasons: 
a. The substrate can be converted to a metabolite that causes reversible 
enzyme inhibition;  
b. The substrate causes irreversible enzyme inactivation;  
c. There is spontaneous (drug-independent) loss of enzyme activity. 
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The partitioning of drugs into microsomes (i.e., the fraction of free drug in a microsomal 
incubation) can be determined experimentally by equilibrium dialysis, ultrafiltration or 
ultracentrifugation. Alternatively, fumic values can be estimated for any concentration of 
microsomal protein (Cp) based on logP or logD7.4 values. Values of logP (the log octanol-
water partition coefficient of neutral [unionized] drug) and logD7.4 (the log octanol-water 
partition coefficient of both neutral and ionized [total] drug at pH 7.4) can be determined 
experimentally or estimated with free software programs such as MarvinSketch 5.9.0 
(ChemAxon, Cambridge, MA [www.chemaxon.com]). For basic drugs, estimates of fumic 
are based on logP whereas logD7.4 is used to estimate fumic for acidic drugs. In the case 
of neutral drugs, either logP or logD7.4 can be used because the values are identical. As 
shown in Table 1.2, several equations to determine fumic have been reported in the 
literature. Estimates of fumic tend to become less reliable with highly lipophilic drugs (logP 
or logD7.4 > 5). 
The unbound fraction of drug in the extracellular medium of in vitro incubations of 
hepatocytes (fuhep) can be estimated from the following equations (Kilford et al., 2008); 
 𝑓𝑓𝑑𝑑ℎ𝑒𝑒𝑒𝑒 =  
1
1 +  
𝐾𝐾𝑒𝑒 ∙ 𝑉𝑉𝑅𝑅  
𝐾𝐾𝑚𝑚 ∙ 𝑃𝑃
 �1 − 𝑓𝑓𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚𝑓𝑓𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚
�
 
Equation 1.9 
 
 𝑓𝑓𝑑𝑑ℎ𝑒𝑒𝑒𝑒 =
1
1 + 𝐾𝐾𝑚𝑚 ∙ 𝑉𝑉𝑅𝑅 ∙ 100.072 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙/𝐷𝐷
2 +0.067 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙/𝐷𝐷−1.126  Equation 1.10 
 
 𝑓𝑓𝑑𝑑ℎ𝑒𝑒𝑒𝑒 =
1
1 + 125 ∙ �0.005 ∙ 𝐸𝐸𝑉𝑉� ∙ 10
0.072 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙/𝐷𝐷2 +0.067 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙/𝐷𝐷−1.126 
 
Equation 1.11 
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where Kp is the ratio of the concentration of drug in hepatocytes versus the concentration 
of drug in medium, Ka is a microsomes-to-hepatocytes scaling factor (= 125 for 1 mg 
microsomal protein/mL and 1 million hepatocytes/mL), VR is the ratio of the volume of 
hepatocytes to the volume of medium (= 0.005 for 1 million cells/mL), P is the 
concentration of microsomal protein used to measure or estimate fumic, n is the number 
of million hepatocytes in the incubation, V is the incubation volume and logP/D is the logP 
value for basic drugs and the logD7.4 value for acidic and neutral drugs. The application 
of fuhep to values of in vitro half-life determined with hepatocytes is analogous to the 
application of fumic to values in vitro half-life determined with microsomes (Table 1.2); the 
end result being an estimate of CLint based on the unbound concentration of drug in the 
in vitro incubation system.  
The term fuhep, the fraction unbound in hepatocytes, can be misleading. It is a measure 
of the unbound concentration of drug in the medium, not in the hepatocyte. The equations 
for calculating fuhep (Equation 1.9, Equation 1.10 and Equation 1.11) are based on 
experiments with inactive or disrupted hepatocytes. Consequently, they do not account 
for active processes such as transporter-mediated uptake or ion-partitioning into acidic 
lysosomes, processes that lead to drug accumulation in hepatocytes (Kazmi et al., 2013). 
Suffice it to say here that, in the case of drugs that are actively transported into 
hepatocytes, such as the OATP substrate atorvastatin, the concentration of unbound drug 
in the hepatocyte incubation medium and the rate of metabolic clearance both decrease 
with increasing concentration of hepatocytes and do so to a much greater extent than is 
observed with non-transported drugs (Nordell et al., 2013). 
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Figure 1.2. The effect of membrane partitioning of a drug into microsomes on its in 
vitro half-life, the apparent incubation volume (Vd,app) and clearance: The top panel 
represents total drug concentration and the bottom panel represents unbound 
(free) drug concentration. 
The time course of disappearance of a drug is shown for two concentrations of liver 
microsomes (0.1 and 1.0 mg protein/mL). The fraction of unbound drug (fumic) is 0.8 at 
0.1 mg protein/mL and 0.2 at 1.0 mg protein/mL. When corrected for membrane 
partitioning, the elimination rate constant (kel) and, hence, half-life (t½) do not change; the 
lines in the bottom panel have the same slope as those in the top panel. However, the 
apparent incubation volume (Vd,app) increases in proportion to fumic. Without correcting for 
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membrane partitioning (top panel), the 10-fold increase in microsomal protein 
concentration caused only a 2.5-fold increase in intrinsic clearance (CLint).  With the 
correction for fumic (bottom panel), the 10-fold increase in microsomal protein 
concentration caused a 10-fold increase in CLint. 
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Figure 1.3. The impact of membrane partitioning on the time course of 
disappearance of paroxetine (left panel) and tienilic acid (right panel) by human 
liver microsomes at two protein concentrations (0.1 and 1.0 mg/mL). 
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Tienilic acid is a substrate for ‒ and a metabolism-dependent inhibitor of ‒ CYP2C9; it 
partitions only marginally (12%) into human liver microsomes at 1 mg protein/mL. 
Paroxetine is a substrate for ‒ and a metabolism-dependent inhibitor ‒ of CYP2D6; it 
partitions extensively into human liver microsomes (55% and 86% at 0.1 and 1.0 mg/mL, 
respectively). In the case of tienilic acid, increasing the concentration of human liver 
microsomes 10 fold caused more than a 10-fold decrease in half-life. In the case of 
paroxetine, increasing the concentration of human liver microsomes 10 fold caused only 
a 2.6-fold decrease in half-life. However, when corrected for partitioning into microsomes 
(fumic), the intrinsic clearance (CLuint) at 1.0 mg/mL was comparable to that at 0.1 mg/mL. 
Values are presented in Table 1.1. Data are from Parkinson et al. (2011). 
  
30 
 
Table 1.1. The effect of correcting for microsomal partitioning on drug clearance 
based on measurements of the in vitro half-life of paroxetine (high partitioning) and 
tienilic acid (low partitioning) by human liver microsomes (HLM) at 0.1 and 1.0 mg 
protein/mL 
Substrate 
[HLM]  
(mg/mL) 
fumic1 
[S]T  
and 
[S]U 
(µM)2 
In vitro 
half-
life (t½) 
Elimination 
rate constant 
(kel) 
CLint 
(µL/min
/mg 
protein) 
CLuint 
(µL/min
/mg 
protein) 
Unbound 
CLH,int  
(Multiple 
of QH) 
Tienilic 
acid  
0.1 1.0  
0.50 
0.50 
50 min 0.014 min-1 140 140 
554 L/h 
(~6 x QH) 
1.0 0.88  
0.50 
0.44 
2.1 min 0.330 min-1 340 375 
1,490 L/h 
(~17 x QH) 
Paroxetine  
0.1 0.45  
0.20 
0.09 
25 min 0.028 min-1 280 620 
2,460 L/h 
(~27 x QH) 
1.0 0.14  
0.20 
0.028 
9.5 min 0.073 min-1 43 521 
2,060 L/h  
(~23 x QH) 
 
1 Fraction unbound in microsomes (determined experimentally) 
2  [S]T and [S]U are the total and unbound substrate concentration, respectively 
 
𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 =  𝑘𝑘𝑒𝑒𝑙𝑙 ∙  
𝑣𝑣𝐸𝐸𝐸𝐸𝑑𝑑𝐸𝐸𝑟𝑟 𝐸𝐸𝑓𝑓 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 (µL)
𝐸𝐸𝑑𝑑 𝐸𝐸𝐸𝐸𝑐𝑐𝑟𝑟𝐸𝐸𝑚𝑚𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑝𝑝𝑟𝑟𝐸𝐸𝐸𝐸𝑟𝑟𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸 𝐸𝐸ℎ𝑟𝑟 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
 
 
𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖 =
𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
𝑓𝑓𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚
  
 
𝐶𝐶𝐶𝐶𝐻𝐻,𝑖𝑖𝑖𝑖𝑖𝑖 =  𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 ∙ 𝑃𝑃𝑃𝑃𝑆𝑆𝑃𝑃(66,000) ∙ 60𝐸𝐸𝐸𝐸𝐸𝐸/ℎ ∙ 10−6 𝐶𝐶/µ𝐶𝐶 
 
𝑄𝑄𝐻𝐻 = ℎ𝑟𝑟𝑝𝑝𝐸𝐸𝐸𝐸𝐸𝐸𝑐𝑐 𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝑑𝑑 𝑓𝑓𝐸𝐸𝐸𝐸𝑓𝑓 = 90 𝐶𝐶/ℎ 
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Table 1.2. Methods to calculate the in vitro free fraction of drug in the presence of 
microsomes (fumic). 
Reference Neutral 
Austin et al., 2005 fumic = � 11 + Cp × 100.56×logP/D7.4-1.41� 
Hallifax and Houston, 2006 fumic =� 1
1 + Cp × 100.072×logP/D7.42+0.067×logP/D7.4-1.126
� 
Turner et al., 2007 fumic =� 11 + Cp × 100.46×logP-1.51� 
Poulin and Haddad, 2011 
 
fumic =� 1Pma� 
Where: 
             Pma = Fwm+ 
Pnla × Fnlm
1 + Im
 
Reference Bases 
Austin et al., 2005 fumic =� 11 + Cp × 100.56×logP-1.41� 
Hallifax and Houston, 2006 fumic =� 1
1+Cp×100.072×logP2+0.067×logP-1.126
� 
Turner et al., 2007 fumic =� 11 + Cp × 100.58×logP-2.02� 
Poulin and Haddad, 2011 
 
fumic =� 1Pma� 
Where: 
Pma=Fwm+ 
Pnla ×Fnlm+Im ×Papla ×Faplm
1+Im
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Reference Acids 
Austin et al., 2005 fumic =� 11 + Cp × 100.56×logD-1.41� 
Hallifax and Houston, 2006 fumic =� 1
1+ Cp × 100.072×logD2+0.067×logD-1.126
� 
Turner et al., 2007 fumic =� 11 + Cp × 100.20×logP-1.54� 
Poulin and Haddad, 2011 
 
fumic =� 1Pma� 
Where: 
             Pma = Fwm+ 
Pnla × Fnlm
1 + Im
 
 
Note: logP is the log n-octanol-water partition ratio of unionized (neutral) drug (usually determined 
at a pH where the unionized form of the drug predominates). logD is the log n-octanol-buffer 
partition ratio of total (unionized + ionized) drug at pH 7.4. For neutral drugs logP = logDpH 7.4. Cp 
is the microsomal protein concentration (mg/mL); Pma is the medium-aqueous phase partition 
coefficient; Fwm is the fractional volume of water equivalent in the incubation medium; Fnlm is the 
fractional volume of neutral lipids equivalent in the incubation medium; Faplm is the fractional 
volume of acidic phospholipids equivalent in the incubation volume; Pnla is the ratio of a drug 
between the neutral lipids and the aqueous phase in the incubation medium (estimated from logP 
at 37°C; logP37°C = logP25°C +0.009/°C x Δ°C); Im is the ionization term for the incubation medium 
where Im = 0 for neutrals, Im = 10pKa-pH for bases, and Im = 10pH-pKa for acids; Papla is the ratio of a 
drug between the acidic phospholipids and aqueous phase in the incubation medium calculated 
as described by Poulin and Haddad (2011) 
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1.6. Extrapolation of in vitro CLint to in vivo clearance (IVIVE) – 
models and the importance of Rb, QH and fuB 
There are two major restrictions on hepatic drug clearance in vivo, namely hepatic blood 
flow and plasma protein binding. Hepatic blood flow imposes an upper limit on the hepatic 
clearance of drugs; drugs cannot be eliminated by the liver any faster than blood flow can 
deliver them to the liver (90 L/h in humans). The binding of some – but not all – drugs to 
plasma proteins impedes their hepatic uptake and, hence, their metabolic and biliary 
clearance by the liver.   
According to Ramanathan and Vachharajani (2010), the binding of drugs to plasma 
proteins can be classified as follows: 
Very highly bound >99% 
Highly bound = 95-99% 
Moderately highly bound = 85-95% 
Poorly bound <80% 
It is widely accepted that unbound drug concentration determines the efficacy or toxicity 
of a drug; this is known as the free-drug hypothesis or principle (Trainor, 2007). The 
metabolism of drugs by cytochrome P450 and most other drug-metabolizing enzymes 
occurs intracellularly where the measurement of unbound drug concentration is difficult. 
The pharmacokinetics of drugs and the clearance of drugs from blood, the so-called 
central compartment, are typically based on measurements of total drug concentrations 
in plasma and measurements of the unbound concentration of drugs in plasma (fuP) and 
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Rb, the ratio of the concentration of drug in whole blood and plasma (discussed later in 
this section). Although plasma contains more than 60 different soluble proteins, fuP is 
largely determined by the binding of drugs to three proteins, namely albumin, α1-acid 
glycoprotein (αAGP) and, to a lesser extent, lipoproteins (Ramanathan and Vachharajani, 
2010). Although albumin and αAGP have been shown to bind both acidic and basic drugs, 
albumin preferentially binds acidic drugs and αAGP generally binds basic drugs. 
Lipoproteins generally bind neutral, lipophilic drugs (Ermondi et al., 2004; Ramanathan 
and Vachharajani, 2010). The concentration of albumin (MW 67 kDa) is so high (35-50 
mg/mL; 500-700 μM) that drugs rarely saturate binding to this plasma protein. The 
concentration of αAGP (MW 38-48 kDa), which is quite variable and influenced by several 
disease states, is normally much lower (0.4-1 mg/mL; 12-31 μM) and saturation of binding 
is more likely. Albumin is often described as a low affinity, high capacity binding protein 
whereas αAGP is high affinity, low capacity binding protein.  Lastly, lipoproteins play a 
role in the plasma binding of various lipophilic drugs, and include high density lipoproteins 
(HDL), low density lipoproteins (LDL) and very low density lipoproteins (VLDL), which 
have circulating levels less than 5 mg/mL. In contrast to albumin and αAGP, lipoproteins 
do not have specific drug-binding sites; rather drugs partition nonspecifically into the lipid 
core, a process that is unlikely to be saturated (Ramanathan and Vachharajani, 2010). 
There is little question that binding of certain acidic (anionic) drugs to albumin and binding 
of certain basic (cationic) drugs to αAGP can restrict rates of hepatic clearance.  For 
example, the hepatic clearance of warfarin, which binds with high affinity to albumin, is 
highly correlated with the concentration of free (unbound) warfarin in plasma (Routledge 
et al., 1979) whereas the hepatic clearance of 7-hydroxystaurosporine (UCN-01) is 
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restricted by its high affinity binding to αAGP (Fuse et al., 1998; Fuse et al., 1999). The 
latter is interesting because high affinity binding of 7-hydroxystaurosporine to αAGP 
occurs in humans but not in nonclinical species. However, the fraction of unbound drug 
in plasma, as determined by various in vitro techniques (equilibrium dialysis, ultrafiltration 
and ultracentrifugation), may underestimate the fraction of drug available for hepatic 
uptake and clearance. In the hepatic sinusoids a drug may bind to active uptake 
transporters (such as OATP1B1 and 1B3) with higher affinity than it binds to albumin or 
other plasma proteins. Binding affinity to albumin (the equilibrium dissociation constant 
KD) is determined by koff/kon (the ratio of the first order rate constant for dissociation and 
the second order rate constant for association of the albumin-drug complex). With a 
sufficiently high koff, a drug can dissociate during its transit through the liver and can enter 
the liver under so-called sink conditions (conditions under which the loss of unbound drug 
due to hepatic uptake is replaced by dissociation of the plasma protein-drug complex 
during its transit through the liver). Baker and Parton (2007) reported that, for most drugs, 
koff is not low enough (<1 s-1) to limit the hepatic extraction of plasma protein-bound drugs; 
however, in some cases, kon can be sufficiently high for plasma proteins to compete with 
hepatic uptake by transporters and passive diffusion. Baker and Parton (2007) concluded 
that, for many drugs, values of fuP tend to underestimate the amount of drug available for 
hepatic uptake and that koff is a better indicator of the maximum amount of drug available 
for hepatic uptake during the passage of blood through the liver. Unfortunately, whereas 
fuP is known for most approved drugs, koff is known for relatively few drugs. As discussed 
later, if the unbound concentration of drug in plasma at equilibrium underestimates the 
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fraction of drug available for hepatic uptake then the use of fuB in IVIVE will lead to 
underpredictions of hepatic clearance in vivo. 
The vast majority of pharmacokinetic studies are based on measurements of the time 
course of changes in the concentration of drug in plasma rather than whole blood, which 
is technically more difficult to work with. However, hepatic drug clearance in vivo is 
evaluated in terms of hepatic blood flow, not hepatic plasma flow. Consequently, drug 
concentrations in plasma must be converted to drug concentrations in blood, which is 
based on Rb, the blood-to-plasma concentration ratio: 
 𝑅𝑅𝑏𝑏 =  
 [𝐷𝐷𝑟𝑟𝑑𝑑𝑑𝑑]𝐵𝐵𝑙𝑙𝑙𝑙𝑙𝑙𝐵𝐵
[𝐷𝐷𝑟𝑟𝑑𝑑𝑑𝑑]𝑙𝑙𝑙𝑙𝑚𝑚𝑃𝑃𝑚𝑚𝑚𝑚
 Equation 1.12 
Hence, 
 [𝐷𝐷𝑟𝑟𝑑𝑑𝑑𝑑]𝐵𝐵𝑙𝑙𝑙𝑙𝑙𝑙𝐵𝐵 =  [𝐷𝐷𝑟𝑟𝑑𝑑𝑑𝑑]𝑙𝑙𝑙𝑙𝑚𝑚𝑃𝑃𝑚𝑚𝑚𝑚 ∙  𝑅𝑅𝑏𝑏 Equation 1.13 
Rb can be determined experimentally (with in vivo or, more commonly, in vitro samples) 
or it can be estimated based on the properties of the drug (whether it’s neutral, basic, 
acidic or zwitterionic) and based on the fact that plasma accounts for ~55% of blood 
volume with cells (mainly erythrocytes) accounting for ~45% (Table 1.3). In the case of 
acidic and zwitterionic drugs, estimates of Rb are based on the assumption that these 
drugs, which are charged at pH 7.4, do not readily penetrate into blood cells but are 
largely confined to plasma (where they bind extensively to albumin); accordingly, Rb is 
assumed to be 0.55 for acidic and zwitterionic drugs (Hallifax et al., 2010). In the case of 
neutral and basic drugs, Rb is assumed to be 1.0 because these drugs often (but not 
always) freely diffuse in and out of erythrocytes and are evenly distributed between 
plasma and erythrocytes (Hallifax et al., 2010). From time to time the assumed values of 
Rb (as opposed to the experimentally determined values) can produce misleading 
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predictions of in vivo hepatic clearance; notably when the value of Rb is greater than unity, 
which occurs when certain drugs bind preferentially (but reversibly) to erythrocytes (either 
to the surface or to intracellular sites). In such cases, estimates of blood clearance from 
measurements of plasma clearance can exceed hepatic blood flow, which can give the 
false impression that non-hepatic clearance mechanisms must also contribute to the 
drug’s clearance. The basis for this over-prediction is illustrated in Figure 1.4, which 
depicts the in vivo plasma and blood clearance of three drugs, A, B and C. The first drug 
(an acidic or zwitterionic drug) is excluded from erythrocytes; for simplicity its Rb value is 
set to 0.5.  The second drug (a neutral or basic drug) is distributed evenly between plasma 
and blood; hence, its Rb value is 1.0. The third drug is a basic drug that binds preferentially 
to erythrocytes (but not in a restricted manner); its Rb value is set to 2.0. For illustrative 
purposes, all three drugs are flow-limited, hepatically cleared drugs such that, in all three 
cases, their clearance from blood is 90 L/h, which corresponds to hepatic blood flow. 
What is the plasma clearance of each drug? In the case of Drug B, which is evenly 
distributed between plasma and erythrocytes (Rb = 1.0), plasma clearance equals blood 
clearance (90 L/h). In the case of Drug A, which is largely excluded from erythrocytes (Rb 
= 0.5), plasma clearance is half hepatic blood flow (and close to hepatic plasma flow). In 
the case of Drug C, which is preferentially distributed in erythrocytes, plasma clearance 
is 180 L/h, which is twice hepatic blood flow. If Drug C were assumed to have an Rb value 
of 1.0, its clearance from blood would be estimated to equal its clearance from plasma 
(180 L/h). Given that the estimated blood clearance is twice hepatic blood flow, it might 
be incorrectly assumed that Drug C must be cleared by renal excretion or extrahepatic 
metabolism; i.e., some mechanism in addition to hepatic clearance.   
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It is apparent from Figure 1.4 that the drug’s half-life (and, hence, kel) is the same 
regardless of whether the concentrations of drug are measured in plasma or blood; this 
is true across all values of Rb. However, whether the concentrations of drug are measured 
in plasma or blood affects the apparent volume of distribution and it is differences in Vd 
that cause changes in clearance between blood and plasma.  
It is noteworthy that the pharmacokinetic behavior of Drugs B and C in Figure 1.4 
assumes that the portion of drug in erythrocytes is just as available for uptake into 
hepatocytes as the portion of drug in plasma. Although this might seem counter-intuitive, 
the clinical observation that the hepatic clearance of many basic/neutral drugs does in 
fact occur at rates equal to hepatic blood flow (as represented by Drug B) or greater than 
hepatic blood flow (as represented by Drug C) establishes that the localization of drugs 
in erythrocytes is not necessarily an impediment to their hepatic uptake. However, there 
are also drugs that bind preferentially to erythrocytes (Rb > 1) but the binding is restrictive, 
meaning dissociation of the drug from erythrocytes is slow compared with the transit time 
of blood through the liver. Drugs with large blood-to-plasma concentration ratios (some 
more than an order of magnitude) and drugs with slow rates of erythrocyte partitioning 
are reviewed in Hinderling (1997). They include chlorthalidone, dorzolamide and 
methazolamide, diuretic drugs that bind with high affinity to carbonic anhydrase, an 
abundant enzyme in erythrocytes, and have Rb values of 30.7, >100 and 241, 
respectively. 
Finally, it is worth noting that Rb, the blood-to-plasma concentration ratio, is also used to 
convert plasma clearance (CLP) to blood clearance (CLB) and unbound fraction of drug in 
blood (fuB) from unbound fraction in plasma (fuP) as follows: 
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 𝐶𝐶𝐶𝐶𝐵𝐵 =  
𝐶𝐶𝐶𝐶𝑙𝑙
𝑅𝑅𝑏𝑏
 Equation 1.14 
 
 𝑓𝑓𝑑𝑑𝐵𝐵 =  
𝑓𝑓𝑑𝑑𝑙𝑙
𝑅𝑅𝑏𝑏
 Equation 1.15 
As noted above, Equation 1.14 is appropriate for drugs with an Rb > 1 only if the 
preferential binding of the drug to erythrocytes in not restrictive (i.e., if dissociation of the 
drug from erythrocytes is not slow compared with the transit time of blood through the 
liver) (Hinderling, 1997). 
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Figure 1.4. Differences between plasma and blood clearance for a drug excluded 
from erythrocytes (Panel A), a drug evenly distributed between plasma and 
erythrocytes (Panel B) and a drug preferentially distributed in erythrocytes. 
Panel A depicts the situation for most acidic/zwitterionic drugs. Panel B depicts the 
situation with many basic/neutral drugs. Panel C depicts the situation with a small number 
of basic/neutral drugs that distribute preferentially into erythrocytes compared with 
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plasma.  Note that plasma clearance is half the rate of blood clearance in Panel A (45 
versus 90 L/h); is equal to blood clearance in Panel B (90 L/h) but exceeds total blood 
flow by a factor of two in Panel C (180 L/h versus 90 L/h).  In all three cases the value of 
total blood clearance is equal to hepatic blood flow (90 L/h). This figure illustrates the 
importance of knowing Rb, the ratio of blood-to-plasma drug concentration, when 
calculating rates of blood clearance from experimentally determined rates of plasma 
clearance. 
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Table 1.3. Physiological data and physiologically based scaling factors (PBSF) for 
in vitro to in vivo extrapolation (IVIVE) 
Physiological parameter Human Monkey Dog Rat Mouse 
A. Body weight  70 kg 5 kg 13.5 kg 0.3 kg 0.0262 kg 
B. Liver weight (g) 1,650 134 480 9.0 1.5 
C. Liver blood flow (QH) 
(L/h) 90 15 40.6 1.03 0.157 
D. Hematocrit (PCV) 0.44 0.42 0.45 0.43 0.40 
E. MPPGL (mg/g liver) 40 NA 55 58 NA 
F. HPGL (million cells/g 
liver) 120 NA 169 127 135 
G. PBSF for microsomes 
(E x B).  Units: total mg of 
microsomal protein per 
whole liver1 
66,000 NA 26,400 522 NA 
H. PBSF for hepatocytes 
(F x B).  Units: number of 
million hepatocytes per 
whole liver2 
198,000 NA 81,120 1143 202.5 
 
NA: Not available 
1 This PBSF is used for studies with microsomes to convert in vitro clearance rates (CLint) based on 
µL/min/mg microsomal protein to in vivo hepatic clearance rates.  For example, with human liver 
microsomes: 
   In vivo CLH,int = In vitro CLint x 66,000 
2 This PBSF is used for studies with hepatocytes to convert in vitro clearance rates (CLint) based on 
µL/min/106 hepatocytes to in vivo hepatic clearance rates. For example, with human hepatocytes: 
   In vivo CLH,int = In vitro CLint x 198,000 
Data from:  Barter et al., 2007; Barter et al., 2008; Boxenbaum et al., 1980; Brunton et al., 2006; Davies 
and Morris, 1993; de la Grandmaison et al., 2001; Gerlowski and Jain, 1983; Hakooz et al., 2006; Howgate 
et al., 2006; Johnson et al., 2005; Naritomi et al., 2001; Price et al., 2003; Smith et al., 2008; Soars et al., 
2002; Sohlenius-Sternbeck et al., 2006; Storb et al., 1970; Windberger et al., 2003; Youdim et al., 2008. 
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There are three major models of hepatic drug clearance (Roberts and Rowland, 1986b; 
Roberts and Rowland, 1986d; Roberts and Rowland, 1986f; Roberts and Rowland, 
1986a; Ching et al., 1989; Ridgway et al., 2003; Roberts, 2010): 
1. The well-stirred model (a.k.a. the venous equilibrium model) assumes the drug is 
mixed infinitely well inside the liver and that the hepatic drug concentration is equal 
to the outflow drug concentration. In chemical engineering terms, it is analogous 
to a perfectly mixed reactor. 
2. The parallel-tube model (a.k.a. the undistributed sinusoidal perfusion model) views 
the hepatic sinusoids as a series of parallel tubes that are all identical with respect 
to blood flow and metabolic activity of the surrounding cells (i.e., all tubes have the 
same intrinsic clearance capacity). This model assumes the drug is mixed in a 
highly restricted (infinitesimally small) section of the liver along the sinusoidal flow 
path from input to output of the liver (which is the extreme opposite of the well-
stirred model) and that hepatic drug concentration is equal to the logarithm of the 
mean of the inflow and outflow drug concentrations. In chemical engineering terms, 
it is a continuous tubular reactor (a.k.a. a plug-flow reactor). 
3. The dispersion model (a.k.a. the convection-dispersion model or the distributed 
sinusoidal model) also views the hepatic sinusoids as a series of parallel tubes but 
it differs from the parallel-tube model by assuming that blood flow through each 
tube and the metabolic activity (intrinsic clearance) of the cells surrounding the 
tubes are not constant but can vary from one tube to the next. According to the 
dispersion model, hepatic drug concentration exhibits axial dispersion analogous 
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to that in a packed-bed chemical reactor. The dispersion model uses a parameter, 
DN, to describe the degree of axial mixing of drug in blood within the sinusoids. 
The average sinusoidal drug concentration lies somewhere between the 
logarithmic mean of the inflow and outflow drug concentration (the drug 
concentration for the parallel tube model) and the outflow concentration (the drug 
concentration for the well-stirred model). 
These three models are used for IVIVE, the extrapolation of in vitro measurements of 
intrinsic hepatic clearance (CLint) to in vivo estimates of hepatic clearance (CLH). All three 
models assume that (1) distribution of drug into liver is limited by the rate of liver perfusion 
and not by diffusion barriers, (2) only unbound drug in blood can enter the liver, and (3) 
drug-metabolizing enzymes are homogenously distributed throughout the liver (Ito and 
Houston, 2004). The equations for all three models incorporate QH and CLint, which can 
be adjusted for drug binding, as discussed later in this section.  The basic IVIVE equations 
(without correction for unbound drug in blood or the in vitro test system) for the three 
models are as follows: 
Well-stirred model IVIVE equation: 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  
𝑄𝑄𝐻𝐻  ×  𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻 +  𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
 
 
Equation 1.16 
Parallel-tube model IVIVE equation 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  𝑄𝑄𝐻𝐻 × �1 − 𝑟𝑟
−𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻 � 
 
Equation 1.17 
Dispersion model IVIVE equation 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  𝑄𝑄𝐻𝐻(1 −  𝑃𝑃𝐻𝐻) Equation 1.18 
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where FH, hepatic availability, is determined from: 
 
𝑃𝑃𝐻𝐻  
=  �
4𝐸𝐸
(1 − 𝐸𝐸)2 ∙ exp �𝐸𝐸 − 12𝐷𝐷𝑁𝑁
� −  (1 − 𝐸𝐸)2 ∙ 𝑟𝑟𝑒𝑒𝑝𝑝 �−𝐸𝐸 + 12𝐷𝐷𝑁𝑁
�
� 
 
Equation 1.19 
 
where 𝐸𝐸 = �1 + 4 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻
∙ 𝐷𝐷𝑁𝑁�
0.5
 
DN = the dispersion number 
 
 
The well-stirred model and the parallel tube model can be viewed as opposite models of 
hepatic drug disposition. The former regards the liver as a well-stirred compartment; it 
assumes the concentration of drug in the liver is in equilibrium with that in the emergent 
blood. The latter regards the liver as a series of parallel tubes with enzymes distributed 
evenly around the tubes; it assumes the concentration of drug declines along the length 
of the tube (i.e., there is a sinusoidal concentration gradient from input to output). The 
dispersion model is intermediate between these two extremes. The dispersion number is 
a measure of the extent to which drugs (and other solutes) disperse throughout the liver; 
values of DN range from 0 to 1. At these two numerical extremes of DN, the dispersion 
model becomes the well-stirred model (when DN = 1 and there is complete dispersion) or 
the parallel tube model (when DN = 0 and there is no dispersion).  Experimentally 
determined values of DN depend on the solute. A value of 0.17 is commonly used for 
IVIVE of drug clearance (Roberts and Rowland, 1986b; Roberts and Rowland, 1986d; 
Naritomi et al., 2001; Ito and Houston, 2004; Chiba et al., 2009). 
All three models are widely used in IVIVE. Their relative strengths and weaknesses in 
terms of their ability to accurately predict in vivo hepatic clearance from in vitro data are 
reviewed in Chiba et al. (2009) and Hallifax et al., (2010). Each equation can be (and 
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usually is) modified to take into account the binding of drugs to blood (fuB, which is often 
calculated from fuP/Rb) and the binding of drugs to the in vitro incubation test system (fumic 
or fuhep depending on whether metabolic clearance in vitro is determined with microsomes 
or hepatocytes). When only in vitro binding is taken into account, CLint becomes CLuint 
(i.e., intrinsic clearance based on the unbound fraction of drug), and the IVIVE equation 
for the well-stirred model becomes: 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  
𝑄𝑄𝐻𝐻 ∙
𝐶𝐶𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖
𝑓𝑓𝑑𝑑𝑖𝑖𝑖𝑖𝑚𝑚  
𝑄𝑄𝐻𝐻 +
𝐶𝐶𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖
𝑓𝑓𝑑𝑑𝑖𝑖𝑖𝑖𝑚𝑚
 =   
𝑄𝑄𝐻𝐻 ∙  𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻 +  𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
 
 
Equation 1.20 
When only binding of drug to blood is taken into account, the IVIVE equation for the well-
stirred model becomes: 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  
𝑄𝑄𝐻𝐻 ∙ 𝑓𝑓𝑑𝑑𝐵𝐵 ∙ 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻 +  𝑓𝑓𝑑𝑑𝐵𝐵 ∙ 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
 
 
Equation 1.21 
When both are taken into account, the IVIVE equation for the well-stirred model becomes: 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  
𝑄𝑄𝐻𝐻 ∙ 𝑓𝑓𝑑𝑑𝐵𝐵 ∙ 𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻 + 𝑓𝑓𝑑𝑑𝐵𝐵 ∙ 𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
 
 
Equation 1.22 
Through the use of Rb, the blood-to-plasma concentration ratio, and fuP, the unbound 
fraction of drug in plasma (which is determined experimentally more often that the 
unbound fraction of drug in whole blood), Equation 1.22 can be modified to calculate the 
hepatic clearance of drug in plasma (CLH,P) (Yang et al., 2007): 
 
𝐶𝐶𝐶𝐶𝐻𝐻,𝑙𝑙 =  
𝑄𝑄𝐻𝐻 ∙ 𝑓𝑓𝑑𝑑𝑙𝑙 ∙ 𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻 +  
𝑓𝑓𝑑𝑑𝑙𝑙 ∙ 𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
𝑅𝑅𝑏𝑏
 
 
Equation 1.23 
From Equation 1.24 it is apparent that hepatic clearance in vivo is determined by three 
factors, namely hepatic blood flow, which is relatively constant, and fuB and CLuint, which 
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vary enormously from one drug to the next. Gillette coined the terms “restrictive 
clearance” and “nonrestrictive clearance” (Gillette, 1973). Restrictive clearance applies to 
low-clearance compounds when either the unbound fraction and/or intrinsic clearance is 
so low that the term QH + f uB • CLuint approximates to QH and Equation 1.22 simplifies to 
CLH = f uB • CLuint. Nonrestrictive clearance applies to high-clearance compounds when 
the unbound fraction and/or intrinsic clearance is so high that the term QH + f uB • CLuint  
approximates to fuB • CLuint  and Equation 1.22 simplifies to CLH = QH. For such 
compounds, the intrinsic clearance will be very high and the rate of dissociation of the 
drug-protein complex must exceed the liver transit time (discussed below). Nonrestricted 
clearance is also known as flow-limited clearance or flow-limited extraction; it applies to 
high extraction drugs. Restricted clearance is also known as capacity-limited clearance 
or capacity-limited extraction; it applies to low extraction drugs.  
For hepatically cleared drugs, the extent of hepatic extraction influences the 
pharmacokinetic consequences of alterations in hepatic clearance, as might occur with 
drug-drug interactions (DDIs) based on inhibition or induction of drug-metabolizing 
enzymes. For high extraction (flow-limited) drugs, DDIs mostly affect plasma Cmax (they 
inhibit or induce first pass clearance) but not systemic clearance (not plasma half-life). 
For low extraction (capacity-limited) drugs, DDIs mostly affect systemic clearance 
(plasma half-life) and not plasma Cmax. (Gillette, 1973; Kirby and Unadkat, 2010; Rowland 
and Tozer, 2011). 
These pharmacokinetic principles are further illustrated based on a consideration of the 
impact of plasma protein binding and intrinsic metabolic clearance on hepatic extraction 
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ratio. Hepatic clearance is related to hepatic blood flow and hepatic extraction ratio as 
follows: 
 𝐶𝐶𝐶𝐶𝐻𝐻 = 𝑄𝑄𝐻𝐻 ∙ 𝐸𝐸𝐻𝐻  Equation 1.24 
From Equation 1.22 and Equation 1.24, hepatic extraction ratio is given by the following 
equation: 
 𝐸𝐸𝐻𝐻 =  
𝑓𝑓𝑑𝑑𝐵𝐵 ∙ 𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
𝑄𝑄𝐻𝐻 + 𝑓𝑓𝑑𝑑𝐵𝐵 ∙ 𝐶𝐶𝐶𝐶𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖
 
 
Equation 1.25 
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Figure 1.5. The mutual impact of intrinsic clearance (CLint) and the unbound fraction 
of drug in blood (fuB) on hepatic extraction ratio (EH; left axis) and hepatic clearance 
(CLH; right axis) 
High (EH > 0.7), intermediate (EH = 0.3-0.7) and low (EH < 0.3) refer to the classification 
of drugs based on hepatic extraction ratio. 
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Table 1.4. Examples of hepatically cleared drugs classified as having a low, 
medium or high hepatic extraction ratio based on intravenous dosing 
Fraction 
unbound in 
blood 
Low extraction 
(EH <0.3) 
Medium extraction 
(EH = 0.3 ‒ 0.7)) 
High extraction 
(EH >0.7) 
fuB < 0.01 
(>99% bound) 
Amiodarone 
Mibefradil 
Montelukast 
Rosiglitazone 
Verlukast 
Amlodipine 
Felodipine 
Itraconazole 
Nefazodone 
Nicardipine 
Eltanolone 
Fluvastatin 
Maxipost 
Nisoldipine 
fuB = 0.01 ‒ 0.1 
(90-99% bound) 
Alfentanil 
Aripiprazole 
Clozapine 
Diazepam 
Diclofenac 
Erythromycin 
Gemfibrozil 
Ibuprofen 
Lansoprazole 
Lorazepam 
Naproxen 
Oxazepam 
Pantoprazole 
Rabeprazole 
Ritonavir 
Tacrolimus 
Temazepam 
Warfarin 
Valproic acid 
Atomoxetine 
Carvedilol 
Chlorpromazine 
Clomipramine 
Cyclosporine 
Ethinylestradiol 
Fluoxetine 
Lovastatin acid 
Midazolam 
Nifedipine 
Omeprazole 
Propafenone 
Repaglinide 
Sildenafil 
Sufentanil 
Tiprolidine 
Tolamolol 
Vardenafil 
Buprenorphine 
Idarubicin 
Nicardipine 
Nilvadipine 
Propofol 
Trimipramine 
 
fuB = 0.1 ‒ 0.5 
(50-90% bound) 
Aprepitant 
Citalopram 
Chloramphenicol 
Chlorpheniramine 
Carbamazepine 
Dapsone 
Paclitaxel 
Pentobarbital 
Phenytoin 
Phenobarbital 
Tolbutamide 
Triazolam 
Zolpidem 
Bufuralol 
Desipramine 
Diltiazem 
Diphenhydramine 
Imipramine 
Lidocaine 
Mexiletine 
Nortriptyline 
Ondansetron 
Timolol 
Alprenolol 
Butorphanol 
Cocaine 
Doxorubicin 
Indinavir 
Labetalol 
Meperidine 
Nitroglycerin 
Pentamidine 
Propoxyphene 
Propranolol 
Verapamil 
fuB >0.5 
(0-50% bound) 
Acetaminophen 
Alprazolam 
Antipyrine 
Caffeine 
Cyclophosphamide 
Hexobarbital 
Ifosphamide 
Metoclopramide 
Theophylline 
Codeine 
Famotidine 
Metoprolol 
Venlafaxine 
Flumazenil 
Ketamine 
Morphine 
Nicotine 
Phenacetin 
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In each category of hepatic extraction ratio the drugs are organized on the basis of their unbound 
fraction in blood (fuB). Drugs in bold are borderline; some estimates of in vivo clearance place 
them in the previous category. Based on hepatic blood flow of 90 L/h, the cut-off extraction ratios 
of 0.3 and 0.7 correspond to in vivo clearances of 27 and 63 L/h (or 6.4 and 15 mL/min/kg), 
respectively. 
Adapted from Benet and Hoener (2002); Obach et al. (2008); Hallifax et al. (2010), and Rowland 
and Tozer (2011). 
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Figure 1.5 shows the relationship between hepatic extraction ratio and CLuint (panel A) 
and fuB (panel B) based on Equation 1.25. Values of CLuint ranged from one-tenth to 100 
times hepatic blood flow (i.e., from 9 to 9,000 L/h), which are realistic values based on 
the data for P450-dependent clearance in Table 1.6. Values of fuB ranged from 1 (no 
binding to plasma protein) to 0.001 (99.9% binding). Based on an analysis of 222 drugs, 
Zhang et al. (2012) reported that ~50% of drugs are more than 90% bound to plasma 
proteins and ~12% are bound 80-90%. Slightly less than 5% of drugs are bound less than 
10% to plasma proteins. Accordingly, fuB values of 0.1 or less are applicable to half the 
drugs and fuB values of 0.9 or more are applicable to ~5% of drugs. 
The upper panel in Figure 1.5 shows that the impact of changes in hepatic metabolic 
clearance on hepatic extraction ratio depends on the degree of plasma protein binding. 
The relationship is almost linear for highly protein-bound drugs (fuB <0.01); however, as 
fuB values increase above 0.01 there is a progressive departure from near-linearity and a 
progressive move towards a plateau, at which point the hepatic extraction ratio is 
relatively constant (i.e., roughly equal to hepatic blood flow) over a wide range of CLuint 
values (from 900 to 9,000 L/h, which is 10 to 100 times hepatic flow).   
The lower panel of Figure 1.5 shows that the impact of changes in plasma protein binding 
on hepatic extraction ratio depends on intrinsic clearance. For low clearance drugs (when 
CLuint is less than hepatic blood flow [90 L/h]), there is a near-linear relationship between 
EH and fuB; however, as CLuint values increase and exceed hepatic blood flow there is a 
progressive departure from near-linearity and a progressive move towards a plateau, at 
which point the hepatic extraction ratio is relatively constant (i.e., roughly equal to hepatic 
blood flow) over a wide range of fuB values (from 0.1 to 1.0). Based on in vitro studies 
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with perfused rat liver, propranolol (blue), diazepam (green), phenytoin (purple) and 
tolbutamide (gray) are reasonably well represented by the colored lines in the lower panel 
of Figure 1.5 (Shand et al., 1976; Schary and Rowland, 1983; Rowland et al., 1984; Jones 
et al., 1985). For a low extraction drug administered intravenously, a second drug that 
competes for plasma protein binding (a displacer) can increase tissue uptake and hepatic 
clearance, which decreases total blood levels with no discernible change in fuB (the 
increase in unbound fraction is transient). For a high extraction drug administered 
intravenously, a displacer can potentially increase fuB (with no change in total drug 
concentration) because the increase in unbound drug does not increase hepatic 
clearance, which is blood-flow limited (Benet and Hoener, 2002; Rowland and Tozer, 
2011). 
Hepatically cleared drugs are classified as low extraction (EH <0.3), medium extraction 
(EH 0.3-0.7), and high extraction (EH >0.7). Examples are given in Table 1.4, which shows 
that in all three categories of hepatic extraction ratio (low, medium and high), there are 
drugs in all categories of plasma protein binding, from very highly protein-bound drugs 
(fuB <0.01) to very poorly bound drugs (fuB > 0.5). From Table 1.4 and Figure 1.5 it is 
apparent that categorizing drugs on the basis of hepatic extraction ratio is not based on 
CLuint alone or fuB alone but is based on a combination of both these parameters. These 
two parameters are normally determined in separate in vitro experiments. However, a 
single measurement of in vitro intrinsic clearance in the presence of plasma or serum can 
potentially provide information on in vivo hepatic extraction ratio. 
From Equation 1.24 it is apparent that hepatic clearance is determined by both hepatic 
blood flow and hepatic extraction ratio. Some drugs alter hepatic blood flow and this can 
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alter the clearance of intermediate and high extraction drugs. For example, the β-blockers 
metoprolol and propranolol, which decrease cardiac output and, hence, hepatic blood 
flow, decrease the hepatic clearance of lidocaine (Conrad et al., 1983).  
The binding of drugs to plasma proteins and erythrocytes restricts their hepatic uptake 
and clearance, for which reason IVIVE is generally based on the unbound drug fraction 
in blood (fuB), which is determined from Equation 1.15 based on measurements of fuP, 
the binding of drug to plasma, and Rb, the blood-to-plasma concentration ratio. The 
restriction on hepatic clearance imposed by the binding of drugs to plasma proteins and 
erythrocytes can be appreciated from the data in Table 1.6, which estimates the in vivo 
hepatic clearance of the high-turnover substrates that are commonly used to measure 
P450 activity in vitro. The estimates of hepatic clearance shown in Table 1.6 are NOT 
corrected for in vitro binding to microsomes or in vivo binding to blood. In many cases, 
the estimated in vivo hepatic clearance exceeds hepatic flow (sometimes by two orders 
of magnitude) and yet many of these drugs are cleared in vivo at rates that are well below 
hepatic blood flow. Midazolam serves as a good example. 
The in vivo parameters for midazolam (Rawden et al., 2005; Hallifax et al., 2010) are as 
follows: 
 Blood-to-plasma concentration ratio (Rb) = 0.55 
 Unbound drug in plasma (fuP) = 0.031 
 Unbound drug in blood (fuB) = fuP/Rb = 0.0564  
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Plasma clearance with iv dosing (CLP) = 5.30 – 6.16 mL/min/kg = 22.3 - 25.9 L/h 
(average 24.1 L/h) 
Blood clearance with iv dosing (CLB) = CLP/Rb = = ~43.8 L/h 
The in vivo blood clearance of intravenously administered midazolam, which is largely 
dependent on hepatic metabolism, is ~44 L/h, which is about 50% of hepatic blood flow 
(EH = 0.5). However, without correction for the binding of midazolam to blood in vivo or 
human liver microsomes in vitro (fumic = 0.92 at 0.05 mg protein/mL based on logD7.4 = 
3.9), the in vivo hepatic clearance of midazolam predicted from in vitro studies of Vmax/Km 
with human liver microsomes is 2,700 L/h (Table 1.6), which is about 30 times hepatic 
blood flow. This ~61-fold difference between predicted and observed in vivo clearance is 
largely attributable to the extensive binding (~94.4%) of midazolam to blood (fuB = 
0.0564). The actual in vivo clearance of midazolam predicted from the Vmax/Km data in 
Table 1.6 and an expanded version of Equation 1.25 is as follows: 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  
𝑄𝑄𝐻𝐻 ∙ 𝑓𝑓𝑑𝑑𝐵𝐵 ∙
𝐶𝐶𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖
𝑓𝑓𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚  
𝑄𝑄𝐻𝐻 + 𝑓𝑓𝑑𝑑𝐵𝐵 ∙
𝐶𝐶𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖
𝑓𝑓𝑑𝑑𝑚𝑚𝑖𝑖𝑚𝑚
 
 
Equation 1.26 
 𝐶𝐶𝐶𝐶𝐻𝐻 =  
90 𝐶𝐶/ℎ ∙ 0.0564 ∙ 2700 𝐶𝐶/ℎ0.92  
90 𝐶𝐶/ℎ + 0.0564 ∙ 2700 𝐶𝐶/ℎ0.92
 = ~58.3 𝐶𝐶/ℎ 
 
 
When corrected for both microsomal and blood binding, the in vivo hepatic clearance of 
midazolam predicted from Vmax/Km measurements in human liver microsomes (∼58 L/h) 
is slightly greater than the actual in vivo blood clearance (∼44 L/h). The over-prediction of 
in vivo clearance from in vitro data is the exception rather than the rule. In fact, several 
groups have reported that estimates of drug clearance based on in vitro measurements 
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of Vmax/Km or in vitro half-life systematically underestimate in vivo rates of hepatic 
clearance in humans, reasons for which are discussed in the next section. 
1.7. The underprediction of in vivo hepatic intrinsic clearance (CLH) 
This section examines why measurements of in vitro clearance with human liver 
microsomes or hepatocytes, when corrected for drug binding to the test system in vitro 
and to blood in vivo, systematically underpredict in vivo hepatic metabolic clearance 
(CLH). Based on a review of several databases, Chiba et al. (2009) reported that, on 
average, human liver microsomes underpredict in vivo clearance by a factor of 9 and 
hepatocytes underpredict by a factor of 3-6. However, for high clearance drugs, 
hepatocytes tend to underpredict to a greater extent than microsomes (Lu et al., 2006; 
Hallifax et al., 2010). 
Several studies have compared predictions of hepatic clearance in vivo from in vitro 
studies with human liver microsomes and hepatocytes (Hallifax et al., 2005; Riley et al., 
2005; Lu et al., 2006; Brown et al., 2007b; Hallifax et al., 2010; Foster et al., 2011). For 
drugs whose clearance is determined by P450-dependent metabolism, these two in vitro 
systems would be expected to provide similar estimates of in vivo clearance even if that 
estimate was an underprediction of in vivo clearance. The agreement between 
microsomes and hepatocytes is quite good except for drugs with high intrinsic metabolic 
clearance, in which case hepatocytes underpredict in vivo clearance more so than 
microsomes. These comparisons are based on experiments with hepatocytes and 
microsomes prepared from different human livers. Foster et al. (2011) measured the 
intrinsic clearance of several drugs (all of them cleared predominantly by P450-dependent 
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metabolism, with the possible exception of diclofenac, which is also directly 
glucuronidated [Kumar et al. (2002)]) in hepatocytes and microsomes prepared from the 
same four individuals. Intrinsic clearance was measured based on in vitro half-life or 
Vmax/Km for the major metabolite(s) formed by cytochrome P450. Data for just three drugs 
are shown in Table 1.5 and Figure 1.6. In the case of tolbutamide, an anionic drug 
metabolized primarily by CYP2C9, human liver microsomes and hepatocytes supported 
comparable rates of intrinsic clearance (within a factor of three). In the case of bufuralol, 
a basic drug metabolized primarily by CYP2D6, hepatocytes supported higher rates of 
clearance than microsomes (by a factor of 3.1 to 12 fold) whereas in the case of 
midazolam, a neutral drug metabolized by CYP3A4, microsomes supported higher rates 
of clearance than hepatocytes (by a factor of 5.6 to 41 fold). For drugs with low-to-medium 
intrinsic clearance (namely tolbutamide, bufuralol, alprenolol and triazolam), clearance in 
hepatocytes was equal to or greater than clearance in microsomes. In contrast, for drugs 
with high intrinsic clearance (namely midazolam, nifedipine and diclofenac), clearance in 
hepatocytes was less than that in microsomes. Foster et al. (2011) observed that, when 
scaled to whole liver, measurements of intrinsic clearance in hepatocytes over- or 
underpredicted intrinsic clearance in microsomes by a factor that was dependent on 
intrinsic clearance: hepatocytes overpredicted microsomal clearance by 1.5 fold for low 
intrinsic clearance drugs (<40 L/h), underpredicted clearance by 1.5 fold for medium 
intrinsic clearance drugs (40-400 L/h), and underpredicted clearance by fourfold for high 
intrinsic clearance drugs (>400 L/h). The authors derived the following equation to relate 
metabolic CLint determined with microsomes with metabolic CLint determined with 
hepatocytes. 
58 
 
 𝐸𝐸𝐸𝐸𝑑𝑑𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖,ℎ𝑒𝑒𝑒𝑒𝑚𝑚𝑖𝑖𝑙𝑙𝑚𝑚𝑒𝑒𝑖𝑖𝑒𝑒𝑃𝑃 = 0.582 ∙ 𝐸𝐸𝐸𝐸𝑑𝑑𝐶𝐶𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖,𝑚𝑚𝑖𝑖𝑚𝑚𝑚𝑚𝑙𝑙𝑃𝑃𝑙𝑙𝑚𝑚𝑒𝑒𝑃𝑃 + 0.435 Equation 1.27 
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Table 1.5. Comparison of in vitro intrinsic clearance (based on Vmax/Km) by 
microsomes and hepatocytes prepared from the same four human livers. 
Data are adapted from Foster et al. (2011). 
 
Vmax values are in units of nmol/min/g liver based on 40 mg microsomal protein/g liver and 120 
million hepatocytes/g liver. 
Km values are in units of μM based on the total concentration of drug. 
CLuint values are in units of L/h based on the unbound drug concentration.  The published values 
were in units of mL/min/kg based on Vmax/Km values corrected for fumic or fuhep and based on 21.4 
g liver/kg body weight (i.e., 1,500 g liver for 70 kg body weight).  They were converted to L/h 
based on an average body weight of 70 kg.  For comparative purposes, hepatic blood flow is 90 
L/h.   
Ratio calculation: (hepatocyte clearance/microsome clearance) 
The overall physiologically based scaling factors (PBSF) were 60,000 mg microsomal protein/liver 
for microsomes (based on 40 mg microsomal protein/g liver and an average liver weight of 1,500 
g) and 180,000 million hepatocytes/liver for hepatocytes (based on 120 million cells/g liver and 
an average liver weight of 1,500 g). These values differ slightly from those in Table 1.3 (66,000 
and 198,000, respectively, which are based on an average liver weight of 1,650 g)     
Test System 
CYP2C9 
(Tolbutamide 4’-hydroxylation) 
CYP2D6 
(Bufuralol 1’-Hydroxylation) 
CYP3A4 
(Midazolam 1’-hydroxylation) 
Vmax Km CLuint Ratio Vmax Km CLuint Ratio Vmax Km CLuint Ratio 
Microsome 0408 
Hepatocyte 0408 
14.3 
4.20 
252 
46.6 
5.75 
15.2 2.6 
3.65 
10.2 
14.3 
9.71 
31.6 
138 4.4 
48.0 
15.9 
2.87 
10.1 
2190 
171 0.078 
Microsome 8053 
Hepatocyte 8053 
14.9 
15.2 
90.6 
129 
15.2 
8.40 0.55 
3.50 
9.85 
6.75 
8.15 
54.2 
168 3.1 
66.6 
5.19 
4.80 
8.76 
1860 
44.9 0.024 
Microsome 8040 
Hepatocyte 8040 
18.1 
5.00 
166 
67.4 
12.8 
9.41 0.74 
1.05 
3.88 
91.1 
36.6 
0.991 
11.6 12 
162 
30.1 
3.54 
4.05 
6090 
827 0.14 
Microsome 8043 
Hepatocyte 8043 
9.27 
3.53 
233 
65.8 
3.82 
10.3 2.7 
1.59 
6.99 
10.1 
6.53 
17.6 
187 11 
13.6 
4.04 
4.63 
6.44 
403 
72.2 0.18 
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Figure 1.6. Relationship between unbound intrinsic clearance (CLuint) in human 
hepatocytes and microsomes from the same four donors. 
The hepatocyte and microsome values of CLuint for CYP2D6 (bufuralol 1´-hydroxylation), 
CYP2C9 (tolbutamide 4-hydroxylation) and CYP3A4 (midazolam 1´-hydroxylation) are 
from Table 1.5. Data are adapted from Foster et al. (2011). 
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For P450-metabolized drugs, greater rates of clearance in hepatocytes compared with 
microsomes (as observed with the low-clearance drug bufuralol), might reflect the 
transporter-mediated uptake of drug into hepatocytes, the ability of hepatocytes to further 
metabolize (e.g., conjugate) metabolites that might otherwise inhibit the metabolism of 
the parent drug, or the greater stability of P450 enzymes in hepatocytes compared with 
NADPH-fortified microsomes (Zomorodi et al., 1995; Jones and Houston, 2004). On the 
other hand, lower rates of clearance in hepatocytes compared with microsomes (as 
observed with the high clearance drug midazolam) could occur if the uptake of the drug 
into hepatocytes limited its rate of metabolism by cytochrome P450 (Lu et al., 2006). 
However, if transporter-mediated uptake into hepatocytes promoted metabolism in the 
case of bufuralol or if slow hepatocyte uptake restricted metabolism in the case of 
midazolam, one would expect to see differences in apparent Km (i.e., a lower Km for 
bufuralol metabolism in hepatocytes relative to microsomes and a higher Km for 
midazolam metabolism in hepatocytes relative to microsomes). From Table 1.5 it is 
apparent that such differences in Km were not observed (even when Km values are based 
on the fraction of unbound drug). Based on an analysis of 10 P450 substrates, Brown et 
al., (2007b) reported that Km values in microsomes and hepatocytes are similar: on 
average, unbound Km values (ranging from 0.5 to 140 µM) were only 50% lower in human 
hepatocytes compared with human liver microsomes and no Km value for the same drug 
differed more than threefold between the two systems. Foster et al. (2011) proposed that 
the metabolism of midazolam (and other high intrinsic clearance drugs) in hepatocytes is 
restricted not by uptake but by the availability of cofactor (NADPH), which is present in 
great excess in microsomal incubations.   
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Equation 1.27 addresses the difference between the two in vitro test systems but it does 
not explain the important issue that, even for drugs known to be cleared predominantly 
by P450-dependent metabolism, studies with human liver microsomes and hepatocytes 
both systematically underpredict hepatic clearance in vivo (Chiba et al., 2009). Possible 
sources of error that might lead to a general underprediction of hepatic clearance in vivo 
are: 
1. The mathematical models of hepatic clearance are inadequate; 
2. The physiologically based scaling factors are too low;  
3. Values of fuB based on in vitro measurements of plasma protein binding (fuP) 
and the blood-to-plasma concentration ratio Rb) do not reflect the fraction of 
drug available for hepatic uptake; 
4. In vitro values of CLuint are erroneously low due to an overestimation of fumic or 
fuhep; 
5. In vitro values of CLuint are erroneously low because drug-metabolizing enzyme 
activities in vitro do not reflect those in vivo; 
6. The role of hepatic metabolism in hepatic clearance is overestimated because 
the rate-determining step in hepatic clearance is transporter-mediated hepatic 
uptake. 
Points 1 and 2. There are reports that, for high clearance drugs, the parallel-tube and 
dispersion models provide improved predictions of in vivo hepatic clearance over the well-
stirred model (Ito and Houston, 2004), but the general consensus appears to be that 
neither the IVIVE models nor the physiologically based scaling factors (PBSF) are largely 
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responsible for the systematic underprediction of CLH in vivo (Hallifax et al., 2010). From 
Equation 1.19, it is apparent that the extrapolation of in vitro CLint to in vivo CLH is 
dependent on three variables: hepatic blood flow (QH), the fraction of unbound drug in 
blood (fuB) and CLU,int, intrinsic clearance corrected for the in vitro binding of drug to 
microsomes (fumic) or hepatocytes (fuhep). (Equation 1.19 is for the well-stirred model but 
the following arguments are applicable to the parallel tube and dispersion models of 
hepatic clearance). Although hepatic blood flow can vary (and can affect the hepatic 
extraction of high clearance [flow-limited] drugs), there is no reason to suspect that drugs 
can be delivered to the liver at four to five times greater than 90L/h, the accepted value 
of QH. 
Point 3. In the case of fuB, hepatic clearance will be underpredicted if the amount of drug 
available for hepatic uptake is greater than the unbound fraction in blood. Basing 
estimates of hepatic clearance on the unbound fraction of drug in blood can, in some 
cases, lead to underpredictions of in vivo clearance for reasons outlined in the preceding 
section, where it was noted that the amount of drug available for hepatic uptake can 
exceed the fraction unbound in blood if the dissociation of the drug from its binding sites, 
such as albumin, is sufficiently rapid relative to blood transit time through the liver that 
unbound drug lost to hepatic uptake is replenished (under so-called sink conditions). 
Baker and Parton (2007) reported that, for most plasma protein-bound drugs, koff is not 
low enough (<1 s-1) to limit their hepatic extraction. Chao et al. (2010) suggested that, 
especially for drugs highly bound to plasma proteins, measurement of koff (the first-order 
rate of dissociation of the protein-drug complex) would likely provide a better indicator of 
the amount of drug available for hepatic uptake than measurements of the unbound 
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fraction of drug in plasma or blood at equilibrium (which is determined by koff/kon). 
Accordingly, they proposed extrapolating in vitro clearance to in vivo clearance based on 
koff and hepatic residence time (tp) as follows: 
 𝐸𝐸𝐸𝐸 𝑣𝑣𝐸𝐸𝑣𝑣𝐸𝐸 𝐶𝐶𝐶𝐶 =
𝐸𝐸𝐸𝐸 𝑣𝑣𝐸𝐸𝐸𝐸𝑟𝑟𝐸𝐸 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
1 + � 1𝑘𝑘𝑙𝑙𝑓𝑓𝑓𝑓 ∙ 𝐸𝐸𝑒𝑒
�
  
Equation 1.28 
An alternative to measuring the rate of dissociation of plasma protein-drug complexes 
(koff) involves performing in vitro measurements of intrinsic clearance in the presence of 
plasma or serum to achieve in vitro the same concentration of unbound drug (with the 
same koff  rate) as that present in vivo (Skaggs et al., 2006; Lu et al., 2007; Kazmi et al., 
2009; Mao et al., 2012). This approach can improve estimates of in vivo hepatic 
clearance, which suggests that, in some cases, an extrapolation of in vitro clearance 
based on fuB does lead to an underestimation of in vivo clearance.  
Prompted by the possibility that values of fuP underestimate the amount of drug in plasma 
that is available for hepatic uptake and clearance, Berezhkovskiy (2011) and Poulin et al. 
(2012) proposed replacing fuP with fuP-app or fuliver, respectively, to improve predictions of 
in vivo clearance of those drugs that are highly bound to plasma proteins.  The apparent 
unbound drug concentration in plasma (fuP-app) proposed by Berezhkovskiy is based on 
a pH difference between plasma (pH 7.4) and intracellular water (pH 7.0), which alters 
the degree of ionization of basic and acidic drugs. The ratio of the fraction of neutral 
(unionized) drug in plasma (fnplasma) to that in hepatocytes (fnliver), termed, FI, is determined 
not only by the pH difference between plasma and hepatocytes but also by the pKa values 
of the ionizable groups on the acidic and basic drugs, as shown below: 
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 𝑓𝑓𝑑𝑑𝑚𝑚𝑒𝑒𝑒𝑒  =  𝑓𝑓𝑑𝑑𝑙𝑙 ∙ 𝑃𝑃𝐼𝐼   =  𝑓𝑓𝑑𝑑𝑙𝑙 ∙
𝑓𝑓𝑒𝑒𝑙𝑙𝑚𝑚𝑃𝑃𝑚𝑚𝑚𝑚𝑖𝑖
𝑓𝑓𝑙𝑙𝑖𝑖𝑙𝑙𝑒𝑒𝑚𝑚𝑖𝑖
 Equation 1.29 
where 
 𝑃𝑃𝐸𝐸𝑟𝑟 𝐸𝐸𝑐𝑐𝐸𝐸𝑑𝑑𝐸𝐸𝑐𝑐 𝑑𝑑𝑟𝑟𝑑𝑑𝑑𝑑𝑚𝑚:        𝑓𝑓𝑖𝑖  =  
1
1 + 10𝑒𝑒𝐻𝐻−𝑒𝑒𝑝𝑝𝑚𝑚
 Equation 1.30 
 
 𝑃𝑃𝐸𝐸𝑟𝑟 𝑖𝑖𝐸𝐸𝑚𝑚𝐸𝐸𝑐𝑐 𝑑𝑑𝑟𝑟𝑑𝑑𝑑𝑑𝑚𝑚:       𝑓𝑓𝑖𝑖  =  
1
1 + 10𝑒𝑒𝑝𝑝𝑚𝑚−𝑒𝑒𝐻𝐻
 Equation 1.31 
 
Poulin et al. (2012) advanced Berezhkovskiy’s concept of fuP-app  by taking into account 
not only a difference in pH between plasma and liver but also a difference in the 
concentration of albumin. PLR, the plasma/liver protein (albumin) ratio, was used with fuP-
app  to derive fuliver  as follows: 
 𝑓𝑓𝑑𝑑𝑙𝑙𝑖𝑖𝑙𝑙𝑒𝑒𝑚𝑚 =
𝑃𝑃𝐶𝐶𝑅𝑅 ∙ 𝑓𝑓𝑑𝑑𝑙𝑙−𝑚𝑚𝑒𝑒𝑒𝑒
1 + �(𝑃𝑃𝐶𝐶𝑅𝑅 − 1) ∙ 𝑓𝑓𝑑𝑑𝑙𝑙−𝑚𝑚𝑒𝑒𝑒𝑒�
 Equation 1.32 
Poulin et al. (2012) estimated PLR to be 13.3. 
Berezhkovskiy (2011) and Poulin et al. (2012) both reported improved predictions of in 
vivo metabolic clearance based on an analysis of 21 and 25 drugs, respectively. Hallifax 
and Houston (2012) evaluated these methods with a larger database: 89 drugs tested in 
human hepatocytes and 64 tested in human liver microsomes (of which 46 were tested 
in both systems). Based on the conventional fuB method (Equation 1.22), estimates of in 
vitro clearance in microsomes and hepatocytes underpredicted in vivo clearance by 4.9- 
and 3.8-fold, respectively, and clearance of basic drugs was underpredicted to a slightly 
greater extent than clearance of acidic drugs. Correcting for ionization alone (applying 
Berezhkovskiy’s method) improved predictions of in vivo clearance for basic drugs (4.4 
66 
 
→ 2.0 fold underprediction with hepatocytes and 5.4 → 2.5 fold underprediction with 
microsomes) but worsened predictions for acidic drugs (3.4 → 8.0 fold underprediction 
with hepatocytes and 3.7 → 7.3 fold underprediction with microsomes). The worsening of 
predictions for acidic drugs by considering only the pH differential and drug ionization 
status (Berezhkovskiy’s method) was resolved by also taking into account the plasma-to-
liver albumin ratio (Poulin’s method). Applying Poulin’s method gave good predictions of 
in vivo clearance of basic drugs (4.4  → 2.0 fold underprediction with hepatocytes and 5.4 
→ 2.5 fold underprediction with microsomes) due the pH differential/ionization status, and 
it improved predictions for acidic drugs (5.4 fold underprediction → 1.3 fold overprediction 
with hepatocytes and 3.4 fold underprediction → 1.3 fold overprediction with 
microsomes). Berezhkovskiy’s method had no impact on predictions of in vivo clearance 
of neutral drugs whereas Poulin’s method improved predictions of in vivo clearance (2.7 
fold underprediction → 1.7 fold overprediction with hepatocytes and 5.0 → 1.5 fold 
underprediction with microsomes). 
The method of Poulin et al. (2012) improves predictions of in vivo clearance of basic, 
acidic and neutral drugs, which suggests differences between intracellular and 
extracellular pH together with a relatively high concentration of albumin in liver (7.5% of 
that in plasma based on a PLR of 13.3) are important determinants of in vivo clearance 
that are not represented in in vitro systems. A pH of 7.0 is the lower limit of reported 
values of intracellular pH, which range from 7.0 to 7.4 (reviewed in Hallifax and Houston 
(2012)). As acknowledged by Poulin and colleagues, the PLR value of 13.3 is not based 
on the intracellular concentration of albumin but based on the concentration of albumin in 
interstitial space, which was converted to a whole-liver-to-plasma ratio of 13.3 based on 
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the well-stirred model (which is of questionable relevance to large molecules like 
albumin). There is uncertainty, therefore, as to whether the intracellular-extracellular pH 
difference in human liver is as large as 0.4 units and whether a PLR of 13.3 actually 
represents the ratio of albumin in liver versus plasma. Furthermore, the pH difference 
and, hence, differences in ionization status become evident only after the drug dissociates 
from albumin and enters the hepatocyte.  The same applies to PLR; whether the 
concentration of albumin in the interstitial space differs from that in plasma, the drug must 
dissociate from albumin prior to its uptake into hepatocytes. These parameters, if not 
physiologically relevant to the hepatic uptake of drugs bound to plasma proteins, will 
mean the improvements in predicting in vivo clearance offered by Equation 1.29, Equation 
1.30, Equation 1.31, and Equation 1.32 are akin to an empirical correction factor, such as 
those proposed by several groups (Chiba et al., 2009; Foster et al., 2011). One reason 
for questioning the physiological relevance of the assumptions inherent in Equation 1.29, 
Equation 1.30, Equation 1.31, and Equation 1.32 is that they appear useful for improving 
predictions of drug clearance in humans but they are not required to accurately predict in 
vivo clearance of drugs in rats, which is discussed under “Points 5 and 6”. 
Point 4. Estimates of CLH in vivo would be generally underestimated from measurements 
of in vitro CLuint if the amount of unbound drug (fumic and fuhep) were systematically 
underestimated. On a case-by-basis, extensive non-specific binding of drugs to the 
reaction vessel does occur and is not accounted for in calculations of fumic and fuhep, but 
it would require drugs across all classes and at all concentrations to bind 75-80% to the 
glass or plastic reaction vessel in order to produce a systematic four- to fivefold 
underestimation of the concentration of unbound drug in vitro, which is not the case.  
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Points 5 and 6.  In 1999, Obach enumerated several assumptions inherent in the use of 
liver microsomes to measure CLint, one of which was that rates of metabolism and enzyme 
activities in vitro are truly reflective of those that exist in vivo. In the same paper, Obach 
also pointed out that “facilitated transport processes that could possibly be responsible 
for drug uptake or drug efflux from hepatocytes are not accounted for in in vitro studies 
with microsomes,” which applies equally well to recombinant enzymes and even 
hepatocytes depending on the experimental design.  The following discussion leads to 
two general conclusions:   
First, in the case of neutral and basic drugs, the reported underprediction of in vivo hepatic 
clearance based on measurements of metabolic CLuint with human liver microsomes or 
hepatocytes is often due to in vitro enzymes activities being lower than those in vivo.  
Second, in the case of acidic and zwitterionic drugs, the underprediction occurs partly 
because human liver microsomes and hepatocytes have low enzyme activity but, more 
importantly, because transporter-mediated uptake, not metabolic clearance, is the rate-
determining step in hepatic clearance in vivo.  
These conclusions are based on studies with liver microsomes and hepatocytes from 
rats. Ito and Houston (2004) and Jones and Houston (2004) reported some differences 
between predicted and observed in vivo drug clearance in rats but observed no 
systematic underprediction based on in vitro studies with rat liver microsomes (52 drugs) 
or rat hepatocytes (35 drugs) although the latter gave a narrower range of under- and 
overpredictions. In studies of 200 AstraZeneca drug candidates, Soars et al. (2007, 2009) 
observed no systematic underprediction of in vivo clearance for neutral and basic drugs 
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but observed systematic underprediction of acidic and zwitterionic drugs. In the latter 
case, in vivo clearance was correctly predicted when in vitro clearance was based on 
rates of hepatocyte uptake by the so-called ‘medium-loss’ assay. This assay, which can 
distinguish rates of hepatic uptake from rate of metabolic clearance, is discussed in 
Chapter 2 and used in Chapter 3.  
The finding that in vitro studies with rat liver microsomes and hepatocytes do not 
systematically underpredict in vivo metabolic clearance of neutral and basic drugs but in 
vitro studies with the corresponding human systems do suggests that the latter have 
impaired enzyme activities, which is a distinct possibility because rat microsomes and 
hepatocytes are prepared from fresh liver that is processed immediately whereas most 
samples of human liver microsomes and hepatocytes are prepared from donor livers that 
are removed and perfused with ice-cold medium (such as Belzer UW solution) after up to 
30-min cross-clamp time and are processed after many hours (up to 18 h) of 
transportation at 4°C (Parkinson et al., 2004). Human livers that are not perfused with 
Belzer UW solution are severely degraded (Parkinson et al., 2004); microsomes from 
such livers have little or no CYP1, CYP2 or CYP3 activities although they do exhibit CYP4 
enzyme activity perhaps because in this family of P450 enzyme the heme moiety is 
covalently attached to the apocytochrome (Ortiz de Montellano, 2008). The possibility that 
some studies of in vitro drug metabolism were performed with microsomes from partially 
degraded human livers is suggested by the finding that in vitro estimates of drug 
clearance show greater sample-to-sample variation than the inter-individual variation in 
in vivo clearance, a discordance that is not observed if the in vitro studies are performed 
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with liver biopsy (fresh) samples from the same study subjects (Thummel et al., 1994a; 
Thummel et al., 1994b).  
Differences in the extent of tissue degradation are probably a major contributor to inter-
laboratory differences in CLint values determined with human liver microsomes or 
hepatocytes (Riley et al., 2005). Such differences can be appreciated from the data for 
midazolam clearance in Table 1.5 and Table 1.6 and other published values. Based on 
measurements of Vmax and Km with pooled human liver microsomes, CLint for midazolam 
(based only the 1ʹ-hydroxylation pathway) was determined to be 693 µL/min/mg protein 
(Table 1.6) and, based on fumic of 0.92, CLuint was 753 µL/min/mg protein (see the end of 
the previous section). Based on the data in Table 1.5 for four samples of human liver 
microsomes (with matching hepatocyte samples), the values of CLuint for midazolam 
(again based on midazolam 1ʹ-hydroxylation) ranged from 112 to 1,691 µL/min/mg protein 
and averaged 732 µL/min/mg protein. (Note: the CLuint values shown in Table 1.5 are 
scaled values of CLuint so the values were divided by 40 mg microsomal protein/g liver 
and a liver weight of 1500 g [the same values used by Foster et al. (2011)]). In other 
words, the data in Table 1.5 and Table 1.6, which were determined with different 
commercial sources of human liver microsomes, gave comparable values of CLuint for 
midazolam. As shown at the end of the last section, such values of CLuint (i.e., 753 
µL/min/mg protein for pooled microsomes and 732 µL/min/mg protein for the average of 
four individual samples) slightly over-predict in vivo hepatic clearance. However, in a 
previous study of midazolam clearance by 9 samples of human liver microsomes (again 
based on Vmax/Km for midazolam 1ʹ-hydroxylation), the same laboratory reported CLuint 
values ranging from 8.2 to 159 µL/min/mg protein (Rawden et al., 2005). The average 
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value (53 µL/min/mg protein) is more than an order of magnitude lower than that reported 
with microsomal samples obtained from different sources and probably reflects sample 
degradation prior to tissue processing. It seems reasonable to assume that studies with 
microsomes and hepatocytes from partially degraded samples of human liver have 
contributed to the systematic 9-fold underprediction reported for microsomes and the 3- 
to 6-fold underpredictions reported for hepatocytes (Chiba et al., 2009). 
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Table 1.6. Estimates of in vivo clearance (CLH,int) from in vitro clearance values 
(CLint) determined from Vmax/Km for P450 marker substrates with human liver 
microsomes and their relationship to hepatic blood flow (QH) 
Enzyme Marker substrate and reaction 
Km 
(μM) 
Vmax 
(pmol/mg 
protein/min) 
CLint 
(µL/min/ 
mg 
protein) 
CLH,int 
(whole 
liver) 
(L/h) 
Fraction of 
hepatic 
blood flow 
(QH = 90 L/h) 
CYP1A2 Phenacetin  O-dealkylation 49 1140 23.3 92 1.0 
CYP2A6 Coumarin  7-hydroxylation 0.75 1780 2,370 9400 100 
CYP2B6 Bupropion hydroxylation 47 1350 28.7 110 1.3 
CYP2B6 Efavirenz  8-hydroxylation 4.0 250 62.5 250 2.8 
CYP2C8 
Amodiaquine  
N-dealkylation 1.6 4100 2,560 10000 110 
Paclitaxel  
6α-hydroxylation 9.9 650 65.7 260 2.9 
CYP2C9 Diclofenac  4´-hydroxylation 6.5 3240 499 2000 22 
CYP2C19 S-Mephenytoin  4´-hydroxylation 45 210 4.67 18 0.21 
CYP2D6 Dextromethorphan O-demethylation 8.9 297 33.4 130 1.5 
CYP2E1 Chlorzoxazone  6-hydroxylation a 24 1960 81.7 320 3.6 
CYP3A4/5 
Testosterone  
6β-hydroxylation b 53 5330 101 400 4.4 
Midazolam  
1´-hydroxylation 2.8 1940 693 2700 30 
Nifedipine  
oxidation 9.3 4960 533 2100 23 
Atorvastatin  
ortho-hydroxylation 42 810 19.3 76 0.85 
Human liver microsomes used are a mixed-gender pool of sixteen individual human liver microsomal 
samples. 
a The values for chlorzoxazone 6-hydroxylation represent the high affinity component only. 
b For testosterone 6β-hydroxylation, the Km column represents the S50 with a Hill coefficient of 1.4 and the 
CLint value represents: 
𝐶𝐶𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 =  
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
𝑆𝑆50
 ∙  
𝐸𝐸 − 1
𝐸𝐸(𝐸𝐸 − 1)
1
𝑖𝑖
 
All other values of CLint are based on Vmax/Km.  
𝐶𝐶𝐶𝐶𝐻𝐻,𝑖𝑖𝑖𝑖𝑖𝑖 =  𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 ∙ 𝑃𝑃𝑃𝑃𝑆𝑆𝑃𝑃(66,000) ∙ 60𝐸𝐸𝐸𝐸𝐸𝐸/ℎ ∙ 10−6 𝐶𝐶/µ𝐶𝐶 
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Tissue degradation might be part of the reason why, based on the studies reviewed by 
Chiba et al. (2009), in vitro studies with microsomes underpredict in vivo clearance to a 
greater extent than hepatocytes. Microsomes can be isolated from extensively degraded 
livers; viable hepatocytes cannot. Therefore, in vitro studies are more likely to be 
performed with low quality microsomes than low quality hepatocytes. However, there is 
another reason microsomes tend to underpredict the clearance of P450-metabolized drug 
more so than hepatocytes, namely enzyme stability and/or the accumulation of inhibitory 
metabolites during the in vitro incubation. In studies of in vitro half-life of triazolam, 
diazepam and clonazepam, Jones and Houston (2004) observed monoexponential loss 
of all three drugs and all concentrations of rat hepatocytes (0.5 x 106 to 4.0 x 106 cells/mL) 
but they observed biexponential loss of clonazepam at all concentrations of rat liver 
microsomes (0.1 - 5.0 mg/mL). When triazolam and diazepam were incubated with rat 
liver microsomes, monoexponential loss was observed at low protein concentrations (0.1 
– 1.0 mg/mL) whereas biexponential loss was observed at high protein concentrations (2 
and 5 mg/mL). Jones and Houston (2004) observed greater time-dependent loss of P450 
activity from NADPH-fortified microsomes compared with hepatocytes and the rate of loss 
in microsomes increased with increasing protein concentration (so much so that, after 45 
min, microsomes incubated at 5 mg protein/mL had less P450 activity than microsomes 
incubated at 0.5 mg protein/mL). The marked “spontaneous loss” of P450 activity in 
microsomes was observed during incubations in the presence of NADPH but in the 
absence of drug substrate (which was added at different times for a short incubation 
period to measure P450 activity). P450 activities spontaneously decline over time when 
human liver microsomes are incubated with NADPH in the absence of a drug substrate. 
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The loss varies from one P450 enzyme to the next and is slowed by the addition of organic 
solvent (such as those commonly used to add drug substrates). The differential loss of 
P450 activities, the greater loss observed with increasing protein concentration and the 
protective effect of organic solvents on the spontaneous loss of P450 activity over time 
make it difficult to develop a general formula for correcting in vitro metabolic rates for the 
spontaneous loss of P450 activity in liver microsomes. 
Although P450 enzymes are relatively unstable when microsomes are incubated at 37°C 
in the presence of NAPDH, all P450 activities are remarkably stable (for years) in human 
liver microsomes stored at -80°C and in cyropreserved hepatocytes stored in liquid 
nitrogen (Pearce et al., 1996a; Griffin and Houston, 2004; McGinnity et al., 2004). P450 
activities in microsomes are stable to repeated cycles of freezing-thawing and 
hepatocytes can be frozen and thawed through at least two cycles (although cells are lost 
at each cycle). Consequently, it is possible to prepare large pools of human liver 
microsomes (from 150 or 200 donors) and large pools of human hepatocytes (from up to 
100 donors). Although such pooled samples may have enzyme activities that are lower 
than the average in vivo activities, the in vitro activities are consistent from batch-to-batch; 
they are so large that replacing 5 or 10% of donors from one batch to the next has little 
impact on P450 activities. This consistency is advantageous especially if empirical scaling 
factors are developed and used to correct a general underprediction of in vivo clearance 
from in vitro data. 
Microsomes from human liver are often prepared from frozen tissue. A human liver 
typically weighs between one and two kilograms, which is difficult to process all at once. 
Freezing human liver causes no discernible harm to microsomal membranes but it does 
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rupture cells and organelles like mitochondria (Parkinson et al., 2004). In contrast to 
microsomes prepared from fresh liver, microsomes prepared from frozen liver are 
contaminated with membranes and proteins from other organelles, which is why, for 
example, liver microsomes from frozen liver have appreciable monoamine oxidase 
activity, an enzyme located in the outer mitochondria membrane. The additional protein 
associated with microsomes prepared from frozen liver decreases the specific activity of 
all microsomal enzyme activities (i.e., all P450, UGT and carboxylesterase activities) by 
about 30% (Pearce et al., 1996a). Accordingly, an argument could be made that CLuint 
values or the PBSF value for microsomes (66,000 mg microsomal protein/human liver) 
should be increased by 1.4 when in vitro studies of drug clearance are performed with 
liver microsomes prepared from frozen human liver. Such considerations are not an issue 
with hepatocytes, which can only be isolated from fresh (unfrozen) liver. 
In the case of intestinal microsomes, the method of tissue processing is critical. 
Microsomes prepared from intestinal scrapings have negligible P450 activity (less than 
5%) compared with microsomes prepared from enterocytes, which can be isolated by 
incubating intestinal tissue with EDTA-containing buffers (Zhang et al., 1999; Cotreau et 
al., 2000; Emoto et al., 2000). 
In certain cases, such as cytosolic aldehyde oxidase and microsomal UDP-
glucuronosyltransferase, there is good evidence that enzyme activities in vitro do not 
reflect those in vivo. Human aldehyde oxidase is a cytosolic molybdozyme involved in the 
oxidative metabolism of numerous heterocyclic aromatic amines (Pryde et al., 2010; 
Parkinson et al., 2013). Based on an analysis of 11 drugs known to be predominantly 
cleared in vivo by metabolism by aldehyde oxidase, including zaleplon, 6-
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deoxypenciclovir, zoniporide, O6-benzylgaunine, DACA and carbazeran, Zientek et al. 
(2010) reported that measurements of intrinsic clearance by post-mitochondrial (S9) 
fraction of human liver underpredicted in vivo clearance by an average of 11 fold (ranging 
from 0.7 to 52 fold). Predictions based on studies with human liver cytosol were slightly 
worse; they underpredicted in vivo clearance by ~15 fold; the difference possibly reflecting 
further loss of aldehyde oxidase activity during the 60-min ultracentrifugation step 
required to prepare cytosol from S9 fraction. 
For drugs that are primarily eliminated by glucuronidation, in vitro studies with rat or 
human liver microsomes incubated in conventional buffer systems greatly underpredict in 
vivo clearance (Mistry and Houston, 1987; Boase and Miners, 2002; Soars et al., 2002; 
Miners et al., 2006; Miners et al., 2010a). Rates of morphine, naloxone and 
buprenorphine glucuronidation by rat liver and intestinal microsomes follow the same rank 
order as in vivo rates of glucuronidation but in vitro rates of clearance underpredict in vivo 
clearance by 18-33 fold (Mistry and Houston, 1987). For 7 drugs whose in vivo 
glucuronidation accounted for at least 50% of total metabolic clearance, rates of 
glucuronidation by human liver, intestinal and kidney microsomes collectively 
underpredicted in vivo clearance by an order of magnitude or more (Boase and Miners, 
2002; Soars et al., 2002). In contrast, rates of glucuronidation of the same 7 drugs by 
fresh or cryopreserved human hepatocytes did not systematically underpredict in vivo 
clearance by glucuronidation (Soars et al., 2002; Miners et al., 2006). 
Regardless of which UGT enzyme is responsible for glucuronidating a drug, in vitro rates 
of glucuronidation by human liver microsomes increase in the presence of detergents 
(such as CHAPS or Brij58) or the pore-forming peptide alamethicin because these agents 
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increase enzyme access to the highly polar cofactor UDP-glucuronic acid (UDP-GlcUA) 
(Miners et al., 2010a). However, it was recently reported that UDP-GlcUA uptake in HLM 
is mediated by a specific transporter and this may have an impact on in vitro UGT-
mediated clearance (Rowland et al., 2015). In the case of UGT2B7 and UGT1A9, the 
presence of bovine serum albumin (BSA) increases activity by removing long-chain fatty 
acids (such as linoleic and arachidonic acid) that are released during the microsomal 
incubation and which competitively inhibit these two UGT enzymes (but not UGT1A1, 
UGT1A4 or UGT1A6) (Uchaipichat et al., 2006; Rowland et al., 2007; Rowland et al., 
2008a; Rowland et al., 2008c). This so-called “albumin effect” can be accomplished with 
intestinal fatty acid binding protein (IFABP), which also binds fatty acids that otherwise 
inhibit certain UGT enzymes (Rowland et al., 2009). For drugs that are glucuronidated by 
UGT2B7 and, to a lesser extent, by UGT1A9, alamethicin increases their clearance by 
increasing Vmax and BSA increases their clearance by lowering Km. Several groups have 
improved the prediction of in vivo rates of glucuronidation by conducting studies with 
human liver, intestinal and kidney microsomes in the presence of both alamethicin and 
BSA (Kilford et al., 2009; Miners et al., 2010a; Gill et al., 2012; Wattanachai et al., 2012). 
The benefit of adding BSA to improve the intrinsic clearance of glucuronidated drugs is 
restricted to certain UGT enzymes (UGT2B7 and UGT1A9) and is restricted to 
microsomal preparations. Soars et al. (2002) demonstrated that adding BSA to rat 
hepatocytes does not enhance drug glucuronidation; in fact, it markedly decreases (by 
an order of magnitude) the glucuronidation of acidic drugs (drugs that bind extensively to 
albumin). 
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CYP2C8 and CYP2C9 play a role in the metabolism of fatty acids and their derivatives 
(Parkinson et al., 2013). It is interesting that the addition of BSA to human liver 
microsomes lowers the Km of CYP2C8 for paclitaxel (Wattanachai et al., 2011) and the 
Km of CYP2C9 for phenytoin and tolbutamide (Ludden et al., 1997; Carlile et al., 1999; 
Tang et al., 2002; Rowland et al., 2008a; Kilford et al., 2009). BSA also decreases the Km 
of CYP1A2 for phenacetin (Wattanachai et al., 2012). These results suggest that, for 
certain P450 and UGT enzymes, in vitro clearance by liver microsomes underestimates 
in vivo clearance because of the presence of inhibitory fatty acids, a phenomenon that 
appears not to occur in hepatocytes. The possibility that fatty acids competitively inhibit 
CYP2C9 and CYP2C8 in human liver microsomes is of interest because these enzymes 
metabolize small and large acidic drugs, respectively; the same drugs that bind 
extensively to albumin. Inhibition of CYP2C9 and CYP2C8 by fatty acids may be a factor 
in the general underprediction of in vivo clearance of highly protein-bound drugs although 
such underprediction would be relevant to microsomes and not hepatocytes. 
Loss of enzyme activity during the procurement, shipping and processing of human 
organs and tissues, the spontaneous loss of microsomal P450 activities during prolonged 
incubations, the presence of inhibitory fatty acids in microsomal membranes, the 
contamination of microsomes prepared from frozen livers with proteins from other 
organelles, and cofactor insufficiency in hepatocytes all appear to play a role in the 
systematic underprediction of in vivo clearance by human liver microsomes and 
hepatocytes. However, for some drugs, notably acidic and zwitterionic drugs, systematic 
underprediction of in vivo clearance stems in large part from the role of drug transporters 
in hepatic uptake and clearance. 
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1.8. Mechanisms of P450 and UGT inhibition 
The inhibition of P450 and UGT enzymes can be mechanistically divided into two types: 
reversible inhibition (a.k.a. direct inhibition) or irreversible inhibition (a.k.a. time- or 
metabolism-dependent inhibition). Generally, only direct inhibition is known to occur with 
UGT enzymes, whereas both direct, time- or metabolism-dependent inhibition can occur 
with P450. Reversible or direct inhibition refers to immediate P450 or UGT inhibition; in 
other words it occurs as soon as the drug binds to the P450 or UGT enzyme (which is on 
the order of milliseconds) and without the need for biotransformation. For example, 
quinidine and ketoconazole are direct, reversible inhibitors of CYP2D6 and CYP3A4, 
respectively (Ching et al., 1995; Boxenbaum, 1999; Ogilvie et al., 2008). Direct inhibition 
can be further divided into two categories: competition between two drugs that are 
metabolized by the same enzyme and competition between two drugs only one of which 
is a substrate for the enzyme. The first scenario is exemplified by the interaction between 
omeprazole and diazepam, both substrates of CYP2C19. When co-administered, 
omeprazole decreases the clearance and prolongs the half-life of diazepam due to the 
competition for metabolism by CYP2C19, which does not occur in CYP2C19 poor 
metabolizers (PMs) (Andersson et al., 1990; Andersson et al., 1994; Ogilvie et al., 2008). 
Incidentally, it has been recently discovered that omeprazole is also a metabolism-
dependent inhibitor of CYP2C19, and prolonged administration of omeprazole leads to 
partial inactivation of CYP2C19 (Ogilvie et al., 2011). A good example of the second 
category of direct inhibition is the interaction between the antitussive agent 
dextromethorphan and quinidine. Dextromethorphan is metabolized by CYP2D6 to its O-
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demethylated metabolite dextrorphan, and this metabolism is impaired in those 
individuals with a CYP2D6 PM genotype. CYP2D6 extensive-metabolizers (EMs) also 
have impaired dextromethorphan metabolism when administered quinidine (a 48-fold 
increase in dextromethorphan AUC), which is a potent inhibitor of CYP2D6 (unbound Ki 
< 1 nM) but is metabolized by CYP3A4 (Nielsen et al., 1999; Margolis and Obach, 2003; 
Pope et al., 2004; Ogilvie et al., 2008). Direct inhibition of P450 enzymes can occur 
through four mechanisms: competitive inhibition, noncompetitive inhibition, mixed 
inhibition and uncompetitive inhibition. Competitive inhibition occurs when an inhibitor and 
substrate compete for binding to the same active site of an enzyme, which results in no 
change in the maximal rate of the enzyme (Vmax) but results in a decrease in the affinity 
of the substrate towards the enzyme (as reflected in an increase in Km). Noncompetitive 
inhibition is when the inhibitor binds to an allosteric site on the enzyme that is not at the 
substrate active site and results in a decrease in Vmax and an unaltered Km. In 
noncompetitive inhibition the inhibitor binds the enzyme and the enzyme-substrate 
complex with equal affinity; and it is thought to be a special case of mixed inhibition (Barr 
and Jones, 2011). Uncompetitive inhibition is characterized by stabilization of the 
enzyme-substrate complex through binding of an inhibitor either at the substrate active 
site or at an allosteric site (after binding of the substrate), ultimately resulting in a decrease 
in Vmax and an decrease in Km (this is because binding of the inhibitor to the enzyme-
substrate complex, which normally exists in equilibrium with the enzyme and substrate, 
shifts the equilibrium to replace the inhibited complex, leading to an increase in substrate 
binding to the enzyme until a new equilibrium is established with enzyme-substrate and 
enzyme-substrate-inhibitor complexes). Lastly, mixed inhibition (also known as 
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competitive-noncompetitive inhibition) is characterized by inhibitor binding to the 
substrate active site as well as an allosteric site on the enzyme, or inhibitor binding to the 
substrate active site without blocking substrate binding and as a result will cause a 
decrease in Vmax and an increase in Km (Ogilvie et al., 2008). For direct inhibition the 
kinetics as well as the affinity with which an inhibitor binds to the enzyme is often 
described by the Ki value (dissociation constant for the enzyme-inhibitor complex) as 
shown in Figure 1.7. 
The second type of P450 inhibition is time-dependent (metabolism-dependent) inhibition 
that can occur through five mechanisms: (1) slow on-rate inhibition which is a reversible 
process, meaning inhibition becomes more potent over time without metabolism, an 
example of which is inhibition of CYP19 (aromatase) by 19-azido-androstenedione 
(Wright et al., 1991); (2) non-enzymatic conversion of a drug to an inhibitory product that 
may occur with unstable compounds such as rabeprazole or some acyl glucuronides (Li 
and Benet, 2003; Li et al., 2004); (3) the conversion of a parent drug to a metabolite that 
is a more potent direct-acting (reversible) inhibitor than the parent, which occurs for the 
drug buproprion whose metabolites erythro-hydrobupropion and threo-hydrobupropion 
are more potent direct-acting inhibitors of CYP2D6 than bupropion itself (Reese et al., 
2008; Parkinson et al., 2010); or (4) the biotransformation of a drug to a metabolite that 
coordinates with the ferrous heme iron in P450 enzymes (i.e. quasi-irreversible inhibition 
of CYP3A4 by troleandomycin) or (5) biotransformation to a reactive metabolite that 
covalently modifies the P450 apoprotein or heme moiety and abolishes enzyme activity 
(i.e. irreversible inhibition of CYP3A4 by mibefradil) (Ogilvie et al., 2008; Foti et al., 2011). 
The fourth and fifth mechanisms are common in metabolism-dependent inhibition. In the 
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literature, the terms time-dependent, metabolism-dependent and mechanism-based 
inhibition are often used interchangeably. However, there are subtle differences between 
each of these terms. Time-dependent inhibition (TDI) refers to a decrease in enzymatic 
activity that increases over time but is not dependent on biotransformation (such that it 
occurs even in the absence of NADPH). The term metabolism-dependent inhibition (MDI) 
refers to the NADPH-dependent loss of enzymatic activity over time, and includes 
inhibition by the formation of more potent direct-acting metabolites, quasi-irreversible 
inhibition and irreversible inhibition. Lastly, mechanism-based inhibition (MBI) refers 
strictly to quasi-irreversible and irreversible inhibition of P450 enzymes (Silverman, 1995; 
Ogilvie et al., 2008). The parameters often generated in these studies are the maximal 
rate of enzyme inactivation (Kinact) and potency of inactivation (KI) as described in Figure 
1.7. 
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Figure 1.7. Current paradigm for performing in vitro P450 and UGT inhibition 
studies 
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The above figure depicts the typical types of experiments performed for the assessment 
of UGT inhibition (direct inhibition) and P450 inhibition (direct and metabolism-dependent 
inhibition [MDI]). 
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1.9. Regulatory perspective on P450 and UGT inhibition 
The FDA and EMA have adopted conservative approaches (summarized in Table 1.7) to 
the interpretation of in vitro P450 and UGT inhibition data because there is typically 
ambiguity regarding the drug concentration at the P450 or UGT active site and the extent 
of first-pass drug metabolism (pre-systemic clearance) (Ogilvie et al., 2008; FDA, 2012; 
EMA, 2013). Furthermore, experimentally determined Ki values for direct inhibition may 
vary with incubation conditions due to factors such as membrane partitioning of the 
inhibitor. The FDA basic static model of predicting the potential for drug interactions by a 
drug from Ki values and some measure of the in vivo concentrations of the drug is as 
follows (Bjornsson et al., 2003): 
 𝐴𝐴𝐴𝐴𝐶𝐶𝑅𝑅 =
𝐴𝐴𝐴𝐴𝐶𝐶𝑖𝑖
𝐴𝐴𝐴𝐴𝐶𝐶𝑢𝑢𝑖𝑖
= 1 +
[𝐼𝐼]
𝐾𝐾𝑖𝑖
 Equation 1.33 
Where AUCR is the plasma area-under-the-curve (AUC) ratio of AUCi (the plasma AUC 
in the presence of inhibitor [the inhibited AUC]) and AUCui (the plasma AUC in the 
absence of inhibitor [the uninhibited AUC]), [I] is the mean plasma Cmax value at steady 
state for total drug (i.e. bound plus unbound) and Ki is the in vitro inhibition constant based 
on unbound drug. As shown in Figure 1.8, the use of the above equation allows for 
predictions of clinical interactions (the theoretical curve is shown in Figure 1.8) (Ito et al., 
2004; Brown et al., 2006; Obach et al., 2006). The FDA criteria for likely clinically 
significant P450 inhibition is [I]/Ki > 1.1 (or [I]/Ki > 11 for drugs that are orally dosed CYP3A 
inhibitors to account for intestinal metabolism; where [I] = [I]gut = molar dose/250 mL 
(Zhang et al., 2008)) (FDA, 2012). The EMA guidance recommends cutoff criteria of [I]/Ki 
> 0.02 (or [I]/Ki > 10 for orally administered CYP3A4 inhibitors; where [I] = [I]gut as 
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described above) where both the parameters [I] and Ki are based on unbound 
concentration of drug (EMA, 2013). Should a drug candidate fail the basic model criteria, 
both the FDA and EMA recommend the use of mechanistic static models that incorporate 
parameters such as the effect of direct and metabolism-dependent inhibition, P450 
induction, and intestinal and hepatic metabolism to yield a net AUC ratio (AUCR) which 
must be within the regulatory range for bioequivalence (80% to 125% of AUC) to avoid a 
clinical study (Fahmi et al., 2009; FDA, 2012; EMA, 2013). There is precedent in the 
literature for the use of these models in the prediction of UGT mediated DDIs (Miners et 
al., 2010g). Other models also exist and have been embraced by the regulatory agencies, 
such as dynamic modeling and physiologically based pharmacokinetic (PBPK) modeling, 
however the initial assessment of clinically relevant in vitro P450 inhibition by new drug 
candidates is typically tested with the basic static model as described above. With respect 
to metabolism-dependent inhibition (MDI) both the FDA and EMA also recommend a 
basic static model which is as follows (Bjornsson et al., 2003; Grimm et al., 2009): 
 
𝐴𝐴𝐴𝐴𝐶𝐶𝑖𝑖
𝐴𝐴𝐴𝐴𝐶𝐶𝑢𝑢𝑖𝑖
 =
(𝐾𝐾𝑙𝑙𝑏𝑏𝑃𝑃 + 𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙)
𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙
 𝑓𝑓ℎ𝑟𝑟𝑟𝑟𝑟𝑟 𝐾𝐾𝑙𝑙𝑏𝑏𝑃𝑃 =  
𝐾𝐾𝑖𝑖𝑖𝑖𝑚𝑚𝑚𝑚𝑖𝑖  × [𝐼𝐼]
(𝐾𝐾𝐼𝐼 + [𝐼𝐼])
 Equation 1.34 
With Kobs representing the apparent inactivation rate constant, Kdeg is the apparent first 
order degradation constant for the given enzyme, Kinact is the maximal inactivation rate 
constant, and KI representing the apparent inactivation constant (it is important to note 
that KI is distinct from Ki with the latter term representing the direct inhibition constant). 
Contrary to the basic static model for direct inhibition, the FDA recommends using the 
total (i.e. bound and unbound) values for KI which was been shown to vary based on 
nonspecific binding of the drug (Tran et al., 2002; Margolis and Obach, 2003; Parkinson 
et al., 2011; FDA, 2012). The inhibitor concentration [I] in this case is the total drug 
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concentration based on the FDA guidance, and the free drug concentration (i.e. unbound) 
based on the EMA guidance. The basis for these models stems from regulatory agency 
concern regarding the possibility of in vitro false negatives (see Figure 1.8) from a public 
safety perspective and has shown this possibility with a review of several new drug 
applications (NDAs), in some of which the in vitro evaluation grossly under-predicted the 
in vivo interaction (Davit et al., 1999; Yao et al., 2001; Ogilvie et al., 2006; Ogilvie et al., 
2008). Drug candidates examined for their potential to inhibit P450 and UGT enzymes in 
vitro may inhibit multiple P450/UGT enzymes, and the various models allow for the rank 
order across different P450/UGT enzymes for the same drug helping to prioritize clinical 
drug-drug interaction evaluations. 
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Table 1.7. FDA and EMA models for the prediction of clinically significant P450 
and UGT inhibition 
Model FDA EMA 
Basic static 
(direct) 1 + 
[𝐼𝐼]
𝐾𝐾𝑖𝑖,𝑢𝑢
 = 𝑅𝑅 
[I] = total Cmax ss; Ki,u = unbound Ki value; R > 
1.1 
For CYP3A inhibitors given orally: 
[I] = [I]gut = molar dose/250 mL; R > 11 
1 + 
[𝐼𝐼]𝑢𝑢
𝐾𝐾𝑖𝑖,𝑢𝑢
 = 𝑅𝑅 
[I]u = unbound Cmax ss; Ki,u = unbound Ki value; 
R ≥ 0.02 
For CYP3A inhibitors given orally: 
[I] = [I]gut = molar dose/250 mL; R ≥ 10 
Basic static 
(MDI) 
(𝐾𝐾𝑙𝑙𝑏𝑏𝑃𝑃 + 𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙)
𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙
𝑊𝑊ℎ𝑟𝑟𝑟𝑟𝑟𝑟   𝐾𝐾𝑙𝑙𝑏𝑏𝑃𝑃  =
𝐾𝐾𝑖𝑖𝑖𝑖𝑚𝑚𝑚𝑚𝑖𝑖 × [𝐼𝐼]
(𝐾𝐾𝐼𝐼 + [𝐼𝐼])
= 𝑅𝑅 
Kobs = apparent inactivation rate constant 
Kdeg = apparent first order degradation 
constant for a given enzyme 
Kinact = maximal inactivation rate constant 
KI = apparent inactivation constant 
[I] = total Cmax ss; R > 1.1  
(𝐾𝐾𝑙𝑙𝑏𝑏𝑃𝑃 + 𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙)
𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙
𝑊𝑊ℎ𝑟𝑟𝑟𝑟𝑟𝑟   𝐾𝐾𝑙𝑙𝑏𝑏𝑃𝑃  =
𝐾𝐾𝑖𝑖𝑖𝑖𝑚𝑚𝑚𝑚𝑖𝑖 × [𝐼𝐼]
(𝐾𝐾𝐼𝐼 + [𝐼𝐼])
= 𝑅𝑅 
Kobs = apparent inactivation rate constant 
Kdeg = apparent first order degradation 
constant for a given enzyme 
Kinact = maximal inactivation rate constant 
KI = apparent inactivation constant 
[I] = unbound Cmax ss; R > 1.25 
Mechanistic 
static 𝐴𝐴𝐴𝐴𝐶𝐶𝑅𝑅 =  �
1
[𝐴𝐴ℎ × 𝑃𝑃ℎ × 𝐶𝐶ℎ]  × 𝑓𝑓𝑚𝑚  ×  (1 − 𝑓𝑓𝑚𝑚)
�  ×  �
1
�𝐴𝐴𝑙𝑙 × 𝑃𝑃𝑙𝑙 × 𝐶𝐶𝑙𝑙�  × �1 − 𝑃𝑃𝑙𝑙� +  𝑃𝑃𝑙𝑙
� 
Where 
𝐴𝐴ℎ =
𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙,ℎ 
𝐾𝐾𝐵𝐵𝑒𝑒𝑙𝑙,ℎ +  
[𝐼𝐼]ℎ × 𝐾𝐾𝑖𝑖𝑖𝑖𝑚𝑚𝑚𝑚𝑖𝑖
[𝐼𝐼]ℎ + 𝐾𝐾𝐼𝐼
                    𝑃𝑃ℎ  = 1 +  
𝑑𝑑 × 𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 × [𝐼𝐼]ℎ 
[𝐼𝐼]ℎ + 𝐸𝐸𝐶𝐶50
                    𝐶𝐶ℎ =  
1
1 + [𝐼𝐼]ℎ𝐾𝐾𝑖𝑖
 
A, B, and C denote MDI, induction, and direct inhibition, respectively. The subscript h and g 
denote hepatic and gut contributions, respectively (note the equations that define A, B, and C 
are identical for liver and gut). AUCR is the net AUC ratio. Fg = fraction available after gut 
metabolism, fm = fraction of systemic clearance of the substrate mediated by the P450 enzyme 
that is subject to inhibition/induction. 
[I]h = fu,b x ([I]max,b+Fa x Ka x Dose/Qh); [I]g = Fa x Ka x Dose/Qen 
Fu,b is fraction unbound in blood, [I]max,b is maximal total (free and bound) inhibitor at steady 
state; Fa is fraction absorbed after oral administration; Ka is first order absorption constant, Qh 
and Qen are blood flow through the liver and enterocytes, respectively. 
If AUCR > 1.25 (inhibition) or AUCR < 0.8 (induction) 
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Figure 1.8. Theoretical prediction of drug-drug interactions involving P450 and 
UGT inhibition on the basis of inhibitory potency 
Based on the equation 
𝐴𝐴𝐴𝐴𝐶𝐶𝑖𝑖
𝐴𝐴𝐴𝐴𝐶𝐶𝑢𝑢𝑖𝑖
= 1 +
[𝐼𝐼]
𝐾𝐾𝑖𝑖
 
Where AUCi is the inhibited area under the curve (AUC), AUCui is the uninhibited AUC, 
[I] is the mean plasma Cmax value at steady state for total drug (i.e. bound plus unbound) 
and Ki is the in vitro inhibition constant based on unbound drug. 
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1.10. Statement of purpose 
As described in Chapter 1 (Background and Introduction), the in vitro-to-in vivo (IVIVE) 
extrapolation of drug clearance and DDI potential are influenced by many factors, 
including intrinsic factors such as limitations within a given in vitro test system or extrinsic 
factors such as incubation conditions. In vitro studies with liver microsomes and 
hepatocytes have both been reported to underpredict the in vivo clearance of drugs 
(Chiba et al., 2009); however, the underprediction is much greater with high CLint drugs 
when the in vitro studies are performed with hepatocytes compared with liver microsomes 
(Lu et al., 2006; Hallifax et al., 2010). Of particular note is the curious case of midazolam, 
a high CLint substrate of CYP3A4/5, where its clearance is underpredicted by hepatocytes 
to a greater extent than liver microsomes. Other researchers have proposed possible 
explanations for this system-dependent clearance that include membrane permeability or 
cofactor limitations (Lu et al., 2006; Foster et al., 2011). The primary purpose of this 
research was to elucidate the mechanism underlying the test system-dependent 
clearance of midazolam and to determine if the restricted clearance of midazolam in 
hepatocytes versus microsomes was a property of other P450 enzymes and other 
CYP3A4/5 substrates, particularly other high CLint substrates of CYP3A4/5. I 
hypothesized that neither membrane permeability nor cofactor availability limited the 
clearance of midazolam by hepatocytes, but rather an extrinsic factor such as incubation 
conditions (such as ionic strength and buffer/medium composition) was the underlying 
cause of the system-dependent clearance of midazolam. During the course of this 
research, studies with the CYP3A4/5 substrate loratadine identified the ability of 
hepatocytes to form not just desloratadine but also 3-hydroxydesloratadine. Despite 
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extensive investigations (Ghosal et al., 2009) the enzyme responsible for converting 
desloratadine to 3-hydroxydesloratadine, its major metabolite in humans, has not be 
identified, in part because no in vitro test system has been shown to catalyze this reaction. 
Having identified the reaction in human hepatocytes for the first time, I conducted a series 
of experiments that lead to the identification the enzyme responsible for converting 
desloratadine to 3-hydroxydesloratadine, which involves a highly unusual mechanism. 
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CHAPTER 2 : MATERIALS AND METHODS 
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Chemicals and Reagents 
1-Aminobenzotriazole, alamethicin, atorvastatin, β-NADPH, chenodeoxycholic acid 
(CDCA), chlorzoxazone, coumarin, desloratadine, dextromethorphan, estradiol 
furafylline, gemfibrozil, hecogenin, ketoconazole, morphine, mibefradil, midazolam, 1-
naphthol, nicotine, nifedipine, oxazepam, paclitaxel, paroxetine, phencyclidine, propofol, 
quinidine, repaglinide, saccharic acid 1,4-lactone, saponin, testosterone, tolbutamide, 
trifluoperazine, verapamil and Waymouth’s medium were purchased from Sigma-Aldrich 
(St. Louis, MO); levomedetomidine was a gift from Orion Corporation (Espoo, Finland); 
Dulbecco’s modified Eagle medium (DMEM) + HEPES was purchased from Gibco (Grand 
Island, NY); Krebs-Henseleit buffer (KHB) and modified Chee’s medium with ITS 
supplement were prepared in house at XenoTech LLC (Lenexa, KS); cerivastatin, 
CYP3cide, esomeprazole, and gemfibrozil glucuronide were purchased from Toronto 
Research Chemicals (Toronto, ON, Canada); montelukast was purchased from Sequoia 
Research Products (Pangbourne, UK); tienilic acid was purchased from Cypex (Dundee, 
Scotland, UK); alfentanil, amodiaquine and troleandomycin were purchased from US 
Pharmacopeia (Rockville, MD); 3-hydroxydesloratadine and clopidogrel glucuronide were 
purchased from Santa Cruz Biotechnology (Dallas, TX); 3-hydroxydesloratadine 
glucuronide, 5-hydroxydesloratadine, 6-hydroxydesloratadine were purchased from TLC 
PharmaChem (Vaughan, ON, Canada); 3-hydroxydesloratadine-d4 was purchased from 
Medical Isotopes, Inc. (Pelham, NH). Testosterone 17-O-glucuronide-d5, oxazepam N-
glucuronide-d5, and prochlorperazine glucuronide were prepared in-house at XenoTech 
LLC (Lenexa, KS). Morphine 3-glucuronide-d3 was purchased from Cerilliant (Round 
Rock, TX). All other deuterated glucuronides were purchased from Toronto Research 
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Chemicals (Toronto, ON, Canada). The sources of all other reagents have been 
described previously (Ogilvie et al., 2006; Parkinson et al., 2011; Kazmi et al., 2014a).  
 
Test system   
Pooled human liver microsomes (HLM, n = 16 or 200, mixed gender), pooled human liver 
S9 fraction (HS9, n = 200, mixed gender) and pooled suspended cryopreserved human 
hepatocytes (CHH, n = 50 or 100, mixed gender) or individual donor CHH (see Table 2.2 
for donor information) were prepared from non-transplantable livers and characterized at 
XenoTech, LLC (Lenexa, KS) as described previously (Pearce et al., 1996c; Parkinson 
et al., 2004). Hepatocytes from Sprague-Dawley rat (male, n = 4), Beagle dog (male, n = 
3), CD1 mouse (male, n = 7), Rhesus monkey (male, n = 3), New Zealand white rabbit 
(male, n = 3) and Gottingen minipig (male, n = 3) were prepared and characterized at 
XenoTech, LLC (Lenexa, KS) as described previously. Recombinant enzymes were 
purchased from Corning (Woburn, MA) or Cypex (Dundee, Scotland, UK). 
 
In vitro hepatocyte clearance determinations 
The in vitro hepatic clearance of dextromethorphan and midazolam was assessed with 
cryopreserved human hepatocytes (CHH) at 1 million cells/mL. Briefly dextromethorphan, 
midazolam, alfentanil, nifedipine and verapamil were incubated with CHH in 160-μL 
incubations at 37°C with 95% humidity and 5% CO2 in KHB medium at 1 μM (and plasma 
Cmax for dextromethorphan [0.014 μM] and midazolam [0.34 μM]) for zero, 10, 20, 30, 60, 
90 and 120 min (midazolam and dextromethorphan) or 0, 30, 60, 90, 120, 150, 180 and 
240 min (for all other substrates). Reactions were initiated with the addition of CHH. At 
each time point reactions were quenched with the addition of an equal volume of 
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acetonitrile containing internal standard (shown in Table 2.3). Precipitated protein was 
removed by centrifugation (10 min at 920 RCF). The supernatant fraction was analyzed 
by liquid chromatography tandem mass spectrometry (LC-MS/MS) to monitor 
dextromethorphan and midazolam disappearance. 
 
In vitro microsome clearance and kinetic determinations 
The in vitro clearance of midazolam, dextromethorphan, alfentanil, nifedipine, and 
verapamil was also assessed in pooled HLM (n = 200) at a protein concentration of 0.33 
mg/mL, which is equivalent to the concentration of microsomes in hepatocytes at 1 million 
cells/mL (Hakooz et al., 2006; Sohlenius-Sternbeck, 2006; Barter et al., 2007). Briefly, 1 
μM midazolam, dextromethorphan, alfentanil, nifedipine or verapamil were incubated for 
1-8 min (midazolam),15-60 min (dextromethorphan), or 5-120 min (all other substrates), 
respectively. with NADPH-fortified HLM at 37°C in 200- μL incubation mixtures containing 
pooled HLM (0.33 mg/mL), potassium phosphate buffer (50 mM, pH 7.4), MgCl2 (3 mM), 
EDTA (1 mM, pH 7.4), and an NADPH-generating system (consisting of 1 mM NADP, 5 
mM glucose 6-phosphate, and 1 unit/mL glucose-6-phosphate dehydrogenase). 
Reactions were initiated by the addition of an NADPH-generating system and quenched 
with the addition of an equal volume of acetonitrile containing the appropriate internal 
standard, followed by precipitation of protein and LC-MS/MS analysis.  
 
The kinetic parameters, Km and Vmax, were determined in HLM (pooled HLM, n = 16) for 
midazolam 1ʹ-hydroxylation and dextromethorphan O-demethylation. Briefly midazolam 
(0.5, 1, 2.5, 5, 10, 15, 20, and 40 μM) and dextromethorphan (0.5, 1, 2.5, 5, 10, 20, 50 
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and 100 μM) were incubated for 10 min at 37°C in 200-μL incubation mixtures containing 
pooled HLM (0.1 mg/mL), potassium phosphate buffer (50 mM, pH 7.4), MgCl2 (3 mM), 
EDTA (1 mM, pH 7.4), and an NADPH-generating system (consisting of 1 mM NADP, 5 
mM glucose 6-phosphate, and 1 unit/mL glucose-6-phosphate dehydrogenase). 
Reactions were initiated by the addition of an NADPH-generating system and terminated 
by the addition of 200 μL of acetonitrile containing the appropriate internal standard. 
Precipitated protein was removed by centrifugation (920 RCF for 10 min at 10°C) followed 
by LC-MS/MS analysis as described below. 
 
Isolation of microsomes from cryopreserved human hepatocytes and assessment 
of CYP2D6 and CYP3A4 activity 
Microsomes were prepared from pooled cryopreserved human hepatocytes (n = 50) as 
described previously (Pearce et al., 1996c; Parkinson et al., 2004). Briefly, cryopreserved 
human hepatocytes were thawed and sonicated for 40 sec with homogenization buffer 
(50 mM Tris-HCl at pH 7.4 containing 150 mM KCl and 2 mM EDTA). Homogenate was 
then centrifuged at ~7000g for 20 min at 4°C. The supernatant fraction was subjected to 
further centrifugation at ~100,000g for 60 min at 4°C. The microsomal pellet was 
resuspended and washed with buffer (150 mM KCl and 10 mM EDTA at pH 7.4). The 
washed pellet was then re-isolated by centrifugation at ~100,000g for 60 min at 4°C. The 
final pellet was resuspended in 250 mM sucrose and protein concentration was 
determined with a Pierce BCA assay (Pierce Chemical, Rockford, IL). CYP3A4 and 
CYP2D6 activity in microsomes isolated from pooled hepatocytes was compared with a 
standard preparation of pooled HLM (both at 0.1 mg/mL) with midazolam and 
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dextromethorphan at 1 μM and Vmax (40 and 75 μM, respectively). Reactions were 
initiated by the addition of an NADPH-generating system and terminated by the addition 
of an equal volume of acetonitrile containing the appropriate internal standard. 
Precipitated protein was removed by centrifugation (920 RCF for 10 min at 10°C) followed 
by LC-MS/MS analysis as described below. 
 
In vitro metabolism of midazolam in hepatocytes with membrane permeabilization 
and cofactor supplementation 
The in vitro metabolism of midazolam was assessed with pooled CHH (n = 50) at 1 million 
cells/mL in KHB. Briefly, midazolam (1 μM) was incubated for zero, 15, 30, 60, 90 and 
120 min at 37°C (95% humidity and 5% CO2). To determine the effect of cofactor 
supplementation or membrane permeability on midazolam metabolism, the following 
treatments were performed: (A) intact cells (control), (B) intact cells + exogenous NADPH 
(0.1 mM), (C) cells disrupted by sonication for 60 sec, (D) cells sonicated for 60 sec + 
exogenous NADPH (0.1 mM), (E) cells treated with saponin (0.01 % saponin, w/v) for 5 
min, and (F) cells treated with 0.01% saponin for 5 min + exogenous NADPH (0.1 mM). 
At the end of each incubated time, the reaction was quenched with the addition of an 
equal volume of acetonitrile containing internal standard (d4-1ʹ-hydroxymidazolam). 
Precipitated protein was removed by centrifugation (920 RCF for 10 min at 10°C) followed 
by LC-MS/MS analysis to determine the rate of midazolam disappearance and the rate 
of formation of 1ʹ-hydroxymidazolam (the major metabolite formed by CYP3A4/5) as 
described below. 
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Whole system and media loss of midazolam in CHH 
The contribution of midazolam metabolism and hepatocellular uptake was assessed by 
comparing the whole system loss of midazolam (which reflects metabolism) versus 
medium loss (which reflects metabolism and cell uptake) (Soars et al., 2007). Briefly, 1 
μM midazolam was incubated with pooled CHH (1 million cells/mL) in KHB at 37°C for 
zero, 0.5, 1, 2, 4, 6, 10, 15, 30, 45, 60, 90 and 120 min. Reactions were initiated with the 
addition of CHH. For the assessment of whole system loss, reactions were stopped at 
each time point with the addition of an equal volume of acetonitrile containing internal 
standard. For the assessment of medium loss, at the end of each incubation period, 
samples were transferred to Eppendorf tubes (Fisher Scientific, Pittsburgh, PA) and 
rapidly centrifuged (5 sec) followed by transfer of the supernatant fraction to an equal 
volume of stop reagent (acetonitrile containing internal standard). Precipitated protein 
was removed by centrifugation (920 RCF for 10 min at 10°C) followed by LC-MS/MS 
analysis. 
 
Assessment of midazolam N-glucuronide as an inhibitor of CYP3A4/5 activity 
Midazolam N-glucuronide was evaluated in an IC50 shift experiment with and without a 
preincubation step as described previously (Parkinson et al., 2011). Briefly, midazolam 
N-glucuronide was incubated at 0.2, 0.6, 2, 6, 20, 60, and 200 μM (for midazolam) or 0.1, 
0.3, 1, 3, 10, 30 and 100 μM (for nifedipine) in 200-μL incubation mixtures containing 
pooled HLM (≤ 0.1 mg/mL), potassium phosphate buffer (50 mM, pH 7.4), MgCl2 (3 mM), 
EDTA (1 mM, pH 7.4), an NADPH-generating system (consisting of 1 mM NADP, 5 mM 
glucose 6-phosphate, and 1 unit/mL glucose-6-phosphate dehydrogenase), for zero or 
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30 min at 37°C followed by the addition of midazolam (4 μM) or nifedipine (10 μM) and 
an additional 5 min incubation. An equal volume of acetonitrile containing the appropriate 
internal standard was added to terminate the reactions, followed by protein precipitation 
and LC/MS-MS analysis. 
 
The effect of buffer ionic strength and cell culture media on P450 activity in human 
liver microsomes 
CYP1A2 (phenacetin O-dealkylation), CYP2A6 (coumarin 7-hydroxylation), CYP2B6 
(bupropion hydroxylation), CYP2C8 (amodiaquine N-dealkylation), CYP2C9 (diclofenac 
4′-hydroxylation), CYP2C19 (S-mephenytoin 4′-hydroxylation), CYP2D6 
(dextromethorphan O-demethylation), CYP2E1 (chlorzoxazone 6-hydroxylation) and 
CYP3A4/5 activity (midazolam 1′-hydroxylation, midazolam 4-hydroxylation, nifedipine 
oxidation, alfentanil N-dealkylation, verapamil N-dealkylation, testosterone 6β-
hydroxylation, and atorvastatin ortho-hydroxylation) in human liver microsomes was 
assessed in 5, 50 and 200 mM potassium phosphate buffer) as well as commonly used 
cell culture media (KHB, MCM+, Waymouth’s, DMEM+HEPES and Williams’ E + HEPES) 
or their salts only versions (see Table 2.1). Briefly, phenacetin (40 μM), coumarin (5 μM), 
bupropion (50 μM), amodiaquine (7 μM), diclofenac (6 μM), S-mephenytoin (40 μM), 
dextromethorphan (7.5 μM), chlorzoxazone (30 μM), midazolam (4 μM), nifedipine (10 
μM), alfentanil (40 μM), verapamil (9 μM), testosterone (70 μM) or atorvastatin (40 μM) 
was incubated at 37°C for 5 min with 0.1 mg/mL human liver microsomes (n = 200) [or 
0.25 mg/mL human liver S9 fraction; n = 200] at three (5, 20 and 200 mM) of 
concentrations of phosphate buffer (each containing 3 mM MgCl2 and 1 mM EDTA at pH 
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7.4) or in different cell culture media. Reactions were initiated with an NADPH 
regenerating system (5 mM glucose 6-phosphate, 1U/mL glucose 6-phoshphate 
dehydrogenase, and 1 mM NADP) and stopped after 5 min with an equal volume of stop 
reagent (acetonitrile with internal standard). The samples were processed and analyzed 
by LC/MS/MS as described previously (Parkinson et al., 2011) 
 
The effect of cell culture media on P450 activity in CHH 
CYP1A2 (phenacetin O-dealkylation), CYP2B6 (bupropion hydroxylation), CYP2C8 
(amodiaquine N-dealkylation), CYP2C9 (tolbutamide hydroxylation), CYP2C19 (S-
mephenytoin 4′-hydroxylation), CYP2D6 (dextromethorphan O-demethylation), and 
CYP3A4/5 activity (midazolam 1′-hydroxylation, midazolam 4-hydroxylation, nifedipine 
oxidation, alfentanil oxidative N-dealkylation, verapamil N-dealkylation, testosterone 6β-
hydroxylation and atorvastatin ortho-hydroxylation) in cryopreserved human hepatocytes 
was assessed in commonly used cell culture media (KHB, MCM+, Waymouth’s, 
DMEM+HEPES and Williams’ E + HEPES). Briefly, phenacetin (40 μM), bupropion (50 
μM), amodiaquine (2 μM), tolbutamide (150 μM), S-mephenytoin (40 μM), 
dextromethorphan (7.5 μM), midazolam (4 μM), nifedipine (10 μM), alfentanil (40 μM), 
verapamil (9 μM), testosterone (70 μM) or atorvastatin (40 μM) was incubated at 37°C at 
95% relative humidity and 5% CO2 for 10-60 min with 1 million cells/mL cryopreserved 
human hepatocytes (n = 50) in different cell culture media. Reactions were initiated in 48 
well plates with the addition of hepatocytes (total incubation volume of 160 μL per well) 
and stopped with an equal volume of stop reagent (acetonitrile with internal standard). 
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The samples were processed and analyzed by LC/MS/MS as described previously 
(Parkinson et al., 2011). 
 
The effect of cell culture media on CHH viability over time 
The viability of CHH (1 million cells/mL) in KHB, Waymouth's, MCM+, DMEM + HEPES 
and Williams’ E + HEPES was assessed in 160-μL incubations at 37°C, 95% humidity 
and 5% CO2 on an orbital shaker (~150 rpm) for zero, 30, 60, 120, and 240 min. At each 
time point, 50 μL was removed for cell viability assessment by trypan blue exclusion (Life 
Technologies, Carlsbad, CA) as described previously (Strober, 2001). 
 
The kinetics of midazolam and chlorzoxazone metabolism in HLM with various cell 
culture media 
The kinetic parameters, Km and Vmax, were determined in HLM (pooled HLM, n = 200) for 
midazolam 1ʹ-hydroxylation and chlorzoxazone 6-hydroxylation in the presence of various 
cell culture media. Briefly midazolam (0.5, 1, 2, 4, 6, 10, 20, and 30 μM) and 
chlorzoxazone (5, 10, 20, 30, 60, 100, 150, and 250 μM) were incubated for 5 min at 37°C 
in 200-μL incubation mixtures containing pooled HLM (0.1 mg/mL), potassium phosphate 
buffer (50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM, pH 7.4); or cell culture media (KHB, 
Waymouth's, MCM+, DMEM + HEPES and Williams’ E + HEPES), and an NADPH-
generating system (consisting of 1 mM NADP, 5 mM glucose 6-phosphate, and 1 unit/mL 
glucose-6-phosphate dehydrogenase). Reactions were initiated by the addition of an 
NADPH-generating system and terminated by the addition of 200 μL of acetonitrile 
containing the appropriate internal standard. Precipitated protein was removed by 
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centrifugation (920 RCF for 10 min at 10°C) followed by LC-MS/MS analysis as described 
below. 
 
The effect of buffer ionic strength and cell culture media on rCYP3A4 and rCYP3A5 
activity 
Human recombinant CYP3A4 and CYP3A5 Bactosomes® (Cypex, Dundee, Scotland, 
UK) with or without cytochrome b5 were tested for their ability to form midazolam 1′-
hydroxylation and midazolam 4-hydroxylation with different cell culture media. Briefly, 4 
μM midazolam was incubated in 200-μL incubation mixtures containing recombinant 
enzyme (20 pmol/mL), potassium phosphate buffer (50, or 200 mM, pH 7.4), MgCl2 (3 
mM), EDTA (1 mM, pH 7.4); or cell culture media (KHB, Waymouth’s, MCM+, DMEM + 
HEPES or Williams’ E + HEPES), an NADPH-generating system (consisting of 1 mM 
NADP, 5 mM glucose 6-phosphate, and 1 unit/mL glucose-6-phosphate dehydrogenase) 
for 5 min at 37°C. An equal volume of acetonitrile containing internal standard was added 
to terminate the reactions, followed by protein precipitation and LC-MS/MS analysis. 
 
The effect of cell culture media on midazolam metabolism by HLM lacking CYP3A5 
activity 
HLM from an individual lacking CYP3A5 (CYP3A5*3/*3; H0204 prepared at XenoTech, 
LLC, Lenexa, KS) were tested for their ability to form midazolam 1′-hydroxylation and 
midazolam 4-hydroxylation with different cell culture media. Briefly, 4 μM midazolam was 
incubated in 200-μL incubation mixtures containing HLM (0.1 mg/mL), potassium 
phosphate buffer (50, pH 7.4), MgCl2 (3 mM), EDTA (1 mM, pH 7.4); or cell culture media 
103 
 
(KHB, Waymouth’s, MCM+, DMEM + HEPES or Williams’ E + HEPES), an NADPH-
generating system (consisting of 1 mM NADP, 5 mM glucose 6-phosphate, and 1 unit/mL 
glucose-6-phosphate dehydrogenase) for 5 min at 37°C. An equal volume of acetonitrile 
containing internal standard was added to terminate the reactions, followed by protein 
precipitation and LC-MS/MS analysis. 
 
Loratadine metabolism in CHH with various cell culture media 
The CYP3A4/5 mediated formation of desloratadine from loratadine was assessed with 
pooled CHH in the presence of various cell culture media. Briefly, 10 μM loratadine was 
incubated at 37°C at 95% relative humidity and 5% CO2 for 60 min with pooled CHH (n = 
50, 1 million cells/mL) in the presence of KHB, Waymouth’s, MCM+, DMEM + HEPES or 
Williams’ E + HEPES cell culture media. Reactions were initiated in 48 well plates with 
the addition of hepatocytes (total incubation volume of 160 μL per well) and stopped with 
an equal volume of stop reagent (acetonitrile with internal standard). The samples were 
processed and analyzed by LC/MS/MS as described below. 
 
In vitro incubations of desloratadine with HLM, HS9 and CHH 
Desloratadine was incubated with HLM, HS9 and CHH to determine if any of these in vitro 
test systems would support the formation of 3-hydroxydesloratadine. Briefly, 1 or 10 μM 
desloratadine was incubated at 37°C in 200-μL incubation mixtures containing pooled 
HLM (0.1 or 1 mg/mL) or HS9 (0.5 or 5 mg/mL), potassium phosphate buffer (50 mM, pH 
7.4), MgCl2 (3 mM), EDTA (1 mM, pH 7.4), an NADPH-generating system (consisting of 
1 mM NADP, 5 mM glucose 6-phosphate, and 1 unit/mL glucose-6-phosphate 
dehydrogenase) for zero, 0.5, 1, 2, and 4 h. For assays with pooled CHH (n = 50), 
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desloratadine incubations were conducted at 37°C with 95% humidity and 5% CO2 on an 
orbital shaker (~150 rpm) in 160-μL incubation mixtures containing pooled CHH (1 million 
cells/mL) and Williams’ E media supplemented with 2 mM glutaMAX (Gibco, Grand 
Island, NY) and 0.1 mM HEPES. Reactions were initiated by the addition of an NADPH-
generating system (for HLM and HS9) or hepatocytes (for CHH assays) and terminated 
by the addition of 200 μL (160 μL for CHH assays) of acetonitrile containing 
3-hydroxydesloratadine-d4 as an internal standard. Precipitated protein was removed by 
centrifugation (920 RCF for 10 min at 10°C) followed by LC-MS/MS analysis as described 
below. 
 
Km and Vmax determination of 3-hydroxydesloratadine formation in CHH 
Desloratadine was incubated at 0.1, 0.2, 0.5, 1, 2, 5, 10, 20 and 30 μM in 160-μL 
incubation mixtures containing pooled CHH (n = 100; 1 million cells/mL) and Williams’ E 
media supplemented with 2 mM glutaMAX (Gibco, Grand Island, NY) and 0.1 mM 
HEPES. Reactions were initiated with the addition of hepatocytes and conducted for 2 h 
at 37°C with 95% humidity and 5% CO2 on an orbital shaker (~150 rpm). An equal volume 
of acetonitrile containing 3-hydroxydesloratadine-d4 as an internal standard was added to 
terminate the reactions, followed by protein precipitation and LC-MS/MS analysis. 
 
Assessment of 3-hydroxydesloratadine formation in animal hepatocytes 
Hepatocytes from rat, dog, mouse, monkey, rabbit, minipig and human (n = 100) were 
assessed for their ability to form 3-hydroxydesloratadine. Briefly, 1 or 10 μM desloratadine 
was incubated in 160-μL incubation mixtures containing pooled hepatocytes (1 million 
cells/mL) and Williams’ E media supplemented with 2 mM glutaMAX (Gibco, Grand 
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Island, NY) and 0.1 mM HEPES. Reactions were initiated with the addition of hepatocytes 
and conducted for 2 h at 37°C with 95% humidity and 5% CO2 on an orbital shaker (~150 
rpm). An equal volume of acetonitrile containing internal standard was added to terminate 
the reactions, followed by protein precipitation and LC-MS/MS analysis. 
 
Recombinant P450 assessment of 3-hydroxydesloratadine formation 
Human recombinant P450 enzymes, namely CYP1A1, CYP1A2, CYP1B1, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2J2, 
CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4F2 Bactosomes® (Cypex, Dundee, 
Scotland, UK); and CYP4F3a, CYP4F3b, CYP4F12, FMO1, FMO3 and FMO5 
Supersomes® (Corning, Woburn, MA) were tested for their ability to form 3-
hydroxydesloratadine. Briefly, 1 or 10 μM desloratadine was incubated in 200-μL 
incubation mixtures containing recombinant enzyme (50 pmol/mL) potassium phosphate 
buffer (50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM, pH 7.4), an NADPH-generating 
system (consisting of 1 mM NADP, 5 mM glucose 6-phosphate, and 1 unit/mL glucose-
6-phosphate dehydrogenase) for 1 h at 37°C. An additional time course experiment was 
conducted with rCYP2C8 (both Bactosomes® and Supersomes®) at 1, 2, 4 and 6 h. An 
equal volume of acetonitrile containing internal standard was added to terminate the 
reactions, followed by protein precipitation and LC-MS/MS analysis. 
 
Chemical inhibition of 3-hydroxydesloratadine formation in CHH 
P450 involvement was assessed using a chemical inhibition approach as described 
previously (Kazmi et al., 2014d). Briefly, pooled CHH (n = 100) at 1 million cells/mL were 
pre-incubated with P450 inhibitors for 30 min (2 h for the strong CYP2C8 inhibitor panel) 
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at 37°C on an orbital shaker (~150 rpm) with 95% humidity and 5% CO2 in 120-μL 
incubation mixtures containing CHH and Williams’ E media supplemented with 2 mM 
glutaMAX (Gibco, Grand Island, NY) and 0.1 mM HEPES. The chemical P450 inhibitors 
used were furafylline (10 μM), phencyclidine (10 μM), gemfibrozil (100 μM), gemfibrozil 
glucuronide (100 μM), montelukast (50 μM), clopidogrel glucuronide (100 μM), 
repaglinide (100 μM), cerivastatin (100 μM), tienilic acid (20 μM), esomeprazole (10 μM), 
paroxetine (1 μM), quinidine (5 μM), mibefradil (1 μM), CYP3cide (2.5 μM), 
troleandomycin (50 μM), ketoconazole (4 μM), and 1-aminobenzotriazole (1 mM). 
Following pre-incubation, 40 μL of desloratadine dissolved in Williams’ E media was 
added to yield a final concentration of 10 μM and the incubation was continued for 2 h; 
or, for those samples pre-incubated with CYP2C8 inhibitors, additional incubations with 
amodiaquine (10 μM) and paclitaxel (10 μM) were conducted for 10 and 30 min 
respectively. Reactions were terminated by the addition of an equal volume of acetonitrile 
containing internal standard, followed by protein precipitation and LC-MS/MS analysis. 
 
Correlation analysis of CHH with a range of CYP2C8 activities 
Individual donor CHH that were pre-characterized with a range of CYP2C8 activities were 
assessed for 3-hydroxydesloratadine formation. Briefly, nine individual lots of 
hepatocytes (Table 2.2) were incubated at 1 million cells/mL with 1 or 10 μM  
desloratadine, amodiaquine or paclitaxel in 160-μL incubation mixtures containing 
Williams’ E media supplemented with 2 mM glutaMAX (Gibco, Grand Island, NY) and 0.1 
mM HEPES. Reactions were initiated by the addition of hepatocytes and conducted for 
10 min (amodiaquine), 30 min (paclitaxel) or 2 h (desloratadine) at 37°C with 95% 
humidity and 5% CO2 on an orbital shaker (~150 rpm). Reactions were terminated by the 
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addition of an equal volume of acetonitrile containing internal standard, followed by 
protein precipitation and LC-MS/MS analysis. 
 
Correlation analysis of individual CHH with UGT2B10 activity 
CHH from nine individual donors were assessed for levomedetomidine formation and 
3-hydroxydesloratadine formation. Briefly, nine individual lots of hepatocytes (1 million 
cells/mL; Table 2.2) were incubated with 1 or 10 μM levomedetomidine or desloratadine 
160-μL incubation mixtures containing Williams’ E media supplemented with 2 mM 
glutaMAX (Gibco) and 0.1 mM HEPES. Reactions were initiated by the addition of 
hepatocytes and conducted for 30 min (2 h for desloratadine) at 37°C with 95% humidity 
and 5% CO2 on an orbital shaker (approximately 150 rpm). Reactions were quenched by 
the addition of an equal volume of acetonitrile containing internal standard, followed by 
protein precipitation and LC-MS/MS analysis. 
 
Exogenous cofactor addition with CHH, HLM or HS9 
Pooled CHH (n=100; 1 million cells/mL) were treated with 0.01% (w/v) saponin (5 min) or 
disrupted with a probe sonicator (45 sec at 40-60% amplitude) followed by incubation in 
160-μL incubation mixtures containing 10 μM desloratadine in Williams’ E media 
supplemented with 2 mM glutaMAX (Gibco, Grand Island, NY) and 0.1 mM HEPES. 
Incubations were conducted in the presence or absence 0.1 mM NADPH and/or 1 mM 
UDP-GlcUA and conducted for 2 h at 37°C with 95% humidity and 5% CO2 on an orbital 
shaker (~150 rpm). For incubations with pooled subcellular fractions, HLM at 0.1 and 1 
mg/mL or HS9 at 0.5 and 5 mg/mL were pretreated for 15 min on ice with 25 μg/mg 
alamethicin followed by incubation with or without 1 mM chemical NADPH and/or 10 mM 
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UDP-GlcUA at 37°C in 200-μL incubation mixtures containing potassium phosphate 
buffer (50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM, pH 7.4) for zero, 1, 2, 4 and 6 h. 
Other cofactors such as NADH, FAD, AMP and ATP were also tested (each at 1 mM). All 
reactions were terminated by the addition of an equal volume of acetonitrile containing 
internal standard, followed by protein precipitation and LC-MS/MS analysis. 
 
Recombinant UGT panel with recombinant CYP2C8 
Recombinant human UGT enzymes, namely UGT1A1, UGT1A3, UGT1A4, UGT1A6, 
UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and 
UGT2B17 Supersomes® (Corning, Woburn, MA) supplemented with recombinant 
CYP2C8 Supersomes® (Corning, Woburn, MA) were evaluated for their ability to form 
3-hydroxydesloratadine. Briefly, 0.125 mg/mL recombinant UGT was supplemented with 
25 pmol/mL of recombinant CYP2C8, followed by addition of 1 or 10 μM desloratadine 
and incubation with 1 mM chemical NADPH and 10 mM UDP-GlcUA at 37°C in 200-μL 
incubation mixtures containing potassium phosphate buffer (50 mM, pH 7.4), MgCl2 (3 
mM), EDTA (0.5 or 1 mM, pH 7.4) for 2 h. Reactions were terminated by the addition of 
an equal volume of acetonitrile containing internal standard, followed by protein 
precipitation and LC-MS/MS analysis. 
 
In vitro P450 inhibition by desloratadine in human liver microsomes 
Desloratadine was evaluated as an inhibitor of P450 enzymes as described previously 
(Parkinson et al., 2011). Briefly, 10 μM desloratadine was incubated at 37°C in 200-μL 
incubation mixtures containing pooled HLM (≤ 0.1 mg/mL), potassium phosphate buffer 
(50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM, pH 7.4), an NADPH-generating system 
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(consisting of 1 mM NADP, 5 mM glucose 6-phosphate, and 1 unit/mL glucose-6-
phosphate dehydrogenase), and a P450 marker substrate at a concentration 
approximately equal to its Km. Substrates included phenacetin (CYP1A2; 40 μM), 
bupropion (CYP2B6; 50 μM), paclitaxel (CYP2C8; 5 μM), diclofenac (CYP2C9; 6 μM), S-
mephenytoin (CYP2C19; 40 μM), dextromethorphan (CYP2D6; 7.5 μM), and midazolam 
(CYP3A4/5, 3 μM). Prior to marker substrate addition, desloratadine was preincubated 
for 0 and 30 min with and without NADPH in HLM to assess direct, time-dependent and 
metabolism-dependent inhibition. Marker reactions were initiated by the addition of an 
NADPH-generating system and terminated after 5 min by the addition of 200 μL of 
acetonitrile containing internal standards. Precipitated protein was removed by 
centrifugation (920 RCF for 10 min at 10°C) followed by liquid chromatography tandem 
mass spectrometry (LC-MS/MS) analysis as described below. 
 
In vitro CYP2C8 inhibition by desloratadine in cryopreserved human hepatocytes 
(CHH) 
Desloratadine was evaluated in an IC50 shift experiment with and without a preincubation 
step as described previously with minor modifications (Kazmi et al., 2014a). Briefly, 
desloratadine was incubated at 0.1, 0.3, 1, 3, 10, 30, and 100 μM in 100-μL incubation 
mixtures containing pooled CHH (n = 100; 0.5 million cells/mL), Williams’ E media 
supplemented with 2 mM glutaMAX (Gibco, Grand Island, NY) and 0.1 mM HEPES, and 
10 μM amodiaquine or paclitaxel. Reactions were initiated by the addition of hepatocytes 
and desloratadine was preincubated with the test system for 0, 30, and 120 min at 37°C 
with 95% humidity and 5% CO2 on an orbital shaker (~150 rpm). Following preincubation, 
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CYP2C8 marker substrates were added and samples were incubated for an additional 10 
(amodiaquine) or 30 min (paclitaxel). An equal volume of acetonitrile containing the 
appropriate internal standard was added to terminate the reactions, followed by protein 
precipitation and LC/MS-MS analysis. 
 
UGT chemical inhibition of 3-hydroxydesloratadine formation in HLM 
UGT1A4 and UGT2B10 involvement in desloratadine metabolism was assessed using a 
chemical inhibition approach. Briefly, pooled HLMs (n = 200) at 0.1 mg/mL were incubated 
at 37°C in 200-μL incubation mixtures containing 1 or 10 μM desloratadine, 5 μM 
levomedetomidine, or 20 μM trifluoperazine; with 100 μM hecogenin (UGT1A4 inhibitor), 
500 μM nicotine (UGT2B10 inhibitor) or both hecogenin and nicotine; Tris-HCl (100 mM, 
pH 7.7), MgCl2 (10 mM), EDTA (1 mM) D-saccharic acid 1,4-lactone (0.1 mM), UDP-
GlcUA (10 mM) and NADPH (1 mM). Reactions were initiated by the addition of an UDP-
GlcUA with NADPH and terminated after 5 min (trifluoperazine), 10 min 
(levomedetomidine) or 2 h (desloratadine) by the addition of 200 μL of acetonitrile 
containing internal standards, followed by protein precipitation and LC-MS/MS analysis. 
 
Analytical methods 
 
P450 marker substrates 
LC-MS/MS analysis of all P450 marker substrates was conducted as described in Table 
2.3 and as described previously (Ogilvie et al., 2006; Paris et al., 2009; Parkinson et al., 
2011; Kazmi et al., 2014a). 
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UGT marker substrates 
For UGT analytes, samples were analyzed by LC-MS/MS with LC gradients applied to a 
Waters Atlantis dC18 column (5 μm, 2.1 x 100 mm). Mobile phases comprised either 
0.2% formic acid in water (A) and methanol (B) or 0.1 mM ammonium acetate in 95:5 
(v/v) water: methanol (A) and methanol (B). Shimadzu Prominence or Nexera LC systems 
(Columbia, MD) were interfaced to AB Sciex API3000 triple quadrupole or API4000 or 
5500 triple quadrupole linear ion trap mass spectrometers (Foster City, CA) by ESI. The 
corresponding internal standard compounds, mass spectrometry modes and MRM 
transitions employed for each specific glucuronide metabolite monitored are shown in 
Table 2.4. 
Desloratadine and its hydroxymetabolites 
Samples were analyzed by LC-MS/MS using a method developed in-house. The LC 
system comprised a Shimadzu SIL-5000 autosampler, two Shimadzu LC-20ADVP pumps 
and a Shimadzu DGU-20A3 degasser (Shimadzu, Columbia, MD). An LC gradient 
employing 0.2% formic acid in water (A) and acetonitrile (B) at 0.6 mL min-1 was applied 
to a Waters XBridge C18 column (5 μm, 4.6 x 100 mm) for separation of desloratadine 
and its metabolites. The gradient consisted of 10% B for 0.5 min followed by a linear ramp 
to 95% B at 9.5 min, a 1 min hold at 95% B and then a 2 min re-equilibration period at 
10% B.  
Analytes were detected with an AB Sciex API4000 QTrap mass spectrometer (AB Sciex, 
Foster City, CA) using positive mode and electrospray ionization. A multiple reaction 
monitoring (MRM) information-dependent acquisition (IDA) detection method was 
developed based on manually derived transitions for known and predicted metabolites of 
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desloratadine. Twenty-seven MRM transitions with 30 msec dwell times were employed, 
including 311/259 for desloratadine (5.3 min retention time); 327/275 for 3-
hydroxydesloratadine and 331/279 for 3-hydroxydesloratadine-d4 (5.2 min), 327/275 for 
5-hydroxydesloratadine (4.9, 5.0 min) and 327/275 for 6-hydroxydesloratadine (4.7 min); 
and 503/327 for 3-hydroxydesloratadine glucuronide (5.1 min). Retention times for these 
5 analytes were confirmed by comparison with reference standards. The electrospray 
voltage applied was 4500 V, the collision gas was set to high, the curtain gas was at 30 
psi, the source temperature was 600°C, and the collision energy for the MRM scans was 
35 eV. The declustering potential applied was 80 V for desloratadine and oxidative 
metabolite transitions and 30 V for labile conjugated metabolite transitions. The IDA 
criteria were set to acquire product ion spectra across the m/z range 80-700 for a peak 
exceeding 500 counts in the survey MRM scan. The product ion spectra were used to 
further confirm detection of the 3-hydroxydesloratadine (characteristic neutral loss of 17 
amu) versus the 5- and 6-hydroxydesloratadine metabolites (characteristic neutral loss of 
18 amu) as reported by Ramanathan et al. (2000). Where applicable, a calibration curve 
comprising six concentration levels prepared in duplicate across the range 0.005 – 1 μM 
was used for 3-hydroxydesloratadine.quantitation with quadratic regression and 1/x2 
weighting.  
 
Data analysis 
All data processing and statistical analysis were conducted with Microsoft Excel 2010 
(Microsoft, Redmond, WA) or SigmaPlot (Systat Software, San Jose, CA). TPSA, logP 
and logDpH 7.4 values were all predicted with MarvinSketch 5.9 (ChemAxon, Cambridge, 
MA). Non-linear fitting and determination of Km and Vmax were performed with GraFit 7.0.2 
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(Erithacus Software Ltd., Horley, Surrey, UK). For IC50 shift experiments, the data were 
processed by non-linear regression with GraFit 7.0.2 using a non-linear regression 
algorithm based on the following two-parameter sigmoidal-logistic IC50 equation: 
 y= 
100%
1+ � xIC50
�
s 
Equation 2.1 
This equation assumes that y falls with increasing x, and s is the slope factor. Data using 
equation 1 are both background and range corrected (i.e. lower data limit is 0 and the 
upper data limit is 100) as percent of control values are utilized.  
 
In vitro intrinsic clearance and In vivo hepatic intrinsic clearance calculations 
The in vitro intrinsic clearance (CLint) was calculated based on the experimental 
elimination rate constant (kel) or Km and Vmax. Briefly, the time course elimination of drugs 
when conforming to first order elimination in vitro (or in plasma) is a process in which a 
constant fraction of drug is removed per unit time. This fraction corresponds to the 
elimination rate constant (kel) (units: min-1) and can be calculated from the slope of a semi-
log plot of log10 [Drug] versus time. From kel, the half-life (t1/2) (units of time) can be 
calculated with the following equation: 
 𝐻𝐻𝐸𝐸𝐸𝐸𝑓𝑓 𝐸𝐸𝐸𝐸𝑓𝑓𝑟𝑟 �𝐸𝐸1/2� =
0.693
𝑘𝑘𝑒𝑒𝑙𝑙
 Equation 2.2 
From both kel and t1/2 the in vitro CLint can be calculated based on the following equations: 
 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 =  𝑘𝑘𝑒𝑒𝑙𝑙  ×  
𝑣𝑣𝐸𝐸𝐸𝐸𝑑𝑑𝐸𝐸𝑟𝑟 𝐸𝐸𝑓𝑓 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
𝐸𝐸𝑑𝑑 𝐸𝐸𝐸𝐸𝑐𝑐𝑟𝑟𝐸𝐸𝑚𝑚𝐸𝐸𝐸𝐸𝑟𝑟𝑚𝑚 𝐸𝐸𝑟𝑟 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑐𝑐𝑟𝑟𝐸𝐸𝐸𝐸𝑚𝑚 ℎ𝑟𝑟𝑝𝑝𝐸𝐸𝐸𝐸𝐸𝐸𝑐𝑐𝑒𝑒𝐸𝐸𝑟𝑟𝑚𝑚 𝐸𝐸𝐸𝐸 𝐸𝐸ℎ𝑟𝑟 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
 Equation 2.3 
Or: 
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𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖
=  
0.693
𝐸𝐸1/2 
 ×  
𝑣𝑣𝐸𝐸𝐸𝐸𝑑𝑑𝐸𝐸𝑟𝑟 𝐸𝐸𝑓𝑓 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
𝐸𝐸𝑑𝑑 𝐸𝐸𝐸𝐸𝑐𝑐𝑟𝑟𝐸𝐸𝑚𝑚𝐸𝐸𝐸𝐸𝑟𝑟𝑚𝑚 𝐸𝐸𝑟𝑟 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑐𝑐𝑟𝑟𝐸𝐸𝐸𝐸𝑚𝑚 ℎ𝑟𝑟𝑝𝑝𝐸𝐸𝐸𝐸𝐸𝐸𝑐𝑐𝑒𝑒𝐸𝐸𝑟𝑟𝑚𝑚 𝐸𝐸𝐸𝐸 𝐸𝐸ℎ𝑟𝑟 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
 Equation 2.4 
An alternative method of calculating CLint involves using the parameters Vmax and Km and 
can be determined according to the following equation: 
 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 =  
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
𝐾𝐾𝑚𝑚
 Equation 2.5 
The scaled in vivo hepatic intrinsic metabolic clearance (in vivo CLH,int) was determined 
with physiologically based scaling factors (PBSF) according to the following equation: 
 
𝐼𝐼𝐸𝐸 𝑣𝑣𝐸𝐸𝑣𝑣𝐸𝐸 𝐶𝐶𝐶𝐶𝐻𝐻,𝑖𝑖𝑖𝑖𝑖𝑖 =  𝐼𝐼𝐸𝐸 𝑣𝑣𝐸𝐸𝐸𝐸𝑟𝑟𝐸𝐸 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖  
× 𝑃𝑃𝑃𝑃𝑆𝑆𝑃𝑃 𝑓𝑓𝐸𝐸𝑟𝑟 𝐸𝐸𝐸𝐸𝑐𝑐𝑟𝑟𝐸𝐸𝑚𝑚𝐸𝐸𝐸𝐸𝑟𝑟𝑚𝑚 𝐸𝐸𝑟𝑟 ℎ𝑟𝑟𝑝𝑝𝐸𝐸𝐸𝐸𝐸𝐸𝑐𝑐𝑒𝑒𝐸𝐸𝑟𝑟𝑚𝑚 Equation 2.6 
Where for human liver microsome scaling: 
 𝐼𝐼𝐸𝐸 𝑣𝑣𝐸𝐸𝑣𝑣𝐸𝐸 𝐶𝐶𝐶𝐶𝐻𝐻,𝑖𝑖𝑖𝑖𝑖𝑖 =  
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
𝐾𝐾𝑚𝑚
×  
40 𝐸𝐸𝑑𝑑 𝐸𝐸𝐸𝐸𝑐𝑐𝑟𝑟𝐸𝐸𝑚𝑚𝐸𝐸𝐸𝐸𝑟𝑟𝑚𝑚
𝑑𝑑 𝐸𝐸𝐸𝐸𝑣𝑣𝑟𝑟𝑟𝑟
×  
1650 𝑑𝑑
𝐸𝐸𝐸𝐸𝑣𝑣𝑟𝑟𝑟𝑟
 Equation 2.7 
For human hepatocyte scaling: 
 
𝐼𝐼𝐸𝐸 𝑣𝑣𝐸𝐸𝑣𝑣𝐸𝐸 𝐶𝐶𝐶𝐶𝐻𝐻,𝑖𝑖𝑖𝑖𝑖𝑖 =  𝐾𝐾𝑒𝑒𝑙𝑙 × 
𝑉𝑉𝐸𝐸𝐸𝐸𝑑𝑑𝐸𝐸𝑟𝑟 𝐸𝐸𝑓𝑓 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑐𝑐𝑟𝑟𝐸𝐸𝐸𝐸𝑚𝑚 𝐸𝐸𝑓𝑓 ℎ𝑟𝑟𝑝𝑝𝐸𝐸𝐸𝐸𝐸𝐸𝑐𝑐𝑒𝑒𝑟𝑟𝑚𝑚 𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸𝑐𝑐𝑑𝑑𝑖𝑖𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
× 
120 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 ℎ𝑟𝑟𝑝𝑝𝐸𝐸𝐸𝐸𝐸𝐸𝑐𝑐𝑒𝑒𝐸𝐸𝑟𝑟𝑚𝑚
𝑑𝑑 𝐸𝐸𝐸𝐸𝑣𝑣𝑟𝑟𝑟𝑟
× 
1650 𝑑𝑑
𝐸𝐸𝐸𝐸𝑣𝑣𝑟𝑟𝑟𝑟
 
Equation 2.8 
The PBSF for microsomes is thus 66,000 (40 mg microsomes per g liver multiplied by 
1650 g liver) whereas for hepatocytes it is 198,000 (120 million hepatocytes per g liver 
multiplied by 1650 g liver), and is based on liver microsomal content and hepatoceullarity 
as described previously (Hakooz et al., 2006; Sohlenius-Sternbeck, 2006; Barter et al., 
2007). 
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Microsomal binding calculations 
Membrane partitioning of drugs to microsomes was calculated by the methods described 
by Hallifax and Houston, (2006) as shown in Table 1.2. 
 
Ionic strength calculations 
Ionic strength (I) is a measure of the concentration of all ions present in a particular 
solution. The ionic strength of in vitro incubation buffers with varying phosphate 
concentration or salts only cell culture media was calculated according to the following 
equation as described previously (IUPAC, 1997). 
 𝐼𝐼 =  
1
2
 �𝑐𝑐𝑖𝑖𝑧𝑧𝑖𝑖2
𝑖𝑖
𝑖𝑖=1
 Equation 2.9 
Where ci is the molar concentration of ion i, zi is the charge number of that ion and the 
sum is taken over all the ions in the solution.  
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Table 2.1. Salt composition and ionic strength of various cell culture media 
Salt 
Final concentration (mg/mL)a 
KHB Waymouth’s MCM+ DMEM Williams’ E 
Calcium Chloride, 2H2O 0.494 0.12 0.265 0.265 0.265 
Magnesium Chloride 6H2O 0.141 0.24    
Potassium Phosphate 
monobasic 
0.16     
Potassium Chloride 0.35 0.15 0.4 0.4 0.4 
Sodium Bicarbonate 2.1 2.24 22.01 3.7 2.2 
Sodium Chloride 6.9 6 4.5 6.4 6.8 
Cupric sulfate 5H2O   0.0003  0.0000001 
Ferric nitrate 9H2O   0.0012 0.0001 0.0000001 
Magnesium Sulfate 
(anhydrous) 
 0.098 0.174 0.098 0.098 
Sodium Phosphate 
monobasic 
 0.08 0.125 0.109 0.14 
Sodium Phosphate dibasic  0.566    
Ionic strength (mM)b 182 169 361 173 163 
 
a Final concentrations (mg/mL) are based on the hydrated salt molecular weights. 
b Values were calculated based only on the salt composition of the various media as described in Equation 
2.9. The ionic strengths of 5, 50 and 200 mM phosphate buffer were calculated to be 35, 282 and 1108 mM 
respectively. 
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Table 2.2. Individual human donor information for CYP2C8 and UGT2B10 
correlation analysis. 
Xenotech Liver  
Number 
Gender Age 
(years) 
Ethnicity 
H924 M 40 Caucasian 
H954 M 55 Caucasian 
H1008 M 36 Hispanic 
H1039 M 61 African American 
H1042 M 51 Caucasian 
H1059 F 21 Caucasian 
H1086 M 63 Caucasian 
H1135 F 54 African American 
H1141 F 20 Asian 
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Table 2.3. Analytical conditions for the measurement of P450 activity in HLM and 
CHH by LC-MS/MS with electrospray ionization (ESI) 
Enzyme P450 activity Ionization 
mode 
Mass 
transition 
monitored  
Internal standard (IS) IS mass 
transition 
monitored 
CYP1A2 Phenacetin O-dealkylation Positive 152 / 110 d4-Acetaminophen 156 / 114 
CYP2A6 Coumarin 7-hydroxylation Negative 161 / 133 d5-7-hydroxycoumarin 166 / 138 
CYP2E1 
Chlorzoxazone 6-
hydroxylation 
Negative 184 / 120 d2-6-Hydroxychlorzoxazone 188 / 122 
CYP2B6 Bupropion hydroxylation Positive 256 / 238 d6-Hydroxybupropion 262 / 244 
CYP2C8 
Amodiaquine N-dealkylation Positive 328 / 283 d5-N-Desethylamodiaquine 333 / 283 
Paclitaxel 6α-hydroxylation Positive 868 / 541 d5-6α-Hydroxypaclitaxel 873 / 541 
CYP2C9 
Diclofenac 4ʹ-hydroxylation Negative 312 / 231 d4-4'-Hydroxydiclofenac 318 / 237 
Tolbutamide 4-
hydroxylation 
Negative 285 / 186 d9-4-Hydroxytolbutamide 294 / 186 
CYP2C19 
S-Mephenytoin 4ʹ-
hydroxylation 
Negative 233 / 190 d3-4'-Hydroxymephenytoin 236 / 193 
CYP2D6 
Dextromethorphan O-
demethylation 
Positive 258 / 157 d3-Dextrorphan 261 / 157 
CYP3A4 
Midazolam 1ʹ-hydroxylation Positive 342 / 324 
d4-1'-Hydroxymidazolam 346 / 203 
Midazolam 4-hydroxylation Positive 342 / 297 
Testosterone 6β-
hydroxylation 
Positive 305 / 269 d3-6β-Hydroxytestosterone 308 / 272 
Nifedipine oxidation Positive 345 / 284 d6-dehydronifedipine 351 / 287 
Alfentanil N-dealkylation Positive 148 / 92 d5-N-Phenylpropionamide 155 / 99 
Verapamil N-dealkylation Positive 291 / 151 d6-D617 297 / 151 
Atorvastatin ortho-
hydroxylation 
Negative 573 / 278 
d5-ortho-
Hydroxyatorvastatin 
578 / 283 
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Table 2.4. Experimental conditions for measuring UGT activity for enzyme 
inhibition and metabolism studies in human liver microsomes (HLM) by LC-MS/MS 
with electrospray ionization (ESI) 
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CHAPTER 3 : TEST SYSTEM-DEPENDENT DRUG CLEARANCE 
PART 1: MIDAZOLAM CLEARANCE IN HUMAN HEPATOCYTES IS 
RESTRICTED COMPARED WITH HUMAN LIVER MICROSOMES BUT 
NOT BY CELL PERMEABILITY OR COFACTOR AVAILABILITY 
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ABSTRACT 
This study confirms previous reports that the intrinsic metabolic clearance of CYP3A4/5 
substrates, especially midazolam, is underpredicted by cryopreserved human 
hepatocytes compared with human liver microsomes (HLM) and examines previous 
proposals namely permeability- and cofactor-restricted clearance in hepatocytes, to 
explain this unexpected system-dependent difference. The clearance of midazolam (high 
CLint CYP3A4/5 substrate) was compared with the clearance of dextromethorphan (low 
CLint CYP2D6 substrate) in pooled CHH (1 million cells/mL) and a physiologically 
equivalent concentration of pooled HLM (0.33 mg/mL), based on hepatic scaling factors. 
Dextromethorphan CLint was similar between test systems (within 2-fold); however, 
midazolam CLint in CHH was approximately one tenth that in HLM. Sonication or saponin 
treatment of CHH (to increase membrane permeability) with and without the addition of 
exogenous NADPH (removal of cofactor availability as a variable) had no effect on 
midazolam metabolism. When midazolam was incubated with CHH, the rate of substrate 
loss from the medium greatly exceeded that from the whole system, suggesting the 
uptake of midazolam is considerably faster than its metabolism.  CYP3A4/5 activity in 
microsomes prepared from the pooled CHH was comparable to that in pooled HLM. 
These results suggest that neither membrane permeability nor cofactor availability limits 
midazolam clearance in CHH. When the clearance of other CYP3A4/5 substrates, namely 
alfentanil, nifedipine and verapamil, was assessed in CHH (1 million cells/mL) and HLM 
(0.33 mg/mL), estimates of hepatic intrinsic metabolic clearance (CLH,int) with HLM were 
2.6- to 3.7-fold greater than those estimated with CHH compared with a ∼9-fold difference 
122 
 
for midazolam. This suggests that the system-dependent clearance of midazolam is more 
pronounced than that of other CYP3A4/5 substrates.  
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INTRODUCTION 
The in vitro to in vivo extrapolation (IVIVE) of drug clearance involves the determination 
of intrinsic clearance in vitro (CLint), based on in vitro measurements of Vmax/Km or half-
life (t1/2) in human liver microsomes (HLM) or cryopreserved human hepatocytes (CHH), 
which are then scaled to predict hepatic clearance in vivo (CLH,int) (Obach, 1999; Griffin 
and Houston, 2004; Jones and Houston, 2004). This is common practice in the 
pharmaceutical industry because CLint values can be used, for example, to assess 
whether metabolism represents a major pathway of clearance in vivo and whether an 
investigational drug is a candidate for once-a-day dosing. Assessing the rank order of in 
vitro CLint values for drug candidates is also useful for evaluating species or gender 
differences in metabolic clearance. Although in vitro values of CLint often underpredict in 
vivo values of CLH,int, especially with human-derived test systems, the values of CLint 
determined with HLM would be expected to match those determined in CHH for drugs 
predominantly cleared by cytochrome P450 enzymes (P450). However, in the case of 
drugs rapidly cleared by CYP3A4/5, there are reports showing that CLint values 
determined in microsomes are much greater than those determined in hepatocytes 
whereas the opposite has been observed with drugs that are slowly cleared by CYP2D6 
(Lu et al., 2006; Brown et al., 2007b; Hallifax et al., 2010). These test system-dependent 
differences in drug clearance raise the possibility that HLM and CHH differ in their 
capacity to support the metabolism of drugs whose clearance is largely dependent on 
metabolism by P450 enzymes.  
Previous investigators have proposed that the lower clearance of midazolam (and other 
high clearance drugs metabolized by CYP3A4) in hepatocytes compared with 
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microsomes may be due a limitation imposed by membrane permeability or the availability 
of cofactor (NADPH), two factors that would restrict midazolam clearance by CHH but not 
by HLM (Lu et al., 2006; Foster et al., 2011). Lu and colleagues (2006) examined the 
impact of membrane partitioning and membrane permeability by assessing the CLint of 7-
ethoxycoumarin, phenacetin, propranolol, and midazolam in rat and human liver 
microsomes as well as hepatocytes. They surmised that higher rates of clearance in 
microsomes than hepatocytes was due to system-dependent differences in the fraction 
of unbound drug and/or because the rate of uptake of drug into hepatocytes limited the 
rate of metabolism, which was consistent with the observation that discrepancies in CLint 
between CHH and HLM tends to be a feature of high clearance drugs. Without correction 
for membrane partitioning, which lowers the fraction of unbound drug immediately 
available for metabolism, midazolam clearance in rat microsomes was shown to be 40-
fold greater than that in rat hepatocytes; however, after correcting for the fraction of 
unbound drug in both microsomes and hepatocytes the difference in midazolam CLint was 
reduced to approximately 4 fold. In the case of human microsomes and hepatocytes, 
correcting for membrane partitioning reduced the difference in CLint to 3.5 fold; however, 
the CLint of midazolam in human hepatocytes was found to be much lower than that in rat 
hepatocytes.  
Foster and colleagues (2011) compared the CLint of seven P450 substrates with a wide 
range of clearance values in HLM and CHH prepared from the same liver donor in an 
attempt to exclude donor variability bias. They found that for the high clearance substrates 
midazolam, nifedipine and diclofenac there was a 4-fold underprediction of CLint by 
hepatocytes versus microsomes. However, in contrast to Lu et al., (2006), they concluded 
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that membrane permeability did not account for the relatively low rate of midazolam 
clearance in CHH because they observed no difference between HLM and CHH in the 
Km for midazolam clearance or metabolite formation. Had membrane permeability 
impeded the cellular uptake of midazolam, the intracellular concentration of midazolam in 
CHH would be lower than that in HLM, which would have increased the apparent Km, but 
this was not observed. Foster et al., (2011) noted that, as the value of CLint increased, Km 
remained unchanged but the maximal rate of drug metabolism (i.e., Vmax) by CHH 
progressively declined relative to Vmax by HLM; accordingly, they proposed that a factor 
other than membrane permeability limited the rate of CYP-dependent drug metabolism in 
hepatocytes. They postulated that cofactor (NADPH) availability might be such a factor.  
In the present study I examined the clearance of the CYP3A4/5 substrate midazolam 
(high intrinsic clearance) and the CYP2D6 substrate dextromethorphan (low intrinsic 
clearance) in HLM and CHH and confirmed previous reports that midazolam clearance in 
hepatocytes is considerably lower than in HLM. Experiments were then undertaken to 
assess whether other substrates of CYP3A4/5 exhibited the same test system-dependent 
clearance and to examine whether membrane permeability or cofactor availability account 
for the relatively low rate of clearance of midazolam in CHH.  
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RESULTS 
3.1. Comparison of midazolam and dextromethorphan clearance in 
HLM and CHH. 
To compare the in vitro clearance of CYP2D6 and CYP3A4/5 substrates, 
dextromethorphan and midazolam were incubated at 1 μM and plasma Cmax (0.014 μM 
and 0.34 μM, respectively) with pooled CHH (n = 50) at 1 million cells/mL for up to 120 
min, as described in Chapter 2. The results are shown in Figure 3.1, and demonstrate 
first-order elimination of both midazolam and dextromethorphan over time with a half-life 
of 75 and 56 min respectively at 1 μM; or 63 and 81 min at plasma Cmax, respectively. The 
clearance of both substrates (1 μM) was also assessed in pooled HLM (n=200) at a 
protein concentration of 0.33 mg/mL, which is equivalent to the concentration of 
microsomal protein in hepatocytes at 1 million cells/mL (Hakooz et al., 2006; Sohlenius-
Sternbeck, 2006; Barter et al., 2007). In HLM, the half-life of midazolam was 8.5 min 
whereas the half-life of dextromethorphan was 85 min, as shown in Figure 3.2. The 
kinetics of dextrorphan and 1ʹ-hydroxymidazolam formation by HLM (0.1 mg/mL) were 
assessed as described in Chapter 2. As shown in Figure 3.3, Vmax and Km for CYP2D6 
were 276 pmol/mg/min and 9.5 μM dextromethorphan, respectively, whereas Vmax and 
Km for CYP3A4 were 1290 pmol/mg/min and 2.4 μM midazolam, respectively. 
Because CHH and HLM were incubated at physiologically equivalent concentrations, the 
half-life of a drug metabolized primarily by P450 would be the same in the absence of test 
system-dependent factors. As shown in Figure 3.1 and Figure 3.2, the half-life of 
dextromethorphan in CHH (56-81 min) was comparable to that in HLM (85 min). However, 
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the half-life of midazolam in CHH (63-75 min) was less than one-tenth the half-life in HLM 
(8.5 min). In vitro values of CLint (based on in vitro half-life or Vmax/Km) were extrapolated 
to in vivo values of hepatic intrinsic metabolic clearance (CLH,int) based on physiologically 
based scaling factors (PBSF; described in the Discussion section), and the results are 
summarized in Table 3.1. With dextromethorphan, the value of CLH,int determined with 
microsomes (97.8 to 115 L/h) was comparable to that determined with hepatocytes (102 
to 147 L/h). In contrast, with midazolam, the value of CLH,int determined with microsomes 
(978 to 2130 L/h) was 7.6- to 19.2-fold (approximately an order of magnitude) greater 
than that determined with hepatocytes (110 to 129 L/h). These results confirmed previous 
reports of system-dependent clearance of midazolam (Lu et al., 2006; Foster et al., 2011). 
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Figure 3.1. The in vitro clearance of midazolam (top) and dextromethorphan 
(bottom) at 1 μM and plasma Cmax in cryopreserved human hepatocytes (CHH) 
Pooled CHH (1 million cells/mL) were incubated with midazolam (colored blue) or 
dextromethorphan (colored red) at 1 μM or at their plasma Cmax concentrations (0.34 and 
0.0014 μM, respectively) for up to 120 min. Disappearance of substrate was measured 
by LC-MS/MS. In vitro half-life and the first-order elimination rate constant (kel) were 
calculated as described in Chapter 2. 
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Figure 3.2. The in vitro clearance of midazolam (top) and dextromethorphan 
(bottom) at 1 µM in pooled human liver microsomes 
As described in Chapter 2, 1 µM midazolam and 1 µM dextromethorphan were incubated 
with pooled human liver microsomes at 0.33 mg/mL, a protein concentration equivalent 
to the microsomal content of human hepatocytes at 1 million cells/mL. Incubations were 
conducted for up to 8 min (midazolam) or 60 min (dextromethorphan). Disappearance of 
substrate was measured by LC-MS/MS. In vitro half-life and the first-order elimination rate 
constant (kel) were calculated as described in Chapter 2.  
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Figure 3.3. Kinetics of 1ʹ-hydroxymidazolam (CYP3A4/5) formation (top) and 
dextrorphan (CYP2D6) formation (bottom) pooled human liver microsomes 
The Km and Vmax of 1ʹ-hydroxymidazolam and dextrorphan formation were determined by 
incubating pooled human liver microsomes (0.1 mg/mL) with eight concentrations of 
midazolam (0.5 to 40 µM) or dextromethorphan (0.5 to 100 µM) for 10 min, as described 
in Chapter 2. 
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Table 3.1. Summary of scaled values of in vivo hepatic intrinsic clearance (CLH,int) 
from values of in vitro intrinsic clearance (CLint) determined with cryopreserved 
human hepatocytes and human liver microsomes 
 
a Hepatocyte CLH,int  based on in vitro half-life (substrate disappearance) was calculated as follows: 
kel x volume of incubation/million cells per incubation x 198,000 PBSF. Units were converted to L/h. 
b Microsomal CLH,int based on in vitro half-life (substrate disappearance) was calculated as follows: 
kel x volume of incubation/mg protein per incubation x 66,000 PBSF. Units were converted to L/h. 
c Microsomal CLH,int based on the kinetics of 1′-hydroxymidazolam formation was calculated as 
follows: Vmax/Km x 66,000 PBSF. Units were converted to L/h. 
Note: CLH,int values were not corrected for substrate binding to microsomes or hepatocytes.  
Substrate 
Cryopreserved human hepatocytes 
In vitro half-life (substrate 
disappearance) with [S] = 1 μM 
and 1 x 106 cells/mL 
In vitro half-life (substrate 
disappearance) with [S] =  
plasma Cmax and 1 x 106 cells/mL  
t1/2  
(min) 
kel 
(min-1) 
CLH,inta 
t1/2  
(min) 
kel 
(min-1) 
CLH,inta 
Dextromethorphan 56 0.01234 147 L/h 81 0.00859 102 L/h 
Midazolam 75 0.00928 110 L/h 63 0.01092 129 L/h 
 
Substrate 
Human liver microsomes 
In vitro half-life (substrate 
disappearance) with [S] = 1 μM 
and HLM at 0.33 mg/mL 
Vmax and Km of 1′-
hydroxymidazolam formation by 
HLM at 0.1 mg/mL 
t1/2  
(min) 
kel 
(min-1) 
CLH,intb 
Vmax 
(pmol/mg/
min) 
Km  
(μM) 
CLH,intc 
Dextromethorphan 85 0.0082 97.8 L/h 276 9.5 115 L/h 
Midazolam 8.5 0.0820 978 L/h 1290 2.4 2130 L/h 
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3.2. Assessment of CYP3A4/5 activity in microsomes prepared from 
CHH compared with a standard preparation of HLM. 
To determine whether the difference in midazolam metabolic clearance between HLM 
and CHH could be attributed to low CYP3A4/5 activity in CHH, microsomes were isolated 
from pooled CHH (n = 50) and both CYP2D6 and CYP3A4/5 activity was compared with 
that in a standard preparation of pooled HLM (n = 200) (i.e., microsomes prepared directly 
from human liver). In each case the microsomes were incubated at 0.1 mg/mL with 1 μM 
substrate or a substrate concentration equal to roughly 10 times Km (so-called Vmax 
conditions), as described in Chapter 2. As shown in Table 3.2, microsomes isolated from 
pooled CHH metabolized both dextromethorphan (CYP2D6) and midazolam (CYP3A4/5) 
are rates comparable (within 20%) to the standard preparation of pooled HLM. These 
results established that the test system-dependent difference in midazolam metabolism 
could not simply be ascribed to an abnormally low activity of CYP3A4/5 in the pooled 
CHH. 
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Table 3.2. Comparison of metabolic rates between microsomes isolated from 
cryopreserved human hepatocytes and a standard preparation of pooled human 
liver microsomes with two concentrations of midazolam (CYP3A4/5) and 
dextromethorphan (CYP2D6) 
Test system 
Rate  
(pmol/mg/min) 
Midazolam  
1ʹ-hydroxylation 
Dextromethorphan  
O-demethylation 
1 μM 40 μM 1 μM 75 μM 
Pooled HLM 
(n = 200) 
263 1132 45 259 
HLM isolated 
from CHH 
(n =50) 
206 893 46 220 
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3.3. Determining the effect of membrane permeabilization and 
cofactor supplementation on midazolam metabolism in CHH.  
To assess the impact of membrane permeability cofactor availability on midazolam 
metabolism in CHH, the plasma membrane of intact cells was disrupted by sonication or 
treatment with the membrane-permeabilizing agent saponin with and without the addition 
of exogenous NADPH. Six different treatment groups were assessed: intact hepatocytes 
with and without NADPH, sonicated hepatocytes with and without NADPH, and saponin-
treated hepatocytes with and without NADPH, as described in Chapter 2. The results are 
shown in Figure 3.4. Sonication or treatment of hepatocytes with saponin had little or no 
effect (<20%) on the rate of disappearance of midazolam or the rate of formation of 
1ʹ-hydroxymidazolam. Likewise, the addition of NADPH to intact hepatocytes or 
hepatocytes permeabilized by sonication or saponin treatment failed to stimulate the 
metabolism of midazolam. These results suggest that neither membrane permeability nor 
cofactor availability limits the rate of metabolism of midazolam by human hepatocytes. 
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Figure 3.4. The effects of membrane permeabilization by sonication or saponin 
treatment and cofactor supplementation on the in vitro metabolism of midazolam 
in cryopreserved human hepatocytes 
Cryopreserved human hepatocytes (CHH) at 1 million cells/mL were either sonicated or 
treated with saponin (0.01% w/v) followed by the addition of 0.1 mM NADPH to select 
treatment groups and then incubation with 1 μM midazolam for up to 120 min. The 
disappearance of midazolam and formation of 1ʹ-hydroxymidazolam were determined as 
described in Chapter 2. Representative data for 1ʹ-hydroxymidazolam formation at t = 60 
min are shown in the right-hand figure. 
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3.4. Assessment of midazolam uptake into CHH.  
To further assess whether midazolam clearance in human hepatocytes is restricted by 
membrane permeability, the combined rate of hepatocellular update and metabolism (i.e., 
the rate of disappearance of midazolam from the cell culture medium) was compared with 
the rate of metabolism of midazolam (i.e., the rate of disappearance of midazolam from 
the whole system). Medium loss and whole-system loss of midazolam (1 µM) were 
assessed with CHH at 1 million cells/mL for up to 120 min, as described in Chapter 2. In 
the whole-system loss assay (cells + medium), drug loss can occur only by metabolism; 
whereas in the medium-loss assay the disappearance of drug from the cell culture 
medium can occur by both metabolism and cellular uptake (which represents membrane 
partitioning of the drug into the plasma membrane, passive diffusion into hepatocytes 
and/or transporter-mediated uptake). As shown in Figure 3.5, the results indicate that 
there is an initial, rapid uptake of midazolam into CHH. Approximately 45% of midazolam 
disappeared from the medium within the first 10 min (due to uptake and metabolism), at 
which point less than 10% of midazolam was lost from the whole system (due to 
metabolism). These results suggest that the rate of midazolam uptake into hepatocytes 
greatly exceeded its rate of metabolism, which provides additional evidence that 
membrane permeability does not restrict the metabolic clearance of midazolam by human 
hepatocytes. 
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Figure 3.5. The contribution of metabolism and uptake as determined by whole-
system loss versus medium loss of midazolam (1 μM) in cryopreserved human 
hepatocytes (1 million cells/mL) 
As described in the Chapter 2, midazolam (1 μM) was incubated with pooled CHHs (1 
million cells/mL) for zero, 0.5, 1, 2, 4, 6, 10, 15, 30, 45, 60, 90 and 120 min. Whole-system 
loss of midazolam was assessed by the addition of stop reagent to each incubation 
sample (cells + medium) whereas medium loss was assessed by transferring an aliquot 
of cell-free medium to the stop reagent. Disappearance of midazolam was measured by 
LC-MS/MS, as described in Chapter 2. 
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3.5. Clearance of four CYP3A4/5 substrates in HLM and CHH. 
The in vitro clearance of midazolam, alfentanil, nifedipine and verapamil was evaluated 
in HLM and CHH at physiologically equivalent concentrations of 0.33 mg protein/mL and 
1 million cells/mL, respectively. The final concentration of each substrate was 1 µM.  The 
half-life of each drug was based on the rate of substrate loss (the initial loss conforming 
to first-order elimination), which was measured at multiple time points for up to 120 min 
with HLM and up to 240 min with CHH (see Figure 3.6). In vitro intrinsic metabolic 
clearance (CLint) and scaled in vivo intrinsic hepatic clearance (CLH,int) were estimated 
from in vitro half-life, as described in Chapter 2. 
As shown in Table 3.4, the in vivo hepatic intrinsic metabolic clearance (CLH,int) of 
alfentanil, nifedipine and verapamil estimated with HLM were 2.6- to 3.7-fold greater than 
those estimated with CHH. In contrast, midazolam CLH,int estimated with HLM was ∼9 
times greater than that estimated with CHH. These results suggest that the system-
dependent clearance of midazolam is more pronounced than that of other CYP3A4/5 
substrates. 
It is particularly noteworthy that, in the case of alfentanil, nifedipine and verapamil, rates 
of in vivo clearance predicted with HLM closely predicted their observed rates of blood 
clearance, but was underestimated by CHH by ~2-fold (Table 3.5). Likewise, blood 
clearance of midazolam was also accurately predicted based on in vitro experiments with 
HLM but was underestimated with CHH approximately 5-fold. These results establish that 
the system-dependent clearance of midazolam is not because HLM metabolize 
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midazolam at an unusually high rate but because CHH metabolize midazolam at an 
unusually low rate. 
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Table 3.3. Characteristics of the four CYP3A4/5 substrates used in measurements 
of intrinsic metabolic clearance in human liver microsomes and cryopreserved 
human hepatocytes 
Characteristic Midazolam Alfentanil Nifedipine Verapamil 
MW 326 417 346 455 
LogP1 3.93  2.81  2.97  5.04  
Total polar surface area (TPSA) 
(Å2)2 25 81 110 64 
Basic pKa2 − 7.5 − 9.0 
Major species at pH 7.4 Neutral Cation Neutral Cation 
Papp (A to B) in MDCK cells (nm/s)3 369 376 389 318 
Papp (A to B) in Caco-2 cells (nm/s)3 324 293 235 138 
Efflux ratio in MDCK or Caco-23 <2 <2 <2 <2 
Contribution of CYP3A 
enzymes to clearance 
in HLM4 
CYP3A 92 
ND 
95 95 
CYP3A4 43 81 54 
CYP3A5 49 14 41 
Plasma clearance (IV dosing) 
(L/h)2,3 22.3 − 25.9 16.4 − 17.6 30.7 − 31.7 49.1 − 75.6 
Rb (blood-to-plasma ratio)3 0.55 0.63 0.67 0.89 
Plasma protein binding (fuP)3 0.031 0.086 0.044 0.093 
Blood binding ((fuB)5 0.0564 0.1365 0.0657 0.1045 
Blood clearance (L/h)6 40.5 – 47.0 26.0 – 27.9 45.8 – 47.3 55.2 – 84.9 
Extraction ratio7 0.45 - 0.52 0.29 - 0.31 0.51 - 0.53 0.61 - 0.94 
Extraction classification 
(Low ≤0.3, high ≥0.7) 
Intermediate Low Intermediate High 
1 LogP values for midazolam and nifedipine are from Obach et al. (2008). LogP value for alfentanil and 
verapamil were estimated with commercial software available at: http://www.chemaxon.com 
2  Values are from Obach et al.(2008) 
3 Values are from Gertz et al. (2010) 
4 Estimates of the contribution of CYP3A enzymes to drug clearance in HLM are from Table 1 in Tseng et 
al. (2014) and are based on studies of in vitro half-life with HLM (from CYP3A4 and CYP3A5 extensive 
metabolizers) in the presence of ketoconazole (an inhibitor of both CYP3A4 and CYP3A5) or CYP3cide 
(a selective CYP3A4 inhibitor). ND: Not determined. 
5 Fraction of unbound drug in blood (fuB) = fuP/Rb. 
6 Blood clearance = plasma clearance/Rb. 
7 Extraction ratio = blood clearance/hepatic blood flow (QH), where QH = 90 L/h.  
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Figure 3.6. The in vitro clearance of the CYP3A4/5 substrates midazolam, alfentanil, 
nifedipine and verapamil at 1 μM in human liver microsomes (top) and 
cryopreserved human hepatocytes (bottom) 
Pooled cryopreserved human hepatocytes (CHH, 1 million cells/mL) or pooled human 
liver microsomes (HLM, 0.33 mg/mL) were incubated with midazolam (colored blue), 
alfentanil (colored red), nifedipine (colored purple) or verapamil (colored green) at 1 μM 
for up to 120 min (HLM) or 240 min (CHH). Disappearance of substrate was measured 
by LC-MS/MS. In vitro half-life and the first-order elimination rate constant (kel) were 
calculated as described in Chapter 2. 
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Table 3.4. Estimates of intrinsic clearance of four CYP3A4/5 substrates by human 
liver microsomes (HLM) and cryopreserved human hepatocytes (CHH) based on in 
vitro half-life. 
Drug Half-life (min) 
CLint 
(µL/min/mg 
protein or 
million cells) 
CLH,int 
(L/h) 
CLH,int 
corrected 
for fu,inc 
(L/h) 
Predicted 
hepatic 
clearance 
(CLH)1 
(L/h) 
Hepatic 
intrinsic 
clearance 
(CLH,int) ratio 
HLM (0.33 mg/mL in 50 mM phosphate buffer) HLM/CHH 
Midazolam 8.5 247 978 1553 44.4 8.9 
Alfentanil 21.9 96 380 432 35.6 3.7 
Nifedipine 11.5 183 723 851 34.5 2.6 
Verapamil 16.2 130 513 2445 66.6 3.1 
CHH (1 million cells/mL in KHB medium) CHH/HLM 
Midazolam 75 9.2 110 174 8.9 0.11 
Alfentanil 80.3 8.6 103 117 13.5 0.27 
Nifedipine 29.6 23.4 278 327 17.3 0.38 
Verapamil 49.6 14.0 166 791 43.1 0.32 
 
Microsomal CLH,int based on in vitro half-life (substrate disappearance) was calculated as follows: kel x 
volume of incubation/mg protein per incubation x 66,000 PBSF. Units were converted to L/h. 
Hepatocyte CLH,int  based on in vitro half-life (substrate disappearance) was calculated as follows: kel x 
volume of incubation/million cells per incubation x 198,000 PBSF. Units were converted to L/h. 
fuinc was calculated according to Hallifax and Houston, (2006) as shown in Table 1.2 based on values from 
Table 3.3 
1 Predicted hepatic clearance (CLH) is CLH,int corrected for both fuinc and fuB. based on Equation 1.8 and 
Equation 1.26. 
In vivo and physicochemical parameters of all drugs are from Table 3.3. 
  
143 
 
Table 3.5. Observed blood clearance of four CYP3A4/5 substrates following 
intravenous administration and blood clearance predicted from in vitro half-lived 
in human liver microsomes (HLM) and cryopreserved human hepatocytes (CHH) 
Drug 
Blood clearance 
(observed) 
(L/h) 
Blood clearance 
(CLH predicted with 
HLM) 
(L/h) 
Blood clearance 
(CLH predicted with 
CHH) 
(L/h) 
Midazolam 40.5 – 47.0 44.4 8.9 
Alfentanil 26.0 – 27.9 35.6 13.5 
Nifedipine 45.8 – 47.3 34.5 17.5 
Verapamil 55.2 – 84.9 66.6 43.1 
 
Predicted CLH values were calculated based on Equation 1.14 and Equation 1.26 respectively. 
Observed blood clearance values of all drugs are from Table 3.3. 
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3.6. Assessment of midazolam N-glucuronide as an inhibitor of 
CYP3A4/5 activity 
One notable difference between CHH and HLM is that hepatocytes convert midazolam to 
an N-glucuronide whereas microsomes supplement with only NADPH do not. To examine 
the possibility that midazolam N-glucuronide in inhibits the CYP3A4/5-dependent 
metabolism of midazolam, midazolam N-glucuronide (0.1−200 µM) was incubated with 
HLM (≤ 0.1 mg/mL) with and without a 30-min preincubation step in the presence of 
NADPH. CYP3A4/5 activity was measured based on the rate of midazolam 1ʹ-
hydroxylation, midazolam 4-hydroxylation and nifedipine oxidation (with each substrate 
at a final concentration roughly equal to Km), as described in Chapter 2. As shown in 
Figure 3.7, midazolam N-glucuronide did not inhibit midazolam nor nifedipine metabolism. 
Preincubating midazolam N-glucuronide for 30 min with HLM in the presence of NADPH 
appeared to increase the rate of midazolam 1′- and 4-hydroxylation but this probably an 
experimental artifact caused by an increase in midazolam concentration due to hydrolysis 
of midazolam N-glucuronide. These results suggest that midazolam N-glucuronide does 
not inhibit CYP3A4/5 activity; hence, formation of midazolam N-glucuronide is unlikely to 
account for the low rate of clearance of midazolam in CHH. 
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Figure 3.7. Evaluation of midazolam N-glucuronide as an inhibitor of CYP3A4/5 
activity toward midazolam 1ʹ-hydroxylation (top), midazolam 4-hydroxylation 
(middle) and nifedipine oxidation (bottom) in human liver microsomes (HLM) 
As described in Chapter 2 the inhibition of CYP3A4/5 as measured by midazolam 1ʹ-
hydroxylation (top), midazolam 4-hydroxylation (middle) and nifedipine oxidation (bottom) 
was performed with 0.1-200 μM midazolam N-glucuronide in HLM (≤ 0.1 mg/mL). 
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Midazolam N-glucuronide was preincubated with HLM for 0 and 30 min, after which 
CYP3A4/5 activity was measured with 5-min incubation with midazolam (4 μM) or 
nifedipine (10 μM).  
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DISCUSSION 
In the pharmaceutical industry HLM and CHH are commonly used to measure the in vitro 
metabolic intrinsic clearance (CLint) of new drug candidates in order to identify candidates 
with favorable pharmacokinetic properties such as once-a-day dosing and low oral dose. 
Physiologically based scaling factors (PBSF) can be used to extrapolate in vitro values of 
CLint to in vivo estimates of intrinsic hepatic metabolic clearance (CLH,int). However, based 
on a review of several databases, Chiba et al. (2009) reported that, on average, HLM 
underpredict in vivo clearance by a factor of 9 and CHHs underpredict by a factor of 3 to 
6. The greater underprediction of in vivo clearance by HLM can be attributed, at least in 
part, to the fact that, in contrast to hepatocytes, microsomes support a limited range of 
metabolic pathways either because a particular drug-metabolizing enzyme is expressed 
in another subcellular fraction (e.g., cytosolic sulfotransferases) or because the 
microsomes are supplemented with NADPH (to support CYP and FMO enzymes) but not, 
for example, with UDP-glucuronic acid (to support glucuronidation). However, for high 
intrinsic clearance drugs that are predominantly metabolized by cytochrome P450, 
hepatocytes underpredict in vivo clearance to a greater extent than microsomes (Lu et 
al., 2006; Hallifax et al., 2010).  
 
Several studies have compared predictions of hepatic clearance in vivo from in vitro 
studies with HLM and CHH (Hallifax et al., 2005; Riley et al., 2005; Lu et al., 2006; Brown 
et al., 2007b; Hallifax et al., 2010; Foster et al., 2011). For drugs whose clearance is 
determined by CYP-dependent metabolism, these two in vitro systems would be expected 
to provide similar estimates of in vivo metabolic clearance even if that estimate were an 
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under- or over-prediction. The agreement between microsomes and hepatocytes is quite 
good except for drugs with high intrinsic metabolic clearance, in which case hepatocytes 
underpredict in vivo clearance to a greater extent than microsomes (Foster et al., 2011). 
In the case of midazolam, a comparison of metabolic clearance by microsomes and 
hepatocytes prepared from the same livers revealed that microsomes support higher 
rates of clearance than hepatocytes by a factor of 5.6 to 41 fold (Foster et al., 2011). In 
the present study, I sought to determine the underlying reason why high clearance drugs 
like midazolam are metabolized relatively slowly in hepatocytes compared with 
microsomes. I initially tested two previously proposed explanations, namely that 
membrane permeability (Lu et al., 2006) or cofactor availability (Foster et al., 2011) 
restricts the metabolic clearance of midazolam in hepatocytes.  
 
The results summarized in Table 3.1 confirmed previous reports of system-dependent 
clearance of midazolam, a high clearance drug, but not dextromethorphan, a low 
clearance drug. In microsomal incubations at 0.33 mg/mL or hepatocyte incubations at 1 
million cells/mL, which contain equivalent amounts of microsomal protein, the half-life of 
dextromethorphan in CHH was comparable (within a factor of 2) to that in HLM. In 
contrast, the half-life of midazolam in CHHs was approximately one-tenth that in HLM. 
Values of in vitro CLint were extrapolated to in vivo values of CLH,int based on PBSFs of 
66,000 mg microsomal protein/liver for HLM and 198,000 million cells/liver for CHH. 
These values are based on the amount of microsomal protein per gram of liver (MPPGL; 
40 mg/g liver) and liver hepatocellularity (120 million cells/g liver) and an average human 
liver weight of 1,650 g, as described previously (Hakooz et al., 2006; Sohlenius-
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Sternbeck, 2006; Barter et al., 2007). The threefold difference in PBSF is the basis for 
equating HLM at 0.33 mg protein/mL with CHH at 1 million cells/mL. 
 
Between test systems, dextromethorphan CLint was similar in hepatocytes (at 1 μM and 
Cmax) and microsomes, which is consistent with previous findings (Brown et al., 2007b) 
whereas midazolam CLint in HLMs was approximately an order of magnitude greater than 
in CHH, as previously reported (Lu et al., 2006; Foster et al., 2011). To exclude the 
possibility that the pooled CHH used in these experiments had abnormally low CYP3A4/5 
activity, microsomes were prepared from the CHH and shown to have CYP3A4/5 activity 
comparable to that in pooled HLM prepared directly from human liver, as shown in Table 
3.2.  
 
Previous reports have proposed that the difference in microsomal and hepatocyte 
clearance of midazolam may be explained by limitations on midazolam clearance 
imposed by membrane permeability or cofactor availability in hepatocytes (Lu et al., 2006; 
Foster et al., 2011). To investigate these possibilities, the metabolic clearance of 
midazolam was measured in CHH that were permeabilized by sonication or saponin 
treatment with and without supplementation with NADPH. If membrane permeability were 
rate limiting, sonication or saponin treatment would be expected to increase the rate of 
midazolam metabolism, but no such increase was observed, as shown in Figure 3.4. 
Furthermore, permeabilization plus NADPH supplementation did not increase the rate of 
midazolam metabolism. These results suggest that neither membrane permeability nor 
cofactor availability accounts for the relatively low rate of midazolam metabolism by CHH. 
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The inability of additional exogenous NADPH to influence the metabolism of midazolam 
is consistent with the abundance of NAPDH cofactor in hepatocytes, which has been 
suggested to reach cytosolic concentrations of at least 100 µM based on data from rat 
livers (Lowry et al., 1961; Veech et al., 1969; Reiss et al., 1984). The Km value for NADPH 
with P450 oxidoreductase (NADPH-cytochrome c reductase) is approximately 5 µM (Sem 
and Kasper, 1993), suggesting that even at 50 µM NADPH (10x Km) all of P450-
oxidoreductase present in the hepatocyte would support near maximal rates of P450 
metabolism. This value (50 µM NADPH) is half the lowest estimate of hepatic NADPH 
levels (and one-tenth the highest estimate) (Lowry et al., 1961; Veech et al., 1969; Reiss 
et al., 1984). Therefore, unless NADPH production is severely compromised in isolated 
hepatocytes, they should contain sufficient NADPH to support near maximal rates of P450 
metabolism. The possibility that membrane permeability restricts midazolam clearance in 
CHH was also investigated in a whole-system loss versus medium loss experiment with 
CHH. As shown in Figure 3.5, the rate of loss of midazolam from the cell culture medium 
(due to a combination of uptake and metabolism) greatly exceeded the rate of whole-
system loss (due to metabolism alone), suggesting that membrane permeability does not 
restrict the metabolic clearance of midazolam by CHHs. These results are consistent with 
observations by Foster and colleagues (2011) that membrane permeability did not 
account for the relatively low rate of midazolam clearance in CHH because no difference 
between HLM and CHH in the Km for midazolam clearance or metabolite formation was 
seen. However, membrane permeability may play a role in the restricted clearance 
between in vitro test systems of some other high CLint CYP3A4/5 substrates. For example, 
simvastatin, saquinivir and tacrolimus have been shown to have much higher CLint values 
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in HLM than midazolam (2.5- to 22-fold higher) (Tseng et al., 2014), but have lower 
passive permeability based on their calculated topological polar surface area values 
(TPSA = 70-178 Å2 versus 30 Å2 for midazolam). Polar surface area has been previously 
shown to be a good measure of the passive permeability of a compound, with high rates 
of passive diffusion shown to occur at low TPSA (<60 Å2) and low rates of passive 
diffusion shown to occur at TPSA values above 75 Å2 (Palm et al., 1997; Smith and 
Dalvie, 2012). Based on these parameters, the rate of clearance of simvastatin, saquinivir 
and tacrolimus would be expected to be limited by membrane permeability in CHH, a 
factor that is not predicted or experimentally evident with midazolam. 
 
In contrast to the situation with midazolam, the clearance of alfentanil, nifedipine and 
verapamil by HLM was up to 3.7-fold greater than that by CHH. In the case of the 
CYP3A4/5 substrates, rates of in vivo clearance predicted with HLM accurately predicted 
their observed rates of blood clearance; however, CHH underestimated in vivo clearance 
by ~2-fold (Table 3.5). Likewise, blood clearance of midazolam was accurately predicted 
based on in vitro experiments with HLM but was underestimated with CHH (approximately 
5-fold). These results establish that the system-dependent clearance of midazolam is not 
because HLM metabolize midazolam at an unusually high rate but because CHH 
metabolize midazolam at an unusually low rate. There is nothing obvious that 
distinguishes alfentanil, nifedipine and verapamil from midazolam, as summarized in 
Table 3.3. All four drugs have a relatively high logP and low TPSA, such that they are 
predicted to cross biological membranes with a high rate of passive diffusion, which is 
supported by their high rates of permeation across monolayers of MDCK and Caco-2 cells 
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(Table 3.3). In HLM from CYP3A4 and CYP3A5 extensive metabolizers (i.e., liver 
microsomes prepared from donors with a *1/*1 genotype for both enzymes), CYP3A5 
contributes significantly to the metabolism of midazolam, but the same is true of verapamil 
and, to a lesser extent, nifedipine (Tseng et al. (2014) and Table 3.3). 
In hepatocytes, midazolam is also converted to an N-glucuronide (Hyland et al., 2009), 
which raises the possibility that the system-dependent clearance of midazolam involves 
inhibition of midazolam hydroxylation by midazolam N-glucuronide, which would form in 
CHH but not in HLM (at least not in the absence of UDPGA). The results presented in 
Figure 3.7 tested this possibility, and no inhibition of midazolam hydroxylation or 
nifedipine oxidation was observed by midazolam N-glucuronide in HLM, suggesting that 
formation of midazolam N-glucuronide does account for the relatively low rate of 
midazolam clearance in hepatocytes. The results presented in Figure 3.4 and Table 3.5 
lend further support to this interpretation. When CHH were permeabilized by sonication 
or saponin treatment, which releases UDPGA and inhibits glucuronidation, there was no 
increase in midazolam hydroxylation even when the permeabilized hepatocytes were 
supplemented with NADPH. Furthermore, N-glucuronidation of midazolam occurs in 
hepatocytes in vitro and in vivo; hence, if midazolam N-glucuronide impeded the 
clearance of midazolam in CHH in vitro it would be expected to have the same effect in 
vivo (Table 3.5).  
 
The results of this study raise several questions. When comparing HLM and CHH, 
system-dependent clearance was observed with midazolam but not dextromethorphan.  
Is this because midazolam is a high clearance drug whereas dextromethorphan is a low 
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clearance drug, or is it because midazolam is a CYP3A4/5 substrate whereas 
dextromethorphan is a CYP2D6 substrate? The clearance of 3 other CYP3A4/5 
substrates, namely alfentanil, nifedipine and verapamil, was also found to be test system 
dependent, with CHH underpredicting in vivo clearance up to 3.7-fold compared to HLM. 
However the clearance of midazolam was underpredicted by CHH ~9-fold in comparison 
to HLM. These results suggest some other factor, such as test system incubation 
conditions, may be involved in the pronounced system-dependent clearance of 
midazolam. These questions are addressed in Chapter 4. 
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CHAPTER 4 : TEST SYSTEM-DEPENDENT DRUG CLEARANCE 
PART 2: THE EFFECT OF BUFFER IONIC STRENGTH AND VARIOUS 
CELL CULTURE MEDIA ON THE IN VITRO METABOLISM OF 
CYTOCHROME P450 SUBSTRATES IN HUMAN LIVER MICROSOMES 
AND CRYOPRESERVED HUMAN HEPATOCYTES 
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ABSTRACT 
In the previous chapter, I verified previous reports that the intrinsic metabolic clearance 
of midazolam by cryopreserved human hepatocytes (CHH) is nearly an order of 
magnitude less than midazolam clearance by human liver microsomes (HLM). This 
discrepancy could not be explained by membrane permeability- or cofactor-restricted 
clearance of midazolam in CHH. Three other CYP3A4/5 substrates also exhibited 
system-dependent clearance but not to the same extent as midazolam. The present study 
examined in vitro factors that might account for system-dependent clearance of 
midazolam. Buffer ionic strength and cell culture media were examined for their effects 
on P450 enzymes in HLM, human S9 fraction (HS9) and CHH, including their effects on 
multiple CYP3A4/5 substrates. CYP3A4/5 and CYP2E1 activities were found to increase 
with increasing buffer ionic strength in HLM, whereas other P450 activities peaked at 50 
mM phosphate. Midazolam metabolism in HLM and HS9 was markedly reduced in the 
presence of certain cell culture media, namely, Waymouth’s, MCM+ and DMEM, but this 
effect was not observed with other substrates of CYP3A4/5, nor was it observed to the 
same extent in CHH. Kinetic analysis of CYP3A4/5 activity in HLM incubated in the 
complete versions and salt-only versions of cell culture media suggested the presence of 
inhibitory components especially in MCM+, which increased the Km for midazolam 
hydroxylation by 50 fold. None of the cell culture media examined improved the prediction 
of midazolam clearance in CHH; hence, none solved the problem of system-dependent 
clearance. Overall, this study was unable to solve or provide a mechanistic basis for the 
system-dependent clearance of midazolam; however, this study provided further insight 
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into the effects of in vitro incubation conditions on P450 activity and supported 
recommendations for improvements in the design of in vitro studies of drug clearance.  
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INTRODUCTION 
Human liver microsomes (HLM) and cryopreserved human hepatocytes (CHH) are the 
two in vitro test systems most commonly used in the pharmaceutical industry for 
predicting drug clearance in vivo. Both of these test systems have been shown to 
underpredict in vivo clearance: microsomes by a factor of 9 and hepatocytes by a factor 
of 3 to 6 depending on the database (Chiba et al., 2009). Although there is a systematic 
underprediction with both test systems, it is reasonable to assume that, in the case of 
drugs whose primary route of clearance involves P450-mediated metabolism, both 
microsomes and hepatocytes should provide similar predictions of in vivo clearance. This 
is the case for most drugs, with the notable exception of certain high intrinsic clearance 
(CLint) drugs like midazolam, where hepatocytes underpredict in vivo clearance to a 
greater extent than liver microsomes (Hallifax et al., 2005; Lu et al., 2006; Foster et al., 
2011). In Chapter 3, I examined the clearance of midazolam, a high intrinsic clearance 
drug metabolized predominantly by CYP3A4 and CYP3A5 (Tseng et al., 2014), in HLM 
at 0.33 mg protein/mL and CHH at 1 million cells/mL, which are physiologically equivalent 
concentrations based on the content of microsomes in human liver (40 mg microsomal 
protein/g liver) and the cellularity of human liver (120 million cells/g liver) (Hakooz et al., 
2006; Sohlenius-Sternbeck, 2006; Barter et al., 2007). When corrected for the unbound 
fraction of drug in the test system (fu,inc) and extrapolated to in vivo clearance based on 
physiologically based scaling factors (PBSF), intrinsic hepatic metabolic clearance in vivo 
(CLH,int) was estimated to be 978 L/h based on the half-life of midazolam in HLM and only 
110 L/h based on the half-life of midazolam in CHH (both determined at 1 µM midazolam). 
The values of CLH,int , which differ by 8.9 fold, assume that hepatic clearance in vivo is 
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not restricted by hepatic blood flow or binding to plasma protein. When hepatic blood flow 
(QH = 90 L/h) and binding of midazolam to blood (fu,B = 0.0564) are taken into 
consideration, HLM and CHH predict in vivo rates of hepatic clearance (CLH) of 44.4 and 
8.9 L/h. Blood clearance of intravenously administered midazolam is approximately 44 
L/h (40.5 to 47.0 L/h); hence, HLM accurately predicted the actual in vivo clearance of 
midazolam whereas CHH underpredicted in vivo clearance by almost a factor of 5.   
Midazolam is the most commonly used in vitro and in vivo probe of CYP3A4/5 activity. 
Accordingly, it is somewhat surprising that the marked difference in midazolam clearance 
between HLM and CHH has received relatively little attention, with the notable exception 
of studies published by Lu et al. (2006) and Foster et al. (2011). Furthermore, based on 
the large number of drugs whose clearance is determined by CYP3A4 (second to no other 
CYP enzyme), the system-dependent clearance of midazolam has potential implications 
for numerous other drugs. It is possible that system-dependent clearance (i.e., lower-
than-expected clearance in CHH compared with HLM) is a characteristic of midazolam 
that is more pronounced than other CYP3A4/5 substrates. It was shown in Chapter 3 that 
three other CYP3A4/5 substrates, namely alfentanil, nifedipine and verapamil, also 
exhibited system-dependent intrinsic clearance (up to 3.7-fold) but not to the same extent 
as midazolam (∼9 fold), and once again HLM accurately predicted the hepatic clearance 
(CLH) of these three CYP3A4/5 substrates, whereas CHH underpredicted CLH by 
approximately a factor of 2. In some respects, this makes the system-dependent 
clearance of midazolam all the more intriguing because it suggests there may be a 
particularly pronounced impairment of midazolam clearance by CHH. 
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In the present study, various in vitro incubation conditions were examined for their effects 
on CYP activity in HLM and CHH in an attempt to identify the basis for the system-
dependent metabolism of midazolam. The effects of buffer ionic strength on the activities 
of a panel of P450 enzymes, namely CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5 (with multiple substrates), were examined 
in HLM and HS9 (hepatic post-mitochondrial supernatant fraction containing microsomes 
and cytosol). The effects of five common cell culture media (KHB, Waymouth’s, MCM+, 
DMEM, and Williams’ E) on P450 activities in CHH and HLM were also examined. The 
aim of the media studies in CHH was to identify a cell culture medium that preferentially 
increases the rate of metabolism of midazolam over that of other CYP3A4/5 substrates. 
The aim of the media studies in HLM was to investigate the possibility that cell culture 
media contain a substance that preferentially inhibits the metabolism of midazolam over 
other CYP3A4/5 substrates. 
  
160 
 
RESULTS 
4.1. Effects of buffer ionic strength and pH on midazolam 
1ʹ-hydroxylation by HLM 
HLM are typically incubated in phosphate buffer (generally 50 or 100 mM phosphate at 
pH 7.4) whereas CHH are always incubated in cell culture medium. Having determined 
that neither membrane permeability nor cofactor availability restricts the metabolic 
clearance of midazolam in CHH (Chapter 3), experiments were conducted to examine the 
effect of buffer ionic strength on CYP3A4/5 midazolam activity in HLM. As described in 
Chapter 2, phosphate buffers of varying ionic strength (at pH 7.4) were incubated with 
NADPH-fortified HLM (0.1 mg/mL) containing 1 μM midazolam. Formation of 1′-
hydroxymidazolam was measured after 5 min. The results are shown in Figure 4.1. 
Increasing the concentration of phosphate buffer from 10 to 200 mM caused a 
progressive increase in the rate of midazolam metabolism.  
To assess whether the effect of phosphate concentration on CYP3A4/5 activity was due 
to ionic strength and not phosphate ion itself, HLM (0.1 mg/mL) were incubated in 10 mM 
phosphate buffer (pH 7.4) containing 50 to 500 mM potassium chloride. As shown in 
Figure 4.1, CYP3A4/5 activity was stimulated by potassium chloride at concentrations up 
to 300 mM. Interestingly, 300 mM potassium chloride stimulated midazolam 1ʹ-
hydroxylation (261% increase) more than midazolam 4-hydroxylation (167% increase). 
To assess the effect of pH on the rate of metabolism of midazolam (1 µM), HLM were 
incubated in three concentrations of phosphate buffer (10, 50 and 200 mM) at six pH 
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values ranging from 6.8 to 8.0. Formation of 1′-hydroxymidazolam was measured after 5 
min. The results are shown in Figure 4.1. The highest rate of midazolam metabolism at 
10, 50 and 200 mM phosphate was observed at pH 8.0, 7.4 and 7.2, respectively, but the 
effects of pH were relatively minor.  
The results suggest that the common practice of incubating HLM in high ionic strength 
buffer is partly responsible for the relatively high rate of midazolam metabolism by HLM 
compared with hepatocytes.  
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Figure 4.1. The effect of phosphate buffer (top), potassium chloride (middle) and 
pH (bottom) on midazolam hydroxylation in human liver microsomes (HLM) 
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The formation of 1ʹ-hydroxymidazolam was assessed in pooled HLM (0.1 mg/mL) 
incubated in various concentrations of potassium phosphate buffer (10-300 mM 
phosphate, pH 7.4; top panel). Furthermore, the formation of 1ʹ-hydroxymidazolam and 
4-hydroxymidazolam was assessed in HLM (0.1 mg/mL) incubated in various 
concentrations of potassium chloride (0-500 mM, middle panel) containing 10 mM 
phosphate. The rate of formation of 1ʹ-hydroxymidazolam was determined in HLM (0.1 
mg/mL) incubated in three concentrations of phosphate (10, colored blue; 50, colored 
purple; and 200 mM, colored yellow) at six pH values (bottom panel). The final 
concentration of midazolam was 1 μM and the incubation time was 5 min. Formation of 
1ʹ-hydroxymidazolam was measured by LC-MS/MS, as described in Chapter 2. The rate 
of formation of 1ʹ-hydroxymidazolam in 50 mM phosphate buffer at pH 7.4 (standard 
buffer conditions) was set to 100%. 
 
  
164 
 
4.2. Effects of buffer ionic strength and cell culture media on various 
P450 activities in HLM 
HLM (0.1 mg/mL) were incubated in three concentrations of phosphate buffer (5, 50 and 
200 mM, all at pH 7.4) or one of five cell culture media, namely KHB, Waymouth’s, MCM+, 
DMEM and Williams’ E, designated A-E, respectively. Based on their salt composition, 
four of these media (KHB, Waymouth’s, DMEM and Williams’ E) have similar ionic 
strengths (163-182 mM) whereas MCM+ has a twofold higher ionic strength (361 mM), 
as shown in Table 4.3 and Table 2.1 in Chapter 2. The activities of CYP1A2 (40 µM 
phenacetin), CYP2A6 (5 µM coumarin), CYP2B6 (50 µM bupropion), CYP2C8 (7 µM 
amodiaquine), CYP2C9 (6 µM diclofenac), CYP2C19 (40 µM S-mephenytoin), CYP2D6 
(7.5 µM dextromethorphan), CYP2E1 (30 µM chlorzoxazone) and CYP3A4/5 (4 µM 
midazolam) were determined with the P450-selective substrates listed in parentheses, as 
described in Chapter 2. The substrate concentration was equal to Km except for the high 
turnover substrates coumarin and amodiaquine, where the concentration of substrate was 
5-10 times Km in order to measure metabolite formation under initial rate conditions.  
As shown in Figure 4.2, when HLM were incubated in phosphate buffer and various cell 
culture media, the CYP enzymes could be divided into three groups (A-C). Group A 
enzymes included CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19 and CYP2D6; their 
activity was highest in 50 mM phosphate buffer and it was higher in Waymouth’s, MCM+ 
and DMEM compared with KHB or Williams’ E (i.e., in the order they are shown in Figure 
4.2, the media show a bell-shaped curve). Group B enzymes included CYP3A4/5 and 
CYP2E1; their activity was highest in 200 mM phosphate buffer and it was higher in KHB 
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and Williams E’ compared with Waymouth’s, MCM+ and DMEM (i.e., in the order they 
are shown in Figure 4.2, the media show an inverse bell-shaped curve). CYP2C9 (Group 
C) had the highest activity in 50 mM phosphate buffer (like the Group A enzymes) but 
showed slightly lower activity in KHB and Williams’ E compared with Waymouth’s, MCM+ 
and DMEM (like the Group B enzymes). 
If the various effects of cell culture media on P450 activity were due to differences in ionic 
strength then MCM+, which has twice the ionic strength of the other four media and 
exceeds that of 50 mM phosphate, would be expected to support the highest activity of 
CYP3A4/5 and CYP2E1, the two enzymes whose activity increased when the 
concentration of phosphate buffer was increased from 50 mM to 200 mM. However, 
MCM+ supported the lowest (or close to the lowest) activity of CYP3A4/5 and CYP2E1. 
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Figure 4.2. The effect of different concentrations of phosphate buffer (5-200 mM, 
pH 7.4) and five cell culture media on CYP enzyme activity in human liver 
microsomes.  
The activities of nine P450 enzymes were assessed in pooled HLM (0.1 mg/mL) with 
marker substrates for CYP1A2 (phenacetin, 40 μM), CYP2A6 (coumarin, 5 μM), CYP2B6 
(bupropion, 50 μM), CYP2C8 (amodiaquine, 7 μM), CYP2C9 (diclofenac, 6 μM), 
CYP2C19 (S-mephenytoin, 40 μM), CYP2D6 (dextromethorphan, 7.5 μM), CYP2E1 
(chlorzoxazone, 30 μM), and CYP3A4/5 (midazolam, 4 μM); with 5, 50, and 200 mM 
phosphate buffer, pH 7.4 or with KHB (A), Waymouth’s (B), MCM+ (C), DMEM (D), and 
Williams’ E (E) cell culture media. P450 activities are phenacetin O-dealkylation 
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(CYP1A2), coumarin 7-hydroxylation (CYP2A6), bupropion hydroxylation (CYP2B6), 
amodiaquine N-dealkylation (CYP2C8), diclofenac 4ʹ-hydroxylation (CYP2C9), S-
mephenytoin 4ʹ-hydroxylation (CYP2C19), dextromethorphan O-demethylation 
(CYP2D6) and midazolam 1ʹ-hydroxylation (CYP3A4), which were measured as 
described in Chapter 2. P450 activity in 50 mM phosphate buffer (standard incubation 
conditions) was set to 100%. 
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4.3. Effects of various cell culture media on P450 activities in CHH. 
The effects of various cell culture media on P450 activity were assessed in pooled CHH 
(n = 50) at 1 million cells/mL. Metabolite formation from CYP-selective substrates was 
measured at 10, 30 and 60 min, as described in Chapter 2. The results for the 30-min 
time point are shown in Figure 4.3. Williams’ E supported slightly higher rates of 
midazolam 1ʹ-hydroxylation than KHB (the medium used to measure midazolam 
clearance in CHH in Chapter 3). However, the increase was too small to correct the large 
underprediction of midazolam clearance in CHH. The other media (Waymouth’s, MCM+ 
and DMEM) supported lower rates of midazolam 1’-hydroxylation than KHB, suggesting 
these media only amplify the system-dependent clearance of midazolam. The effects of 
media on CYP3A4/5 activity in CHH (which showed an inverse bell-shaped curve based 
on their order in Figure 4.3) resembled their effects on CYP3A4/5 activity in HLM (Figure 
4.2), albeit to a lesser extent. 
There were no marked effects of cell culture media on the activity of CYP1A2, CYP2B6, 
CYP2C8, and CYP2D6 in CHH. In contrast to their activity in HLM, the activity of these 
enzymes in CHH was not notably higher in Waymouth’s, MCM+ and DMEM compared 
with KHB and Williams’ E (i.e., there was no bell-shaped curve). MCM+ did support the 
highest activity of CYP2C19 in both HLM and CHH, but this was the exception rather than 
the rule. 
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Figure 4.3. The effect of various media on multiple P450 activities in human 
hepatocytes over time 
Seven P450 activities, namely CYP1A2 (phenacetin, 40 μM), CYP2B6 (bupropion, 50 
μM), CYP2C8 (amodiaquine, 2 μM), CYP2C9 (tolbutamide, 150 μM), CYP2C19 
(S-mephenytoin, 40 μM), CYP2D6 (dextromethorphan, 7.5 μM), and CYP3A4/5 
(midazolam, 4 μM) were assessed with CHH (1 million cells/mL) with five common cell 
culture media for 30 min as described in Chapter 2. The activity in KHB medium was set 
to 100%.  
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4.4. Effects of buffer ionic strength and cell culture media on the 
metabolism of multiple CYP3A4/5 substrates in HLM and HS9 
To determine whether the effect of buffer ionic strength and cell culture media on the 
metabolism of midazolam by HLM occurred with other CYP3A4/5 substrates, HLM (0.1 
mg/mL) and HS9 (0.25 mg/mL) were incubated with three concentrations of phosphate 
buffer (5, 50 and 200 mM) or one of five cell culture media, and one of six CYP3A4/5 
substrates, namely midazolam, nifedipine, alfentanil, verapamil, testosterone and 
atorvastatin. Rates of midazolam 1ʹ- and 4-hydroxylation, nifedipine oxidation, alfentanil 
N-dealkylation, verapamil N-dealkylation, testosterone 6β-hydroxylation, and atorvastatin 
ortho-hydroxylation were measured as described in Chapter 2. 
As shown in Figure 4.4, the activity of CYP3A4/5 in both HLM and HS9 increased toward 
all six substrates when the concentration of phosphate buffer was increased up to 200 
mM. The degree of activation observed when the concentration of phosphate buffer was 
increased from 50 mM to 200 mM varied from one substrate to the next (from 37% to 
172%), and this effect was observed in both HLM and HS9 (to roughly the same extent). 
In contrast to midazolam, the five other CYP3A4/5 substrates (nifedipine, alfentanil, 
verapamil, testosterone and atorvastatin) were all metabolized by HLM and HS9 to a 
similar extent in all five media (within a factor of ∼2 of the rate supported by 50 mM 
phosphate buffer). Two media, namely KHB and Williams’ E (media B and E), also 
supported the 1′- and 4-hydroxylation of midazolam by HLM and HS9 at rates within a 
factor of ∼2 of that supported by 50 mM phosphate buffer. In contrast, midazolam 
metabolism was greatly reduced (~90%) when HLM and HS9 were incubated in 
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Waymouth’s, MCM+ and DMEM (media B, C and D) compared with that in 50 mM 
phosphate buffer. These results suggest that cell culture media affect the metabolism of 
midazolam by HLM and HS9 differently than the other five CYP3A4/5 substrates 
examined. This raises the possibility that cell culture media contain one or more 
substances capable of selectively impairing the metabolism of midazolam. 
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Figure 4.4. The effect of phosphate buffer concentration (5-200 mM, pH 7.4 and cell 
culture media on the metabolism of six CYP3A4/5 substrates by human liver 
microsomes (top) and human S9 fraction (bottom). 
Six CYP3A4/5 marker substrates, namely, midazolam (4 μM), nifedipine (10 μM), 
alfentanil (40 μM), verapamil (9 μM), testosterone (70 μM) and atorvastatin (40 μM) were 
incubated with pooled human liver microsomes (0.1 mg/mL) or pooled human S9 fraction 
(0.25 mg/mL) with 5, 50 and 200 mM phosphate buffer (pH 7.4) or one of five cell culture 
media, namely KHB (A), Waymouth’s (B), MCM+ (C), DMEM (D) and Williams’ E (E). 
Rates of midazolam 1ʹ- and 4-hydroxylation, nifedipine oxidation, alfentanil N-
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dealkylation, verapamil N-dealkylation, testosterone 6β-hydroxylation, and atorvastatin 
ortho-hydroxylation were measured as described in Chapter 2. Downward arrows 
highlight the low rate of midazolam metabolism when HLM or HS9 was incubated in 
Waymouth’s, MCM+ or DMEM (media B, C and D). Rates of metabolism in 50 mM 
phosphate buffer (standard incubation conditions) were set to 100%.  
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4.5. Effects of various cell culture media on the metabolism of 
multiple CYP3A4/5 substrates in CHH. 
To determine the effect of various cell culture media on CYP3A4/5 activity towards 
multiple substrates in hepatocytes, pooled CHH (1 million cells/mL) were incubated in five 
different media and with six different substrates, namely midazolam, nifedipine, alfentanil, 
verapamil, testosterone and atorvastatin. Measurements of CYP3A4/5 activity were 
based on rates of by midazolam 1ʹ-hydroxylation, nifedipine oxidation, alfentanil 
N-dealkylation, verapamil N-dealkylation, testosterone 6β-hydroxylation, and atorvastatin 
ortho-hydroxylation, as described in Chapter 2. The results are shown in Figure 4.5. For 
all six substrates there were negligible differences (<10%) between KHB and Williams’ E 
media. These two media supported the highest rates of metabolism of midazolam and 
nifedipine. Waymouth’s medium supported the highest rate of alfentanil metabolism; 
DMEM supported the highest rate of verapamil metabolism and MCM+ supported the 
highest rates of testosterone and atorvastatin. The results suggest that cell culture media 
can affect CYP3A4/5 activity in CHH in a substrate-dependent manner. 
Cell viability was monitored at various times over a 240-min incubation of CHH in each of 
the five cell culture media, as described in Chapter 2. As shown in Table 4.1, KHB 
supported the highest initial cell viability, but had the lowest overall hepatocyte viability at 
the end of the 4-h incubation (68%). Williams’ E medium supported the highest overall 
viability (79% at 4 h). These results suggest that differences in cell viability are not a major 
contributor to medium-dependent differences in CYP3A4/5 activity in CHH. 
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Figure 4.5. The effect of cell culture media on the metabolism of six CYP3A4/5 
substrates in cryopreserved human hepatocytes. 
The rate of metabolism of six CYP3A4/5 marker substrates, namely, midazolam (4 μM), 
nifedipine (10 μM), alfentanil (40 μM), verapamil (9 μM), testosterone (70 μM) and 
atorvastatin (40 μM), was assessed in pooled cryopreserved human hepatocytes (1 
million cells/mL) suspended in one of five different cell culture media (KHB, Waymouth’s, 
MCM, DMEM and Williams’ E) and incubated for 30 min, as described in Chapter 2. Rates 
of metabolism were based on measurements of midazolam 1ʹ-hydroxylation, nifedipine 
oxidation, alfentanil N-dealkylation, verapamil N-dealkylation, testosterone 6β-
hydroxylation, and atorvastatin ortho-hydroxylation. Rates of metabolism in KHB medium 
were set to 100%. 
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Table 4.1. The effect of various cell culture media on the viability of pooled 
cryopreserved human hepatocytes (1 million cells/mL) over a 240-min incubation 
period 
Incubation 
time  
(min) 
Average Viability  
(%) 
KHB Waymouth’s MCM+ DMEM  Williams’ E  
0 84.1 76.3 77.7 82.5 77.2 
30 71.4 83.6 80.8 69.0 88.8 
60 65.0 77.1 70.1 74.8 80.0 
120 64.5 68.3 68.4 78.3 76.1 
240 52.6 Not determined 71.4 62.1 72.7 
Overall 
Average 67.5 76.3 73.7 73.3 79.0 
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4.6. Effects of cell culture media on the kinetics of midazolam and 
chlorzoxazone metabolism in HLM 
When HLM were used to examine the effects of ionic strength and cell culture media on 
CYP activity (Section 4.1), the various CYP enzymes examined could be divided into 
three groups (A-C). The Group B enzymes, namely CYP2E1 and CYP3A4/5, were 
distinguished by their high activity in 200 mM phosphate buffer and their low activity in 
Waymouth’s, MCM+ and DMEM media (relative to KHB and Williams’ E media), as shown 
in Figure 4.2. Experiments were conducted to determine how cell culture media influence 
the kinetics of midazolam and chlorzoxazone metabolism by HLM. Km and Vmax were 
determined by incubating HLM (0.1 mg/mL) with 5-30 μM midazolam or 5-250 μM 
chlorzoxazone for 5 min, as described in Chapter 2. The kinetic plots are shown in Figure 
4.6 and the results are summarized in Table 4.2 and Figure 4.7. 
The results in Figure 4.7 show the effects of each cell culture medium on Vmax, Km and 
clearance (determined from Vmax/Km) in comparison with values determined when HLM 
were incubated in 50 mM phosphate buffer (standard incubation conditions). Based on 
their effects on CYP3A4/5 activity, the cell culture media could be divided in two groups. 
The first group, namely KHB, Waymouth’s, and DMEM, caused a relatively modest 
increase in Km and a modest decrease in Vmax. The second group, namely MCM+ and 
Williams’ E medium, caused a marked increase in Km and a modest increase in Vmax. 
Compared with 50 mM phosphate buffer, all cell culture media decreased the intrinsic 
clearance (CLint) of midazolam. Similar but not identical results were observed with 
CYP2E1. For example, the same two buffers (MCM+ and Williams’ E) that caused the 
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largest increase in the Km of CYP3A4/5 also caused the largest increase in Km of CYP2E1. 
For both CYP3A4/5 and CYP2E1, the effects of MCM+ and Williams’ E on clearance were 
more pronounced than those of KHB, Waymouth’s and DMEM. 
The marked increase in Km for midazolam hydroxylation observed with MCM+ and 
Williams’ E suggest these media contain a substance that competitively inhibits 
CYP3A4/5 activity in HLM. These two media increased Km and decreased midazolam 
clearance (Vmax/Km) to a greater extent than KHB, Waymouth’s or DMEM; however, these 
latter three media also decreased midazolam CLint by a factor of 3 to 5. The decreases in 
midazolam CLint observed with all five media might be a consequence of their relatively 
low ionic strength (with the exception of MCM+) or it might be due to presence of inhibitory 
substances. These possibilities were examined by comparing each medium with its salt-
only version on CYP3A4/5 activity in HLM, as described in the following section. 
  
179 
 
 
Figure 4.6. Kinetics of midazolam 1ʹ-hydroxylation (CYP3A4/5; top) and 
chlorzoxazone 6-hydroxylation (CYP2E1; bottom) by pooled human liver 
microsomes incubated in 50 mM phosphate buffer or various cell culture media 
The Km and Vmax of 1ʹ-hydroxymidazolam and 6-hydroxychlorzoxazone formation were 
determined in incubations with pooled HLM (0.1 mg/mL) and eight concentrations of 
midazolam (0.5-30 μM) or chlorzoxazone (5-250 μM) for 5 min in the presence of KHB, 
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Waymouth’s, MCM+, DMEM, or Williams’ E cell culture medium as described in Chapter 
2. 
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Table 4.2. Summary of kinetic constants (Km and Vmax) and scaled values of hepatic 
clearance (CLint) based on Vmax/Km for midazolam and chlorzoxazone metabolism 
by human liver microsomes incubated in 50 mM phosphate buffer or various cell 
culture media 
Buffer or Media 
Midazolam 
1ʹ-hydroxylation 
Chlorzoxazone 
6-hydroxylation 
Vmax 
(pmol/mg/min) 
Km 
(μM) 
CLint 
(L/h) 
Vmax 
(pmol/mg/min) 
Km 
(μM) 
CLint 
(L/h) 
50 mM potassium 
phosphate, pH 7.4 2020 2.2 3640 2860 30 378 
KHB 1400 4.4 1260 2350 47 198 
Waymouth’s 1470 5.7 1020 2090 89 93 
MCM+ 5240 111 186 3200 208 61 
DMEM 1270 6.7 750 1670 51 130 
Williams’ E  2570 51 199 2080 137 60 
 
Microsomal CLint was calculated as follows: Vmax/Km x 66,000 PBSF. Units were converted to L/h 
Note: All CLint vales have not been corrected for binding 
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Figure 4.7. Effects of cell culture media on the kinetics of midazolam 1ʹ-
hydroxylation and chlorzoxazone hydroxylation in human liver microsomes: Ratio 
of Vmax, Km and CLint (Vmax/Km) values in media and those determined in 50 mM 
phosphate buffer. 
Values of Vmax, Km and CLint (Vmax/Km) are presented in Table 4.2. The cell culture media 
were KHB (A), Waymouth’s (B), MCM+ (C), DMEM (D) and Williams’ E (E). 
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4.7. Evaluating cell culture media for the presence of CYP3A4/5 
modulators 
To evaluate whether the decrease in midazolam clearance (Vmax/Km) observed when HLM 
were incubated in cell culture media is attributable to an effect of ionic strength or the 
presence of a CYP3A4/5 inhibitor, each cell culture medium was compared with its ‘salt-
only’ version for its effects on the metabolism of six CYP3A4/5 substrates by HLM.  The 
salt-only version of each medium was a solution containing only the inorganic salts 
present in each cell culture medium (at matching concentrations), as shown in Table 4.3 
and Table 2.1 in Chapter 2.  
The differences between a complete medium and its salt-only version were both substrate 
and medium dependent, as shown in Figure 4.8. In the case of nifedipine, alfentanil and 
verapamil metabolism, there were only small differences between the complete and salt-
only versions of each medium. In the case of midazolam, the relatively low rates of 1ʹ- 
and 4-hydroxylation in Waymouth’s, MCM+ and DMEM all increased when HLM were 
incubated in the salt-only versions of these media, suggesting that the complete versions 
of these media contain an inhibitor of midazolam metabolism. Based on this 
interpretation, the complete version of Williams’ E medium may also contain an inhibitor 
because the rate of midazolam 1ʹ- and 4-hydroxylation was higher in the salt-only version 
of Williams’ E medium. In the case of atorvastatin and testosterone, the salt-free versions 
of MCM+ and/or DMEM supported lower rates of metabolism than the corresponding 
complete versions.    
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Figure 4.8. The effect of complete versions or salt-only versions of cell culture 
media on the metabolism of six CYP3A4/5 substrates by human liver microsomes 
Rates of metabolite formation from six CYP3A4/5 marker substrates, namely, midazolam 
(4 μM), nifedipine (10 μM), alfentanil (40 μM), verapamil (9 μM), atorvastatin(40 μM), and 
testosterone (70 μM), were measured in in pooled human liver microsomes (0.1 mg/mL) 
incubated in the complete version (blue) and five salt-only version (purple) of five cell 
culture media, as described in Chapter 2. Rates of metabolism in complete KHB medium 
were set to 100%.  
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Table 4.3. Ion concentration and ionic strength of cell culture medium composed 
of salts only 
Component Units 
Concentration 
KHB Waymouth’s MCM+ DMEM Williams’ E 
Cations 
Sodium 
mM 
144 140 341 155 145 
Potassium 5.84 2.59 5.33 5.33 5.33 
Magnesium 0.695 2.00 1.45 0.814 0.811 
Calcium 3.36 0.816 1.80 1.80 1.80 
Iron (ferric) 
μM 
  3 0.2 0.00025 
Copper (cupric)   1.2  0.00040 
Anions 
Phosphate 
mM 
4.67 5.30 1.04 0.908 1.17 
Chloride 132 107 86.5 119 126 
Bicarbonate 25 26.7 262 44.0 26.2 
Sulfate  0.814 1.45 0.814 0.811 
Nitrate μM   8.9 0.7 0.00074 
Ionic strengtha mM 182 169 361 173 163 
 
a Values were calculated based only on the salt composition of the various media as described in 
Equation 2.9. The ionic strengths of 5, 50 and 200 mM phosphate buffer were calculated to be 
35, 282 and 1108 mM respectively.  
  
186 
 
4.8. Effects of buffer ionic strength and cell culture media on 
midazolam metabolism by HLM, rCYP3A4 and rCYP3A5 with and 
without cytochrome b5. 
When HLM were used to examine the effects of ionic strength and cell culture media on 
CYP activity (Section 4.1), the various CYP enzymes examined could be divided into 
three groups (A-C). The Group B enzymes, namely CYP2E1 and CYP3A4/5, were 
distinguished by their high activity in 200 mM phosphate buffer and their low activity in 
Waymouth’s, MCM+ and DMEM media (relative to KHB and Williams’ E media), as shown 
in Figure 4.2. It is interesting to note that CYP2E1, CYP3A4 and CYP3A5 are the three 
enzymes most affected by cytochrome b5 (Parkinson et al., 2013). Accordingly, buffer 
ionic strength and cell culture media were examined for their effects on midazolam 1ʹ- 
and 4-hydroxylation by recombinant CYP3A4 and CYP3A5 with and without cytochrome 
b5. The results are shown in Figure 4.9. 
When the recombinant enzymes were expressed without cytochrome b5, the effects of 
cell culture media on midazolam 1′- and 4-hydroxylation by both CYP3A4 and CYP3A5 
closely resembled their effects on midazolam metabolism by HLM (i.e., relatively low 
activity was observed with Waymouth’s, MCM+ and DMEM). When the recombinant 
enzymes were expressed with cytochrome b5, low rates of midazolam hydroxylation were 
observed with MCM+ and DMEM but not with Waymouth’s (relative to KHB and Williams’ 
E). In other words, co-expression with cytochrome b5 altered the effect of Waymouth’s 
medium on midazolam hydroxylation by both CYP3A4 and CYP3A5. 
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In HLM, 200 mM phosphate buffer supported higher rates of midazolam 1′- and 4-
hydroxylation compared with 50 mM phosphate buffer (Figure 4.9). The same effect was 
observed with recombinant CYP3A5 with or without cytochrome b5. However, in the case 
of recombinant CYP3A4, increasing the concentration of phosphate buffer to 200 mM 
increased the 4-hydroxylation but not the 1′-hydroxylation of midazolam regardless of 
whether CYP3A4 was co-expressed with cytochrome b5. 
Overall, the results suggest that the effects of ionic strength and cell culture media on 
midazolam metabolism by HLM are attributable to effects on CYP3A4 and CYP3A5 that 
occur independently of cytochrome b5. 
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Figure 4.9. The effect of buffer ionic strength and various media on CYP3A4/5 
midazolam metabolism in HLM, rCYP3A4 and rCYP3A5 
Midazolam 1ʹ- and 4-hydroxylation were measured with recombinant CYP3A4 and 
CYP3A5 (20 pmol/mL) in the absence and presence of cytochrome b5  in50 and 200 mM 
phosphate buffer (pH 7.4) or in one of five cell culture media, namely KHB (A), 
Waymouth’s (B), MCM+ (C), DMEM (D) and Williams’ E (E), as described in the Chapter 
2. The activity in 50 mM phosphate buffer (standard incubation conditions) was set to 
100%.  
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4.9. Effects of cell culture media on midazolam hydroxylation by HLM 
lacking CYP3A5 
The five cell culture media were examined for their effects on 1ʹ- and 4-hydroxylation of 
midazolam by HLM lacking CYP3A5 (i.e., liver microsomes prepared from donors 
genotyped for CYP3A5*3/*3), as described in Chapter 2. As shown in Figure 4.10, MCM+, 
DMEM and, to a lesser extent, Waymouth’s all decreased midazolam hydroxylation 
relative to KHB and Williams’ E. The effects of cell culture media on midazolam 
hydroxylation by HLM lacking CYP3A5 resembled their effects on midazolam 
hydroxylation by pooled HLM (pool of 200) (Figure 4.2) 
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Figure 4.10. Effects of cell culture media on midazolam hydroxylation by human 
liver microsomes lacking CYP3A5. 
The 1′- and 4-hydroxylation of midazolam (4 µM) by human liver microsomes lacking 
CYP3A5 (microsomes prepared from a CYP3A5 *3/*3 individual) was determined after a 
5-min incubation in 50 mM phosphate buffer or one of five cell culture media, namely KHB 
(A), Waymouth’s (B), MCM+ (C), DMEM (D) and Williams’ E (E), as described in Chapter 
2. Rates of midazolam hydroxylation in media are relative to those in 50 mM phosphate 
buffer (standard incubation conditions). 
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4.10. Detection of 3-hydroxydesloratadine during the assessment of 
cell culture media on loratadine metabolism in CHH. 
In an effort to identify other substrates of CYP3A4/5 that resembled midazolam in terms 
of its response to various cell culture media, loratadine was incubated with CHH (1 million 
cells/mL) in KHB, Waymouth’s, MCM+, DMEM and Williams’ E, as described in Chapter 
2. As shown in Figure 4.11, the rate of formation of desloratadine from loratadine by CHH 
(a reaction predominantly catalyzed by CYP3A4/5) was not greatly affected by any of the 
cell culture media examined. In this respect, loratadine differed from midazolam and 
resembled nifedipine, alfentanil, verapamil, testosterone and atorvastatin (as shown in 
Figure 4.5). However, in addition to forming desloratadine (the major metabolite of 
loratadine), CHH also formed 3-hydroxydesloratadine, which was unexpected because 
the formation of 3-hydroxydesloratadine is undetectable when desloratadine is incubated 
with HLM or recombinant CYP enzymes (Ghosal et al., 2009). Accordingly, the enzyme 
responsible for forming 3-hydroxydesloratadine has never been identified even though 
this is the major circulating metabolite of desloratadine in humans. The effects of cell 
culture media on the formation of 3-hydroxydesloratadine by CHH were the opposite of 
their effects on midazolam hydroxylation; the highest rates of 3-hydroxydesloratadine 
formation were supported by Waymouth’s, MCM+ and DMEM (the three media 
supporting the lowest rates of midazolam hydroxylation). These results suggest that CHH 
may be an appropriate in vitro test system to study the enzymology of 
3-hydroxydesloratadine formation. Such studies are described in Chapter 5.  
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Figure 4.11. The effect of various cell culture media on desloratadine (top) and 
3-hydroxydesloratadine (bottom) formation from loratadine in cryopreserved 
human hepatocytes 
The metabolism of loratadine (10 μM) by cryopreserved human hepatocytes (1 million 
cells/mL) was assessed in the presence of five cell culture media (KHB, Waymouth’s, 
MCM+, DMEM and Williams’ E), as described in Chapter 2. Formation of desloratadine 
(colored blue) and 3-hydroxydesloratadine (colored purple) was measured after 60 min 
by LC-MS/MS, as described in Chapter 2. Rates of metabolite formation in KHB medium 
were set to 100%.  
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DISCUSSION 
In the preceding chapter I verified previous reports that the intrinsic metabolic clearance 
of midazolam by human hepatocytes is almost an order of magnitude less than 
midazolam clearance by liver microsomes (Lu et al., 2006; Foster et al., 2011). The 
relatively low clearance of midazolam in CHH, which underpredicts the in vivo hepatic 
clearance of midazolam, could not be explained by membrane- or cofactor-restricted 
midazolam metabolism in hepatocytes. The system-dependent clearance of midazolam 
was observed to a lesser degree with alfentanil, nifedipine and verapamil (Chapter 3). 
With these three CYP3A4/5 substrates, HLM accurately predicted in vivo blood clearance 
(CLH), whereas CHH underpredicted CLH by approximately 2 fold. In contrast, midazolam 
blood clearance was accurately predicted by HLM but underestimated by CHH 
approximately 5 fold. The present study examined in vitro factors that might account for 
the particularly pronounced system-dependent clearance of midazolam. Buffer ionic 
strength and cell culture media were examined for their effects on multiple P450 enzymes 
in HLM, HS9, recombinant enzymes, and CHH and were examined for their effects on 
multiple substrates for CYP3A4/5 
The rate of midazolam hydroxylation by HLM or HS9 increased when the concentration 
of phosphate buffer was increased from 50 mM to 200 mM (Figure 4.2). This is an unusual 
feature of CYP3A4/5 (CYP2E1 was the only other enzyme examined that exhibited this 
property) but not an unusual feature of midazolam. The rates of metabolism of five other 
CYP3A4/5 substrates all increased when the concentration of phosphate buffer was 
increased from 50 mM to 200 mM (Figure 4.4). In contrast, with the exception of CYP2E1, 
the activity of all other CYP enzymes examined, namely CYP1A2, 2A6, 2B6, 2C8, 2C9, 
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2C19 and 2D6, decreased when the concentration of phosphate buffer increased from 50 
to 200 mM (Figure 4.2). Several previous reports have described the effects of buffer ionic 
strength on P450 enzymes in vitro. Gemzik et al. (1990) observed that, in microsomes 
prepared from phenobarbital-induced rats, specific pathways of testosterone 
hydroxylation decreased with buffers of increasing ionic strength for CYP2A1 (6α- and 
7α-hydroxylation), CYP2B1/2 (16β-hydroxylation), and CYP2C2C11 (16α-hydroxylation); 
whereas an increase in testosterone hydroxylation was observed with CYP3A1/2 (1β-, 
2β-, 6β- and 15β-hydroxylation). Reports of the effects of ionic strength on human P450 
enzymes (namely, CYP1A1, CYP1A2, CYP3A4, CYP2C8, CYP2C9, CYP2D6, CYP2E1, 
and CYP3A4) are generally consistent with those shown in Figure 4.1 and Figure 4.2 
(Yamazaki et al., 1997; Maenpaa et al., 1998; Traylor et al., 2011; Kudo et al., 2014).  
CYP3A4, CYP3A5 and CYP2E1, the enzymes stimulated by high ionic strength, are 
unusual inasmuch as their activity is influenced by cytochrome b5 more so than other 
P450 enzymes in HLM (Parkinson et al., 2013). However, the stimulatory effect of high 
ionic strength on CYP3A4/5 activity occurs independently of cytochrome b5 based on the 
finding that 200 mM phosphate buffer stimulated midazolam hydroxylation by 
recombinant CYP3A4 and CYP3A5 in the absence and presence cytochrome b5 (Figure 
4.9). CYP3A4, CYP3A5 and CYP2E1 are also unusual because they have a tendency to 
oligomerize (Davydov et al., 2015). Interestingly, α-naphthoflavone stimulates the activity 
of CYP3A4 only when the enzyme is in an oligomeric state (Davydov et al., 2013). It is 
possible that high ionic strength promotes the dissociation of oligomeric forms of 
CYP3A4, CYP3A5 and CYP2E1 and thereby facilitates their ability to bind substrate 
and/or associate with NADPH-cytochrome P450 reductase. 
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The effects of cell culture media on P450 activity in HLM was both CYP- and substrate-
dependent. For simplicity, only KHB and MCM+ will be discussed here, although in 
general (but with exceptions) Williams’ E resembled KHB whereas Waymouth’s and 
DMEM resembled MCM+. KHB supported higher rates of metabolism by CYP3A4/5 (with 
midazolam), CYP2E1 and CYP2C9 than MCM+, whereas the converse was observed 
with CYP1A2, 2A6, 2B6, 2C8, 2C19 and 2D6. Although MCM+ supported markedly lower 
rates of midazolam 1′- and 4-hydroxylation compared with KHB (in HLM and HS9), the 
difference between these two media was considerably less with other CYP3A4/5 
substrates (alfentanil, nifedipine, testosterone and atorvastatin) and, in the case of 
verapamil, MCM+ supported slightly higher rates of metabolism compared with KHB. 
These results suggest that cell culture media can affect CYP3A4/5 activity in HLM and 
HS9 in a substrate-dependent manner and demonstrate that various media reduce the 
rate of metabolism of midazolam to a greater extent than other CYP3A4/5 substrates. An 
assessment of the effects of cell culture media on midazolam metabolism with HLM from 
an individual lacking CYP3A5 (CYP3A5*3/*3) also yielded results similar to those 
obtained with pooled HLM (Figure 4.10). These results combined with the results from 
studies with rCYP3A4 and rCYP3A5 (Figure 4.9) suggest buffer conditions and cell 
culture media have similar effects on both the CYP3A4- and CYP3A5-dependent 
hydroxylation of midazolam. 
The effects of cell culture media on the kinetics of midazolam 1′-hydroxylation by HLM 
were surprisingly complex and varied. Compared with 50 mM phosphate buffer (standard 
incubation conditions), KHB caused a small increase in Km (from 2.2 to 4.4 µM) and 
decreased Vmax by a factor of ∼3 (Table 4.2). In contrast, MCM+ caused a 50-fold increase 
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in Km. Unexpectedly, MCM+ actually increased Vmax by 2.6 fold. In terms of their effects 
on the kinetics of midazolam 1′-hydroxylation by HLM, Waymouth’s and DMEM 
resembled KHB (they caused relatively small increases in Km and Vmax) whereas Williams’ 
E resembled MCM+ (both caused large increases in Km and a small increase in Vmax). All 
media decreased the intrinsic clearance of midazolam by HLM (based on Vmax/Km) (Table 
4.2 and Figure 4.7). 
One of the aims of this study was to identify a cell culture medium that supported higher 
rates of midazolam clearance in CHH to correct for the underprediction observed with 
KHB. When CHH were incubated in KHB medium, estimates of the in vivo intrinsic hepatic 
clearance of midazolam were roughly an order of magnitude lower than estimates of CLint 
with HLM (Chapter 3). Compared with KHB, Williams’ E and Waymouth’s supported 
comparable rates (within 20%) of midazolam metabolism in CHH whereas MCM+ and 
DMEM supported lower rates (40-45% lower). The ∼45% decrease in midazolam 
metabolism caused by incubating CHH in MCM+ compared with KHB was not observed 
with alfentanil, verapamil, testosterone or atorvastatin, although MCM+ decreased 
nifedipine metabolism by 26%. Compared with KHB, DMEM also decreased the rate of 
metabolism of midazolam, nifedipine, testosterone and atorvastatin (by 32-43%), but 
slightly stimulated the metabolism of alfentanil (13%) and verapamil (45%) (Figure 4.5). 
Therefore, the effects of cell culture media on CYP3A4/5 activity in CHH are substrate 
dependent, as was observed in HLM and HS9. In terms of supporting the metabolism of 
midazolam in CHH, none of the media examined was superior to KHB and some were 
inferior; accordingly, CHH underpredicted the clearance of midazolam regardless of 
which cell culture medium was used. 
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The effects of MCM+ on CYP3A4/5 activity in HLM are particularly noteworthy in terms of 
the possible presence of an inhibitory substance. This medium has roughly twice the ionic 
strength of the other four media. The salt-only version of this medium (with an ionic 
strength of 361 mM) would be expected to support CYP3A4/5 activity to the same extent 
as − or to an even greater extent than − 50 mM phosphate buffer (which has an ionic 
strength of 282 mM). However, when HLM were incubated in the salt-only version of 
MCM+, the rates of metabolism of midazolam, nifedipine, atorvastatin and testosterone 
were at least 40% lower than those supported by all of the other salt-only media, which 
had ionic strengths ranging from 163 to 182 mM. This finding, coupled with the 
observation that MCM+ caused a 50-fold increase in the Km for midazolam 
1′-hydroxylation, suggest that the salt-only and complete versions of MCM+ both contain 
one or more substances that inhibit CYP3A4/5 in a substrate-dependent manner; they 
inhibit the metabolism of midazolam, nifedipine, atorvastatin and testosterone more than 
they inhibit the metabolism of alfentanil and verapamil. 
Certain cell culture media contain components that have been reported to inhibit P450, 
such as menadione in Williams’ E and dexamethasone in MCM+; likewise, divalent 
cations such as Cu2+ (present in Williams’ E and MCM+) and Ca2+ (present in all media 
examined) have been shown to inhibit P450 and/or NADPH-cytochrome P450 reductase 
activity (Tamura et al., 1988; Floreani and Carpenedo, 1990; Gentile et al., 1996; Kim et 
al., 2002). However, media components that inhibit CYP activity in HLM may not do so in 
CHHs due to binding, restricted uptake, efflux or metabolism of these components in 
intact hepatocytes. Overall, the studies of the effects of cell culture media on P450 
activities in HLM produced several interesting and unexpected findings but none pointed 
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to the possibility that all five of the cell culture media examined (all of which underpredict 
the clearance of midazolam − but not the clearance of other CYP3A4/5 substrates − in 
CHH) contain a component or components that selectively impair the metabolism of 
midazolam in CHH.  
The results of this study do not provide a mechanistic rationale for the system-dependent 
clearance of midazolam shown in the previous chapter and described previously by other 
researchers (Lu et al., 2006; Foster et al., 2011). The marked system-dependent 
clearance of midazolam (microsomal CLH,int = ∼10x hepatocyte CLH,int) was observed to 
a lesser extent with other high clearance drugs, namely alfentanil, nifedipine and 
verapamil (microsomal CLH,int <4x hepatocyte CLH,int), suggesting that system-dependent 
clearance is more pronounced with midazolam than with other CYP3A4/5 substrates.  
Although I have been unable to explain the system-dependent clearance of midazolam, 
the results of the studies presented here and in the preceding chapter have excluded 
certain possible explanations (such as restrictive membrane permeability and cofactor 
availability) and, perhaps more importantly, point to possible improvements in the design 
of in vitro studies of drug clearance, which continue to play an important role in drug 
candidate selection. In the present study, the predicted intrinsic hepatic clearance of 
alfentanil, nifedipine and verapamil based on half-life in HLM was up to 3.7-fold greater 
than estimates of CLH,int in CHH. In these studies, HLM were incubated in 50 mM 
potassium phosphate buffer (together with other components, namely MgCl2, EDTA and 
NADPH). This concentration of phosphate buffer supports near-optimum activity of most 
CYP enzymes (Figure 4.2). Incubating HLM in 100 mM phosphate buffer (as is commonly 
done) increases the activity of CYP3A4/5 (and CYP2E1) but decreases the activity of the 
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other drug-metabolizing P450 enzymes in HLM. Therefore, I recommend researchers use 
50 mM phosphate buffer for studies of drug clearance by HLM. 
Compared with midazolam, alfentanil, nifedipine or verapamil exhibited modest system-
dependent clearance when CHH were incubated in KHB medium (Figure 4.5). In general, 
KHB and Williams’ E supported the highest (or close to the highest) activity of most CYP 
enzymes in CHH, especially CYP3A4/5 activity, as shown in Figure 4.3. However, as 
shown in Table 4.1, the viability of human hepatocytes after a 4-h incubation was highest 
with Williams’ E and lowest with KHB. Therefore, KHB is not suitable to support long-term 
incubations of hepatocytes whereas Williams’ E medium can and this has implications for 
its use in long-term metabolism studies. There have been several reports on the use of 
extended hepatocyte incubations (the so-called hepatocyte-relay method, see Figure 
4.12) for assessing the in vitro half-life of low clearance drugs (Di et al., 2012; Di et al., 
2013). With the knowledge that Williams’ E supports CYP3A4/5 activity and cell viability 
better than any of the four other media examined, I recommend that researchers use this 
medium for both short-term and long-term incubations of suspended human hepatocytes 
because even modest increases in the activity of CYP3A4/5 can have a profound impact 
on assay performance.  
In an effort to identify a substrate of CYP3A4/5 with the same system-dependent 
characteristics as midazolam, I tested loratadine, which is converted to desloratadine 
primarily by CYP3A4/5 (Yumibe et al., 1995; Yumibe et al., 1996). All five media 
supported similar rates of loratadine metabolism. In this regard, loratadine did not 
resemble midazolam but resembled the other six CYP3A4/5 substrates examined in this 
study. However, the study of loratadine metabolism by CHH lead to the detection 
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3-hydroxydesloratadine, which was unexpected because no previous in vitro test system 
or non-clinical species has been shown to support the formation of 
3-hydroxydesloratadine (Ramanathan et al., 2006; Ghosal et al., 2009). Accordingly the 
enzyme responsible for forming 3-hydroxydesloratadine, which the major circulating 
metabolite of desloratadine, has remained unknown despite the fact this was a post-
marketing commitment imposed by the FDA on the manufacturer, Schering Plough 
(Schering-Plough, 2001). The observation that CHH can form 3-hydroxydesloratadine 
provided an opportunity to investigate the enzymology of its formation. These studies are 
described in Chapter 5. 
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Figure 4.12. Schematic representation of the hepatocyte relay method to measure 
the in vitro half-life of metabolically stable drugs 
The method depicted in the schematic has been previously described by Di et al., (2012, 
2013). 
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CHAPTER 5 : A LONG-STANDING MYSTERY SOLVED: THE 
FORMATION OF 3-HYDROXYDESLORATADINE IS CATALYZED BY 
CYP2C8 BUT PRIOR GLUCURONIDATION OF DESLORATADINE BY 
UGT2B10 IS AN OBLIGATORY REQUIREMENT 
 
This section is a reprint of the following manuscript:  
Kazmi F, Barbara JE, Yerino P, and Parkinson A. (2015) A Long-Standing 
Mystery Solved: The Formation of 3-Hydroxydesloratadine is Catalyzed by 
CYP2C8 but Prior Glucuronidation of Desloratadine by UGT2B10 is an 
Obligatory Requirement, Drug Metab Dispos, 43:523-533.  
Reprinted with permission of the American Society for Pharmacology and Experimental 
Therapeutics. All rights reserved. Copyright © 2015 by the American Society for 
Pharmacology and Experimental Therapeutics.  
203 
 
ABSTRACT 
Desloratadine (Clarinex®), the major active metabolite of loratadine (Claritin®), is a non-
sedating long-lasting antihistamine widely used for the treatment of allergic rhinitis and 
chronic idiopathic urticaria. For over 20 years, it has remained a mystery as to which 
enzymes are responsible for the formation of 3-hydroxydesloratadine, the major active 
human metabolite, largely due to the inability of any in vitro system tested thus far to 
generate this metabolite. In this study, I demonstrated that cryopreserved human 
hepatocytes (CHH) form 3-hydroxydesloratadine and its corresponding O-glucuronide. 
CHHs catalyzed the formation of 3-hydroxydesloratadine with a Km of 1.6 μM and Vmax of 
1.3 pmol/min/million cells. Chemical inhibition of cytochrome P450 (CYP) enzymes in 
CHH demonstrated that gemfibrozil glucuronide (CYP2C8 inhibitor) and 
1-aminobenzotriazole (general P450 inhibitor) inhibited 3-hydroxydesloratadine formation 
by 91% and 98%, respectively. Other inhibitors of CYP2C8 (gemfibrozil, montelukast, 
clopidogrel glucuronide, repaglinide and cerivastatin) also caused extensive inhibition of 
3-hydroxydesloratadine formation (73-100%). Assessment of desloratadine, 
amodiaquine and paclitaxel metabolism by a panel of individual CHHs demonstrated that 
CYP2C8 marker activity robustly correlated with 3-hydroxydesloratadine formation (r2 of 
0.70-0.90). Detailed mechanistic studies with sonicated or saponin-treated CHHs, human 
liver microsomes and S9 fractions showed that both NADPH and UDP-glucuronic acid 
are both required for 3-hydroxydesloratadine formation, and studies with recombinant 
UGT and CYP enzymes implicated the specific involvement of UGT2B10 in addition to 
CYP2C8. Overall, my results demonstrate for the first time that desloratadine 
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glucuronidation by UGT2B10, followed by CYP2C8 oxidation and a de-conjugation event 
are responsible for the formation of 3-hydroxydesloratadine. 
  
205 
 
INTRODUCTION 
Desloratadine (Clarinex®) is a second generation, non-sedating selective H1-receptor 
histamine antagonist with long-acting activity widely used for the treatment of seasonal 
allergic rhinitis and chronic idiopathic urticaria. Desloratadine is also the major active 
metabolite of the antihistamine loratadine (Claritin®) and has a half-life of 21-27 h with 
moderate plasma protein binding (82-87%) permitting once-daily dosing (Henz, 2001; 
Molimard et al., 2004; Devillier et al., 2008). The major in vivo human active metabolite 
of desloratadine is 3-hydroxydesloratadine which is subsequently glucuronidated to 
3-hydroxydesloratadine O-glucuronide. Both are excreted in roughly equal amounts in 
urine and feces (Ramanathan et al., 2007).  
Furthermore, 3-hydroxydesloratadine and its glucuronide were found to be major 
metabolites in humans, but only trace levels were detectable in nonclinical species such 
as mice, rats and monkeys (Ramanathan et al., 2006), leading to the concern that 
nonclinical species may not have been adequately exposed to these metabolites in safety 
studies. 
The conversion of loratadine to desloratadine (a dealkylation reaction leading to loss of a 
descarboethoxyl moiety) was previously shown to be catalyzed by CYP3A4 and, to a 
lesser extent, by CYP2D6 (Yumibe et al., 1995; Yumibe et al., 1996; Dridi and Marquet, 
2013) However, the enzymology surrounding the conversion of desloratadine to 
3-hydroxydesloratadine has remained a mystery both prior to and since its approval by 
the FDA in 2001 (Schering-Plough, 2001). Ghosal and colleagues (2009) examined the 
metabolism of loratadine and further characterized the in vitro enzymology of the 
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metabolites using pooled human liver microsomes (HLM) and recombinant P450 
enzymes (rCYPs), demonstrating that desloratadine, 5-hydroxydesloratadine and 
6-hydroxydesloratadine formation could be mediated by CYP3A4, CYP2D6 and 
CYP2C19. However, they were unable to detect 3-hydroxydesloratadine in either in vitro 
test system and therefore were unable to identify which enzyme or enzymes were 
involved in its formation. However, the subsequent conjugation of 3-hydroxydesloratadine 
to 3-hydroxydesloratadine-O-glucuronide was previously shown to be catalyzed in vitro 
by recombinant UGT1A1, UGT1A3 and UGT2B15 (Ghosal et al., 2004). 
Clinical pharmacology and safety studies demonstrated that some individuals have a 
phenotypic polymorphism in the metabolism of desloratadine with greatly reduced 
formation of 3-hydroxydesloratadine, resulting in a 3-hydroxydesloratadine to 
desloratadine exposure ratio of <0.1 or a desloratadine half-life of >50 h (Prenner et al., 
2006). These poor metabolizers (PMs) of desloratadine were found to have a general 
population frequency of 6% and were most frequent in African American (17%) compared 
with Caucasian (2%), Native American (8%), Hispanic (2%) and Jordanian populations 
(3%) (Prenner et al., 2006; Hakooz and Salem, 2012). Exposure to desloratadine in PMs 
resulted in a 6-fold increase in desloratadine AUC compared with extensive metabolizers 
(EMs), leaving the FDA unable to rule out an increased risk of adverse events in PMs 
(Schering-Plough, 2001). Because the enzymology of 3-hydroxydesloratadine formation 
has not been elucidated, the genetic basis for the PM phenotype has not been 
determined. 
In the present study, I sought to identify the enzyme or enzymes responsible for the 
formation of 3-hydroxydesloratadine by identifying an in vitro test system capable of 
207 
 
generating the metabolite. In this report, I demonstrate that 3-hydroxydesloratadine can 
be formed in cryopreserved human hepatocytes. Using reaction phenotyping approaches 
(correlation analysis, chemical inhibition and studies with recombinant enzymes), I 
elucidated the main human metabolic enzymes responsible for converting desloratadine 
to 3-hydroxydesloratadine. I established that the 3-hydroxylation of desloratadine is 
catalyzed by CYP2C8, but the reaction is unusual because the prior glucuronidation of 
desloratadine by UGT2B10 is an obligatory step in the reaction. 
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RESULTS 
5.1. Determination of an in vitro test system capable of producing 
3-hydroxydesloratadine.  
To determine whether 3-hydroxydesloratadine could be formed in any conventional in 
vitro test system, desloratadine (1 and 10 μM) was incubated with HLM (0.1 and 1 
mg/mL), HS9 (0.5 and 5 mg/mL) and CHH (1 million cells/mL) in a time course experiment 
up to 4 h as described in Chapter 2. The results for 3-hydroxydesloratadine formation with 
1 μM desloratadine are shown in Figure 5.1 (10 μM desloratadine data were similar and 
not shown). 3-Hydroxydesloratadine formation was not observed in any HLM or HS9 
sample, consistent with previous reports (Ghosal et al., 2009). However, 3-
hydroxydesloratadine was detected in CHH as early as 30 min, with linear metabolite 
formation up to 4 h. Furthermore, 3-hydroxydesloratadine glucuronide was also detected 
in CHH as early as 1 h with 10 μM desloratadine, but only at 4 h with 1 μM desloratadine. 
Additional expected hydroxydesloratadine metabolites such as 5- and 
6-hydroxydesloratadine were detected in all three test systems.  
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Figure 5.1. The formation of 3-hydroxydesloratadine over time in cryopreserved 
human hepatocytes (CHH), human liver microsomes (HLM) and human S9 fraction 
(HS9).  
The time course of formation of 3-hydroxydesloratadine was assessed in hepatocytes (1 
million cells/mL), liver microsomes (0.1 and 1 mg/mL) and liver S9 (0.5 and 5 mg/mL) with 
1 μM desloratadine for up to 4h. 
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5.2. Assessment of the kinetics of 3-hydroxydesloratadine formation.  
Having established that CHH were the only test system capable of forming 
3-hydroxydesloratadine I sought to determine the Km and Vmax of 3-hydroxydesloratadine 
formation from desloratadine. Linearity of 3-hydroxydesloratadine formation was 
established beyond 2 h. Desloratadine was incubated at nine concentrations with pooled 
CHH (1 million cells/mL) for 2 h as described in Chapter 2. As shown in Figure 5.2, 
3-hydroxydesloratadine formation followed Michaelis-Menten kinetics, with Km and Vmax 
values of 1.6 μM and 1.3 pmol/min/million cells, respectively. 
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Figure 5.2. Determination of the enzyme kinetics for the formation of 
3-hydroxydesloratadine from desloratadine in cryopreserved human hepatocytes 
(CHH). 
As described in Chapter 2, the kinetics for the formation of 3-hydroxydesloratadine were 
determined in CHH (1 million cells/mL) with 0.1, 0.2, 0.5, 1, 2, 5, 10, 20 and 30 μM 
desloratadine incubated for 2 h. The left panel represents rate versus substrate 
concentration, and the right panel represents the Eadie-Hofstee plot. 
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5.3. Assessment of the species specificity of 3-hydroxydesloratadine 
formation.  
I evaluated whether 3-hydroxydesloratadine could be formed by hepatocytes from 
different species. Mouse, rat, rabbit, dog, minipig, monkey and human hepatocytes (1 
million cells/mL) were incubated with 1 or 10 μM desloratadine for 2 h as described in 
Chapter 2. The results for 3-hydroxydesloratadine formation (Figure 5.3) showed that at 
1 μM desloratadine, rabbit and human hepatocytes formed similar amounts of 
3-hydroxydesloratadine, whereas dog hepatocytes formed one third as much and monkey 
hepatocytes formed only a trace amount. In contrast, no 3-hydroxydesloratadine was 
detected in incubations of 1 µM desloratadine with mouse, rat or minipig hepatocytes. At 
10 μM desloratadine, only rabbit and human hepatocytes formed 3-hydroxydesloratadine, 
with rabbit forming three times as much 3-hydroxydesloratadine as human hepatocytes. 
No 3-hydroxydesloratadine formation was observed in incubations of 10 μM 
desloratadine with mouse, rat, dog, minipig or monkey hepatocytes. Formation of both 
5- and 6-hydroxydesloratadine in each species was determined simultaneously (shown 
in Figure 5.4), with all animal species forming higher levels of these metabolites than 
human hepatocytes. Rabbit hepatocytes formed the greatest amount of 
5-hydroxydesloratadine, while rabbit and minipig hepatocytes formed the greatest 
amounts of 6-hydroxydesloratadine. 
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Figure 5.3. Formation of 3-hydroxydesloratadine in pooled cryopreserved mouse, 
rat, rabbit, dog, minipig, monkey and human hepatocytes. 
Hepatocytes were incubated at 1 million cells/mL with 1 or 10 μM desloratadine for 2 h. 
Data are represented as the percent of 3 hydroxydesloratadine formation relative to the 
maximum amount formed. 
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Figure 5.4. Formation of 5- and 6-hydroxydesloratadine in hepatocytes from 
mouse, rat, rabbit, dog, minipig, monkey and human. 
Pooled hepatocytes from mouse, rat, rabbit, dog, minipig, monkey and human were 
incubated at 1 million cells/mL with 1 or 10 μM desloratadine for 2 h. Analysis of 5- and 
6-hydroxydesloratadine was conducted as described in Chapter 2.  
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5.4. Identification of the enzyme responsible for 
3-hydroxydesloratadine formation using recombinant enzymes.  
To determine which specific drug-metabolizing enzymes were responsible for the 
formation of 3-hydroxdesloratadine, recombinant P450 and FMO enzymes (50 pmol/mL) 
were incubated with 1 and 10 μM desloratadine and incubated for 1 h as described in 
Chapter 2. The data are summarized in Table 5.1. No 3-hydroxydesloratadine was 
detected in any recombinant P450 or FMO enzyme sample tested, consistent with 
previously reported findings (Ghosal et al., 2009). Both 5- and 6-hydroxydesloratadine 
were readily formed by CYP1A1, CYP2D6 and CYP3A4, with trace metabolite formation 
observed for several other P450 enzymes (Table 5.1). A time course experiment for up 
to 6 h with recombinant CYP2C8 also failed to generate any 3-hydroxydesloratadine (data 
not shown). 
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Table 5.1. Chemical inhibition and formation of 3-hydroxydesloratadine in 
cryopreserved human hepatocytes (CHH) and recombinant enzymes  
Enzyme Inhibitor Inhibition 
of 3-OH 
formation 
(%) 
Recombinant enzyme activity 
3-OH 5-OHa 6-OHa 
CYP 1-Aminobenzotriazole 98 NA 
CYP1A1 NA NA 
None 
Yes Yes 
CYP1A2 Furafylline 0 
Noneb Nonec 
CYP1B1 NA NA CYP2A6 
CYP2B6 Phencyclidine 13.3 
CYP2C8 Gemfibrozil glucuronide 91.3-100 
Gemfibrozil 100 
Montelukast 100 
Clopidogrel glucuronide 78.9 
Repaglinide 73.3 
Cerivastatin 84.6 
CYP2C9 Tienilic acid 0 
CYP2C18 NA NA 
CYP2C19 Esomeprazole 22.5 
CYP2D6 Paroxetine, Quinidine 0 Yes Yes 
CYP2E1 NA NA Noneb Nonec CYP2J2 
CYP3A4/5 Mibefradil  0 
Yes 
(CYP3A4) 
Yes 
(CYP3A4) 
CYP3cide 0 
Troleandomycin 0 
Ketoconazole 27.0 
CYP3A7 
NA NA Noneb Nonec 
CYP4A11 
CYP4F2 
CYP4F3a 
CYP4F3b 
CYP4F12 
FMO1 
FMO3 
FMO5 
 
a Data from 10 uM desloratadine experiments 
b Trace levels detected for CYP1A2, CYP1B1, CYP2B6, CYP2C8, CYP2C18, 
CYP2C19, CYP2J2, CYP3A5 and CYP3A7 with 1 μM desloratadine. 
c Trace levels detected for CYP1A2, CYP1B1, CYP2B6, CYP2C8, CYP2C18, 
CYP2J2 and CYP3A7 with 1 μM desloratadine. 
3-OH: 3-hydroxydesloratadine; 5-OH: 5-hydroxydesloratadine; 6-OH: 
6-hydroxydesloratadine; NA: Not applicable  
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5.5. Identification of the enzyme responsible for 
3-hydroxydesloratadine formation using chemical inhibitors.  
Since a recombinant P450/FMO enzyme approach was unable to identify any enzyme 
capable of forming 3-hydroxydesloratadine, I evaluated the effects of P450-selective 
inhibitors on the formation of 3-hydroxydesloratadine by CHH. Initially, a panel of 
chemical inhibitors specific to different CYP enzymes was used (as summarized in Table 
5.1), namely, furafylline (CYP1A2); phencyclidine (CYP2B6); gemfibrozil glucuronide 
(CYP2C8); tienilic acid (CYP2C9); esomeprazole (CYP2C19); paroxetine and quinidine 
(CYP2D6); mibefradil, CYP3cide, troleandomycin and ketoconazole (CYP3A4/5); in 
addition to the non-specific P450 inhibitor 1-aminobenzotriazole (1-ABT). Desloratadine 
(10 μM) was incubated with CHH for 2 h following pre-incubation of the hepatocytes with 
each individual chemical inhibitor as described in Chapter 2. As shown in Figure 5.5A and 
Table 5.1, the formation of 3-hydroxydesloratadine by CHH was extensively inhibited by 
gemfibrozil glucuronide (91.3% inhibition) and 1-ABT (97.8% inhibition). Furthermore, 
formation of 3-hydroxydesloratadine-O-glucuronide was inhibited completely by the 
CYP2C8 inhibitor gemfibrozil glucuronide and the nonspecific inhibitor 1-ABT, whereas 
the formation of 5- and 6-hydroxydesloratadine was primarily inhibited by inhibitors of 
CYP3A4/5 and 1-ABT (see Figure 5.6). To further explore the involvement of CYP2C8 in 
3-hydroxydesloratadine formation, the panel of CYP2C8 inhibitors was extended to 
include montelukast, repaglinide, cerivastatin, clopidogrel glucuronide, gemfibrozil and its 
acyl glucuronide. As shown in Figure 5.5B, the formation of 3-hydroxydesloratadine by 
CHH was completely inhibited by montelukast, gemfibrozil, and gemfibrozil glucuronide; 
and extensively inhibited by clopidogrel glucuronide (78.9%), repaglinide (73.3%) and 
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cerivastatin (84.6%). In addition to examining their effects on 3-hydroxdesloratadine 
formation, the CYP2C8 inhibitors were also examined for their effects on two CYP2C8 
marker reactions in CHH, namely amodiaquine N-dealkylation and paclitaxel 
6α-hydroxylation. As expected, inhibition of amodiaquine and paclitaxel metabolism by 
the panel of CYP2C8 inhibitors correlated well each other and with the degree of inhibition 
of 3-hydroxydesloratadine formation. 
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Figure 5.5. Effect of specific P450 chemical inhibitors on formation of 
3-hydroxydesloratadine in pooled cryopreserved human hepatocytes (CHH). 
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As shown in panel A, chemical inhibitors towards specific P450 enzymes, namely 
furafylline (10 μM; CYP1A2), phencyclidine (10 μM; CYP2B6), gemfibrozil glucuronide 
(100 μM; CYP2C8), tienilic acid (20 μM, CYP2C9), esomeprazole (10 μM; CYP2C19); 
paroxetine (1 μM; CYP2D6); quinidine (5 μM; CYP2D6), mibefradil (1 μM; CYP3A4/5), 
CYP3cide (2.5 μM; CYP3A4/5), troleandomycin (50 μM; CYP3A4/5), ketoconazole (4 μM, 
CYP3A4/5), and 1 aminobenzotriazole (1 mM; general CYP inhibitor) were incubated with 
CHH (1 million cells/mL) for 30 min, prior to incubation with 10 μM desloratadine for 2 h 
and analysis by LC-MS/MS as described in Chapter 2. Subsequently, multiple inhibitors 
of CYP2C8 (shown in panel B) were examined for their ability to inhibit 
3-hydrodesloratadine formation, amodiaquine N-dealkylation and paclitaxel 6α-
hydroxylation in CHH; namely montelukast (50 μM), gemfibrozil (100 μM), gemfibrozil 
glucuronide (100 μM), clopidogrel glucuronide (100 μM), repaglinide (100 μM) and 
cerivastatin (100 μM) as described in Chapter 2. 
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Figure 5.6. The effect of various P450 chemical inhibitors on 
5-hydroxydesloratadine, 6-hydroxydesloratadine and 3-hydroxydesloratadine 
O-glucuronide formation in cryopreserved human hepatocytes (CHH). 
Various P450 chemical inhibitors were incubated with CHH (1 million cells/mL) for 30 min 
prior to the addition of 10 μM desloratadine followed by incubation for 2 h and analysis of 
5-, 6-hydroxydesloratadine, and 3-hydroxydesloratadine O-glucuronide was conducted 
as described in Chapter 2. 
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5.6. Correlation of 3-hydroxydesloratadine formation with known 
CYP2C8 activities.  
Hepatocytes from nine individual human donors with a range of CYP2C8 activity towards 
amodiaquine and paclitaxel; and levomedetomidine activity (UGT2B10) were assessed 
for their ability to form 3-hydroxydesloratadine, as described in Chapter 2. As shown in 
Figure 5.7, the sample-to-sample variation in the 3-hydroxylation of desloratadine (1 and 
10 μM) correlated well with the 6α-hydroxylation of paclitaxel (1 and 10 μM), r2 values of 
0.84 and 0.90 (at 1 and 10 μM) and with the N-dealkylation of amodiaquine, with r2 values 
of 0.84 and 0.70 (at 1 and 10 μM). When CYP2C8 activity was correlated to both 
UGT2B10 activity and 3-hydroxydelsoratadine formation at 1 μM substrate 
concentrations, r2 values of 0.75 (with amodiaquine) and 0.73 (with paclitaxel) were 
obtained (Figure 5.8). As expected, amodiaquine and paclitaxel activities highly 
correlated with each other, with r2 values of 0.77 and 0.80 (at 1 and 10 μM), as shown in 
Figure 5.9. 
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Figure 5.7. Correlation between CYP2C8 activity and 3-hydroxydesloratadine 
formation in individual donor cryopreserved human hepatocytes (CHH) 
As described in Chapter 2, individual donor CHH from nine donors with varying CYP2C8 
activity were incubated (1 million cells/mL) with 1 or 10 μM amodiaquine, paclitaxel, and 
desloratadine for 10 min, 30 min and 2 h respectively. 
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Figure 5.8. Correlation between CYP2C8 activity, UGT2B10 activity and 3-
hydroxydesloratadine formation in individual donor cryopreserved human 
hepatocytes (CHH) 
Individual donor CHH from nine donors were assessed for CYP2C8 activity (1 μM 
amodiaquine, left panel; or 1 μM paclitaxel, right panel) incubated for 10 min, UGT2B10 
activity (1 μM levomedetomidine) incubated for 30 min, and 3-hydroxydesloratadine 
formation (1 μM desloratadine) in incubated for 2h with 1 million cells/mL as described in 
the Chapter 2. 
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Figure 5.9. Correlation of N-desalkylamodiaquine formation with 
6α-hydroxypaclitaxel formation in a panel of individual donor cryopreserved 
human hepatocytes (CHH). 
Individual donor CHH were assessed for CYP2C8 activity with 1 and 10 μM paclitaxel 
and amodiaquine as described in Chapter 2. 
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5.7. Determining the reason why 3-hydroxydesloratadine forms in 
hepatocytes but not in subcellular fractions.  
As a first approach to understand why CYP2C8 in CHH could convert desloratadine to 
3-hydroxydesloratadine whereas HLM, HS9 and recombinant P450 could not, I examined 
the role of cell integrity and various cofactors involved in xenobiotic metabolism. As 
described in Chapter 2, CHH were treated with 0.01% saponin (to permeabilize the 
plasma membrane) or sonication (to completely disrupt the plasma membrane) in media 
supplemented with 10 μM desloratadine and various cofactors, NADPH, NADH, FAD, 
AMP, ATP, and UDP-GlcUA. As shown in Figure 5.10A, when intact CHH were treated 
with 0.01% saponin, the formation of 3-hydroxydesloratadine was reduced by 90%. 
Addition of exogenous NADPH did not change the rate of 3-hydroxydesloratadine 
formation; however addition of UDP-GlcUA and NADPH + UDP-GlcUA partially restored 
3-hydroxydesloratadine formation to 22% and 37% of that observed in intact CHH, 
respectively. Similarly, when CHH were probe sonicated, 3-hydroxydesloratadine 
formation was almost completely eliminated with only 2.5% activity remaining. Addition of 
exogenous NADPH here also did not alter the level of 3-hydroxydesloratine formation; 
however addition of UDP-GlcUA and NADPH + UDP-GlcUA again partially restored 
3-hydroxydesloratadine formation to 15% and 34% of that observed in intact CHH, 
respectively. To ascertain whether a similar combination of cofactors could confer 
desloratadine 3-hydroxylase activity on subcellular fractions, HLM (0.1 and 1 mg/mL) and 
HS9 (0.5 and 5 mg/mL) were incubated with 10 μM desloratadine for up to 6 h with 
NAPDH and/or UDP-GlcUA, as described in Chapter 2. With either of these subcellular 
fractions, only the addition of a combination of NADPH + UDP-GlcUA resulted in 
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3-hydroxydesloratadine formation; addition of NADPH alone or UDP-GlcUA alone did not. 
Representative data from 1 mg/mL HLM and 5 mg/mL S9 are shown in Figure 5.10B (0.1 
mg/mL HLM and 0.5 mg/mL HS9 data were similar and are shown in Figure 5.11). The 
addition of several other cofactors (NADH, FAD, AMP and ATP) had no effect on the 
formation of 3-hydroxydesloratadine in sonicated or permeabilized CHH or in HLM or HS9 
(data not shown). 
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Figure 5.10. Formation of 3-hydroxydesloratadine in saponin treated or sonicated 
cryopreserved human hepatocytes (CHH) followed by addition of NADPH and/or 
UDP-GlcUA. 
As shown in panel A, CHH (1 million cells/mL) were either pre-treated with 0.01% saponin 
or probe sonicated followed by addition of 0.1 mM NADPH and/or 1 mM UDPGA and 
incubation with 10 μM desloratadine for 2 h. Panel B shows the formation of 
3-hydroxydesloratadine in subcellular fractions, namely human liver microsomes (HLM; 1 
mg/mL) and human S9 fraction (HS9; 5 mg/mL) as assessed over 6 h with or without 1 
mM NADPH and/or 10 mM UDP-GlcUA. 
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Figure 5.11. Time course of 3-hydroxydesloratadine formation in HLM (0.1 mg/mL) 
and HS9 (1 mg/mL) with or without NADPH and/or UDP-GlcUA. 
HLM (0.1 mg/mL) and HS9 (0.5 mg/mL) were incubated with 10 μM in a time course up 
to 6 h with and without the addition of NADPH and/or UDP-GlcUA, as described in 
Chapter 2. 
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5.8. Identification of the UGT enzymes involved in 
3-hydroxydesloratadine formation.  
Having established that a combination of both UDP-GlcUA and NADPH was necessary 
to support 3-hydroxydesloratadine formation by disrupted CHH or subcellular fractions, I 
sought to determine the specific UGT enzyme involved in 3-hydroxydesloratadine 
formation. As described in the Chapter 2, a panel of 13 recombinant UGT enzymes (at 
0.125 mg/mL each) supplemented with recombinant CYP2C8 (25 pmol/mL) was 
incubated for 2 h with 1 or 10 μM desloratadine in the presence of both NADPH with UDP-
GlcUA. As shown in Figure 5.12, 3-hydroxydesloratadine was formed by a combination 
of UGT2B10 and CYP2C8. Formation of 3-hydroxydesloratadine was not observed when 
CYP2C8 was incubated with any other recombinant UGT enzyme. 
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Figure 5.12. Assessment of 3-hydroxydesloratadine formation with a panel of 
recombinant UGT enzymes supplemented with recombinant CYP2C8. 
Thirteen recombinant UGT enzymes (at 0.125 mg/mL) were assessed for their ability to 
form 3-hydroxydesloratadine when supplemented with recombinant CYP2C8 (25 
pmol/mL) and 1 mM NADPH with 10 mM UDP-GlcUA, followed by a 2 h incubation with 
1 or 10  μM desloratadine. 
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Figure 5.13. Proposed metabolic scheme for the formation of 
3-hydroxydesloratadine and its glucuronide in human hepatocytes and liver 
subcellular fractions. 
The proposed metabolic pathway for desloratadine metabolism based on this study. The 
conversion of 3-hydroxydesloratadine to 3-hydroxydesloratadine glucuronide was 
previously described by Ghosal et al. (2004). 
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DISCUSSION 
Loratadine (Claritin®), first introduced to the U.S. market in 1993, is metabolized primarily 
by CYP3A4 and CYP2D6 to its pharmacologically active major metabolite desloratadine 
(Yumibe et al., 1995; Yumibe et al., 1996; Dridi and Marquet, 2013). As a drug in its own 
right, desloratadine (Clarinex® in the US, Aerius® in Europe) received FDA approval in 
2001. It has long been known that the major circulating metabolite of desloratadine in 
humans is 3-hydroxydesloratadine, formed by hydroxylation of the pyridine ring 
(Schering-Plough, 2001). However, as acknowledged in the package insert, the enzyme 
or enzymes responsible for forming 3-hydroxydesloratadine was unknown when 
desloratadine was approved by the FDA in 2001 and has remained unknown since that 
time. Although presumably formed by P450, conventional in vitro test systems do not 
convert desloratadine to the 3-hydroxy metabolite (Ghosal et al., 2009). In the present 
study, I confirmed that human liver microsomes (HLM), human S9 fraction (HS9) and 
recombinant human P450 enzymes all failed to convert desloratadine to 
3-hydroxydesloratadine but I demonstrated for the first time that cryopreserved human 
hepatocytes (CHH) are capable of forming the 3-hydroxy metabolite (Figure 5.1 and Table 
5.1). In vitro formation of this previously elusive metabolite allowed us to investigate the 
enzymology surrounding its formation. The formation of 3-hydroxydesloratadine by CHH 
conformed to simple Michaelis-Menten kinetics with a Vmax of 1.26 pmol/min/million cells 
and a Km of 1.57 μM (Figure 5.2), which is consistent with the reported plasma Cmax of 
desloratadine in humans (1.3 μM) (Schering-Plough, 2001). These results strongly 
suggest that hepatic metabolism is responsible for the formation of 
3-hydroxydesloratadine and are consistent with the urinary and biliary excretion of this 
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metabolite (and its O-glucuronide) in humans (Ramanathan et al., 2006; Ramanathan et 
al., 2007). Data on the metabolism of desloratadine in nonclinical species are limited, with 
5- and 6-hydroxydesloratadine reported as the major excreted metabolites in mouse, rat 
and monkey. In contrast to the situation in humans, 3-hydroxydesloratadine was found to 
be a minor or trace plasma, urinary and fecal metabolite in nonclinical species 
(Ramanathan et al., 2005; Ramanathan et al., 2006). In my assessment of desloratadine 
metabolism in hepatocytes from different species (Figure 5.3), 3-hydroxydesloratadine 
was observed at low levels in mouse, rat and monkey hepatocytes, consistent with 
previously reported in vivo findings (Ramanathan et al., 2006). However, rabbit, dog and 
human were able to form the 3-hydroxy metabolite in incubations at a pharmacologically 
relevant concentration (1 μM desloratadine), whereas only rabbit and human formed it at 
the high concentration (10 μM desloratadine). It is unclear whether rabbits were evaluated 
as nonclinical metabolism species during desloratadine development; however, my data 
suggest they may be appropriate species to model 3-hydroxydesloratadine exposure. 
Formation of 5- and 6-hydroxydesloratadine was faster in hepatocytes from all nonclinical 
species tested compared with human hepatocytes (Figure 5.4), consistent with the in vivo 
data (Ramanathan et al., 2005; Ramanathan et al., 2006). In the present study, formation 
of 5- and 6-hydroxydesloratadine was primarily mediated by recombinant CYP1A1, 
CYP2D6 and CYP3A4, confirming previously reported findings (Ghosal et al., 2009). 
Chemical inhibition experiments in CHH confirmed the involvement of CYP3A4 in 
5-hydroxydesloratadine formation, and likewise confirmed involvement of both CYP2D6 
and CYP3A4 in 6-hydroxydesloratadine formation (Table 5.1 and Figure 5.6). 
 
236 
 
The non-specific inhibitor 1-ABT markedly inhibited (98%) the formation of 
3-hydroxydesloratadine by CHH, confirming expectations that this reaction is catalyzed 
by P450 (Figure 5.5A). Marked inhibition (91%) was also observed with gemfibrozil 
glucuronide (Figure 5.5A). Gemfibrozil glucuronide is an irreversible (mechanism-based) 
inhibitor of CYP2C8 and is widely used as an in vitro diagnostic inhibitor of this enzyme 
(Ogilvie et al., 2006; Parkinson et al., 2011; Kazmi et al., 2014d). To confirm CYP2C8 
involvement in 3-hydroxydesloratadine formation, a panel of known CYP2C8 inhibitors or 
substrates (competitive inhibitors) was evaluated (Figure 5.5B), namely, montelukast, 
repaglinide, cerivastatin, clopidogrel glucuronide, and both gemfibrozil and gemfibrozil 
glucuronide (Bidstrup et al., 2003; Walsky et al., 2005; Ogilvie et al., 2006; Tornio et al., 
2014). Strong inhibition of 3-hydroxydesloratadine formation was observed with all 
CYP2C8 inhibitors and correlated well with the degree of inhibition in the metabolism of 
two CYP2C8 substrates (paclitaxel and amodiaquine), supporting CYP2C8 as the P450 
enzyme responsible for 3-hydroxydesloratadine formation. A comparison of CYP2C8 
activity in nine individual samples of human hepatocytes demonstrated high correlation 
(r2 = 0.7-0.9) between 3-hydroxydesloratadine formation and both amodiaquine N-
dealkylation and paclitaxel 6α-hydroxylation (Figure 5.7). 
 
The results presented so far seem paradoxical. They raise the question: If CYP2C8 is the 
major enzyme responsible for converting desloratadine to 3-hydroxydesloratadine in 
human hepatocytes, based on chemical inhibition and correlation analysis, why is no 
3-hydroxydesloratadine formed by HLM, HS9 or recombinant CYP2C8? I hypothesized 
that perhaps cellular integrity or the presence of specific cofactors was critical for 
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3-hydroxydesloratadine formation. In support of this possibility, I found that permeabilizing 
the plasma membrane of hepatocytes with saponin or completely disrupting the 
membrane by sonication greatly reduced 3-hydroxydesloratadine formation (Figure 
5.10A). Addition of various cofactors to permeabilized/sonicated hepatocytes revealed 
that formation of 3-hydroxydesloratadine could be partially restored by the addition of both 
NAPDH and UDP-GlcUA. Modest recovery was also observed in 
permeabilized/sonicated hepatocytes supplemented with only UDP-GlcUA presumably 
because there was sufficient endogenous NADPH to support some 3-hydroxy metabolite 
formation. Subsequent experiments with HLM and HS9 (Figure 5.10B and Figure 5.11) 
confirmed the requirement of both NADPH and UDP-GlcUA for the formation of 
3-hydroxydesloratadine. 
 
These results suggested that, in addition to oxidation by CYP2C8, glucuronidation plays 
a key role in the formation of 3-hydroxydesloratadine. To explore this possibility further, 
desloratadine was incubated with recombinant CYP2C8 in the absence or presence of a 
panel of recombinant UGT enzymes (with NAPDH and UDP-GlcUA as cofactors). In the 
absence of any UGT enzyme, CYP2C8 did not form 3-hydroxydesloratadine but did so in 
the presence of UGT2B10 (Figure 5.12). These results suggest that desloratadine is 
glucuronidated by UGT2B10 and that desloratadine glucuronide, not desloratadine itself, 
is the substrate that undergoes 3-hydroxylation by CYP2C8. Furthermore, the results 
suggest that the glucuronide moiety introduced by UGT2B10 is cleaved during or shortly 
after metabolism by CYP2C8. When the sample to sample variation of CYP2C8 activities 
238 
 
were correlated to UGT2B10 activity and 3-hydroxydesloratadine formation, good 
correlation was achieved, with r2 = 0.73-0.75 (Figure 5.8). 
 
A proposed metabolic scheme for 3-hydroxydesloratadine formation is shown in Figure 
5.13. The first step is proposed as formation of desloratadine N-glucuronide by UGT2B10, 
followed by hydroxylation to 3-hydroxydesloratadine N-glucuronide by CYP2C8, with 
subsequent de-conjugation to 3-hydroxydesloratadine. Efforts to isolate and characterize 
the proposed intermediary metabolites are currently underway. An N-glucuronide is 
proposed as the initial metabolite because there are no hydroxyl or thiol groups available 
for direct conjugation. UGT2B10 is one of two enzymes, the other being UGT1A4, 
renowned for their ability to catalyze the N-glucuronidation of drugs, with UGT2B10 being 
a high affinity/low capacity enzyme UGT1A4 being a low affinity/high capacity enzyme 
(Zhou et al., 2010; Parkinson et al., 2013). Ketotifen, a structural analog of desloratadine, 
is known to be N-glucuronidated at the piperidine ring to a quaternary N-glucuronide by 
UGT2B10 and UGT1A4. Furthermore, N-glucuronidation of ketotifen is a prominent 
reaction in rabbits and humans, the two species whose hepatocytes catalyzed the highest 
rate of formation of 3-hydroxydesloratadine (Kato et al., 2013; Bolleddula et al., 2014). It 
has been previously reported that rabbits may be a particularly useful species for 
nonclinical studies of drugs that undergo N-glucuronidation in humans (Chiu and Huskey, 
1998). However, N-glucuronidation by UGT2B10 on the pyridine moiety of desloratadine 
cannot be ruled out and has been shown to occur in the case of nicotine and cotinine 
glucuronidation (Murphy et al., 2014). 
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The ability of CYP2C8 to metabolize a glucuronide conjugate is well established 
(Parkinson et al., 2013). For example, whereas the 4′-hydroxylation of diclofenac (parent 
drug) is catalyzed by CYP2C9, the 4′-hydroxylation of diclofenac acyl glucuronide is 
catalyzed by CYP2C8 (Kumar et al., 2002). This same pattern, where the aglycone 
(typically a small acidic substrate) is not metabolized by CYP2C8 (and in some cases is 
metabolized by CYP2C9) whereas the glucuronide metabolite (a large acidic substrate) 
is metabolized by CYP2C8, has been reported  for estradiol 17-O-β-glucuronide and the 
acyl glucuronide conjugates of naproxen, the PPARα agonist MRL-C, and gemfibrozil 
(Delaforge et al., 2005; Kochansky et al., 2005; Ogilvie et al., 2006; Parkinson et al., 
2013). In the case of gemfibrozil, the CYP2C8-mediated hydroxylation of its 1-O-β-
glucuronide forms a benzyl radical intermediate that causes irreversible inhibition of 
CYP2C8 (Ogilvie et al., 2006; Baer et al., 2009).  
 
The conversion of desloratadine by UGT2B10 to an N-glucuronide that is subsequently 
hydroxylated by CYP2C8 is consistent with the known properties of these enzymes.  
Nevertheless, the formation of 3-hydroxydesloratadine is unusual because no 
3-hydroxylation is detectable in the absence of glucuronidation and because the N-
glucuronide is cleaved during or shortly after CYP2C8-dependent hydroxylation. 
Interestingly, while 3-hydroxydesloratadine is produced from an N-glucuronide (formed 
by UGT2B10 and cleaved following hydroxylation by CYP2C8), 3-hydroxydesloratadine 
itself is subsequently converted to an O-glucuronide (at the 3-hydroxy position) by 
UGT1A1, UGT1A3 and UGT2B15 (Ghosal et al., 2004). 
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It is unclear whether there is any potential for drug-drug interactions (DDIs) with 
desloratadine as it has a large therapeutic safety margin. As a perpetrator, desloratadine 
has been shown not to be an inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2D6 or 
CYP3A4 (Barecki et al., 2001). However, to my knowledge, inhibition of CYP2C8 and 
UGT2B10 has not been evaluated, so it is unclear whether desloratadine could cause 
any clinically-relevant interactions with substrates of these enzymes. A recent clinical 
study examining the effect of desloratadine on montelukast serum levels found no 
significant difference in montelukast serum levels in fixed-dose combination with 
desloratadine (Cingi et al., 2013). All other relevant studies have examined the 
pharmacodynamic/pharmacokinetic interaction potential of desloratadine with CYP2D6 
and CYP3A4 substrates, and desloratadine was found to have limited potential for DDI 
(Gupta et al., 2001; Banfield et al., 2002a; Banfield et al., 2002b; Gupta et al., 2004). With 
respect to special populations, patients with moderate hepatic impairment have been 
shown to have elevated levels of desloratadine (2.4-fold increase in AUC); however it has 
been reported that 3-hydroxydesloratadine exposure was similar between hepatically-
impaired and normal patients (Gupta et al., 2007).  
  
The pharmacogenetic basis for the 3-hydroxydesloratadine poor metabolizer (PM) 
phenotype has remained a mystery. It has been reported that the polymorphism 
surrounding 3-hydroxydesloratadine formation occurs in approximately 6% of the general 
population and at a frequency of 17% in African Americans, with PMs having 
approximately 6-fold greater systemic exposure than extensive metabolizers (EMs) 
(Prenner et al., 2006). My results suggest that CYP2C8 and/or UGT2B10 polymorphism 
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may be responsible for the poor metabolizer phenotype. A large number of CYP2C8 
genetic polymorphisms have been identified, with CYP2C8*2, CYP2C8*3, CYP2C8*4, 
CYP2C8*8 and CYP2C8*14 alleles shown to have decreased functional activity (Dai et 
al., 2001; Bahadur et al., 2002; Hichiya et al., 2005; Gao et al., 2010; Hanioka et al., 2010; 
Jiang et al., 2011). However, little is currently known about UGT2B10 polymorphisms, 
although the UGT2B10*2 allele has been shown to correspond to a functional decrease 
in nicotine and cotinine glucuronide formation (Chen et al., 2007). Further studies will be 
necessary to establish whether genetic polymorphisms of CYP2C8 and/or UGT2B10 can 
account for the desloratadine PM phenotype. 
 
In summary, the following evidence suggests that the conversion of desloratadine to 
3-hydroxydesloratadine is mediated by CYP2C8 in conjunction with UGT2B10: 
1. The formation of 3-hydroxydesloratadine by human hepatocytes is inhibited by 
reversible and irreversible inhibitors of CYP2C8; 
2. In human hepatocytes, the sample to sample variation in 3-hydroxydesloratadine 
formation correlates with CYP2C8 activity towards amodiaquine and paclitaxel; 
3. Human liver microsomes and S9 fraction do not form 3-hydroxydesloratadine 
unless supplemented with both NADPH and UDP-GlcUA; 
4. Recombinant CYP2C8 does not form 3-hydroxydesloratadine unless co-incubated 
with recombinant UGT2B10 and both NADPH and UDP-GlcUA; 
5. No other pair of recombinant CYP and UGT enzyme converted desloratadine to 
3-hydroxydesloratadine. 
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I were unable to detect either desloratadine N-glucuronide (formed by UGT2B10) or 
3-hydroxydesloratadine N-glucuronide (the initial metabolite formed by CYP2C8). These 
glucuronides appear to be very unstable, which is a characteristic of certain other 
N-glucuronides (Ciotti et al., 1999). Despite this limitation, the identification of CYP2C8 in 
combination with UGT2B10 in the formation of 3-hydroxydesloratadine contributes to our 
understanding of the long-standing mystery surrounding the enzymology of 
3-hydroxydesloratadine formation in humans, providing a pathway for future investigation 
of the genetic basis for the desloratadine poor metabolizer phenotype. 
  
243 
 
 
 
 
 
 
 
 
 
CHAPTER 6 : FURTHER CHARACTERIZATION OF THE METABOLISM 
OF DESLORATADINE AND ITS CYTOCHROME P450 AND UDP-
GLUCURONOSYLTRANSFERASE (UGT) INHIBITON POTENTIAL: 
IDENTIFICATION OF DESLORATADINE AS A SELECTIVE UGT2B10 
INHIBITOR 
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ABSTRACT 
Desloratadine (Clarinex®), the major active metabolite of loratadine (Claritin®), is a non-
sedating antihistamine used for the treatment of seasonal allergies and hives. In the 
preceding chapter I reported that the formation of 3-hydroxydesloratadine, the major 
human metabolite of desloratadine, involves three sequential reactions, namely 
N-glucuronidation by UGT2B10 followed by 3-hydroxylation by CYP2C8 followed by de-
conjugation (rapid, non-enzymatic hydrolysis of the N-glucuronide). In this chapter I 
assessed the perpetrator potential of desloratadine based on in vitro studies of its 
inhibitory effects cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) 
enzymes in human liver microsomes (HLM). Desloratadine (10 µM) caused no inhibition 
(<15%) of CYP1A2, CYP2C8, CYP2C9, and CYP2C19 and weak inhibition (32-48%) of 
CYP2B6, CYP2D6 and CYP3A4/5 In cryopreserved human hepatocytes (CHH), which 
can form the CYP2C8 substrate desloratadine N-glucuronide, desloratadine did not inhibit 
the CYP2C8-dependent metabolism of paclitaxel or amodiaquine. Assessment of UGT 
inhibition identified desloratadine as a potent and selective inhibitor of UGT2B10 (IC50 
value of 1.6 μM). Chemical inhibition of UGT enzymes in HLM demonstrated that nicotine 
(UGT2B10 inhibitor) but not hecogenin (UGT1A4 inhibitor) completely inhibited the 
conversion of desloratadine (1 µM) to 3-hydroxydesloratadine in HLM fortified with both 
NADPH and UDP-glucuronic acid. Overall, the results of this study confirm the role of 
UGT2B10 in 3-hydroxydesloratadine formation and identify desloratadine as a selective 
in vitro inhibitor of UGT2B10. 
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INTRODUCTION 
Desloratadine (Clarinex®), is a long lasting, non-sedating, second-generation, selective 
H1-receptor histamine antagonist commonly used for the treatment of seasonal allergies 
(allergic rhinitis) and chronic hives (chronic idiopathic urticaria) (Geha and Meltzer, 2001; 
Henz, 2001). Desloratadine is a major and pharmacologically active metabolite of the 
antihistamine loratadine (Claritin®) and is formed primarily by CYP3A4 and to a lesser 
extent by CYP2D6 (Yumibe et al., 1995; Yumibe et al., 1996; Dridi and Marquet, 2013). 
In 2001, desloratadine was approved as a drug in its own right; however, at the time of 
its approval, the enzymology surrounding its metabolism was unknown (Schering-Plough, 
2001). In humans, desloratadine is converted to 3-hydroxydesloratadine (by 
hydroxylation of the pyridine ring) followed by O-glucuronidation to 
3-hydroxydesloratadine O-glucuronide. Both 3-hydroxydesloratadine and its glucuronide 
conjugate are major in vivo metabolites excreted in approximately equal amounts in urine 
and feces (Ramanathan et al., 2007). Conventional in vitro systems such as recombinant 
P450 enzymes, human liver microsomes (HLM) and human liver S9 fractions do not 
convert desloratadine to 3-hydroxydesloratadine; hence, its enzymology and basis for 
certain individuals being identified as poor metabolizers of desloratadine have remained 
a mystery for many years (Ghosal et al., 2009). In Chapter 5, I demonstrated that 
cryopreserved human hepatocytes (CHH) can form 3-hydroxydesloratadine, as can HLM 
provided they are supplemented with both NADPH and UDP-glucuronic acid (UDP-
GlcUA). As shown in Figure 6.1, formation of 3-hydroxydesloratadine involves three 
sequential reactions: (1) N-glucuronidation of desloratadine by UGT2B10; (2) 3-
hydroxylation of desloratadine N-glucuronide by CYP2C8, and (3) de-conjugation of 3-
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hydroxydesloratadine N-glucuronide (rapid non-enzymatic hydrolysis of the glucuronide. 
The N-glucuronide of desloratadine is highly unstable (both before and after 3-
hydroxylation by CYP2C8). I was unable to detect desloratadine N-glucuronide or 
3-hydroxydesloratadine N-glucuronide by LC-MS/MS in the studies described in Chapter 
5. Instability is a characteristic property of certain N-glucuronides (Ciotti et al., 1999). 
The draft FDA guidance (FDA, 2012) and final EMA guidelines (EMA, 2013) on drug-drug 
interactions (DDIs) both recommend that the perpetrator potential of investigational drugs 
be assessed by evaluating their ability to inhibit CYP and UGT enzymes. These regulatory 
agencies further require that, in the case of CYP enzymes, all investigational drugs be 
evaluated for their ability to cause  time-dependent or metabolism-dependent inhibition 
(Grimm et al., 2009). The panel of enzymes recommended for testing and the types of 
inhibition to be evaluated have expanded since the FDA issued its first Guidance for 
Industry on drug interactions (FDA, 1997). Desloratadine was evaluated for its ability to 
inhibit CYP enzymes shortly after the FDA issued its first drug interaction guidance 
(Barecki et al., 2001). This study evaluated desloratadine and 3-hydroxydesloratadine as 
reversible inhibitors of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 but it did not 
evaluate the potential for irreversible (time-dependent) inhibition, nor did it evaluate 
inhibition of CYP2B6 of CYP2C8 (all of which were not recommended by the FDA at the 
time the study was performed). Furthermore, desloratadine was not evaluated as an 
inhibitor of UGT enzymes. In view of the role of CYP2C8 and UGT2B10 in the metabolism 
of desloratadine, it was of interest to evaluate desloratadine as a reversible and 
irreversible inhibitor of the 7 P450 enzymes currently recommended by testing by the FDA 
(namely, CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5) and as a reversible inhibitor of 
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multiple UGT enzymes in HLM (namely, UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B7, 2B10, 2B15 
and 2B17. In addition, because the N-glucuronide metabolites of desloratadine are highly 
unstable, I conducted additional (indirect) studies to evaluate whether the N-
glucuronidation of desloratadine is dependent largely or solely on UGT2B10. 
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Figure 6.1. The metabolic scheme for the conversion of desloratadine to 
3-hydroxydesloratadine 
Desloratadine is converted to its corresponding N-glucuronide followed by hydroxylation 
and de-conjugation to 3-hydroxydesloratadine as described in Chapter 5. 
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RESULTS 
6.1. Assessment of desloratadine as an inhibitor of seven P450 
enzymes. 
To evaluate desloratadine as an inhibitor of P450 enzymes in vitro, desloratadine (10 μM) 
was incubated with HLM (≤ 0.1 mg/mL) with and without a 30-min preincubation step in 
the presence or absence of NADPH. P450 activity was measured with CYP-selective 
substrates (at a final concentration roughly equal to Km), as described in Chapter 2. As 
shown in Figure 6.2 and Table 6.1, desloratadine did not inhibit (<15%) CYP1A2, 
CYP2C8, CYP2C9, or CYP2C19 but caused partial inhibition of CYP2B6 (48%), CYP2D6 
(32%) and CYP3A4/5 (44%). Preincubating desloratadine for 30 min with HLM in the 
absence or presence of NADPH caused little or no increase in P450 inhibition (i.e., there 
was no evidence of time-dependent or metabolism-dependent inhibition). 
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Figure 6.2. Assessment of the inhibition of P450 enzymes by desloratadine. 
The P450 inhibition potential of desloratadine (10 μM) was assessed in HLM (≤ 0.1 
mg/mL) with and without a 30-min preincubation step in the presence or absence of 
NADPH, followed by a 5-min incubation with a CYP-selective marker substrate (at a 
concentration approximately equal to its Km) as indicated in the figure. Details of the 
experimental procedures are described in Chapter 2. 
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Table 6.1. Assessment of desloratadine as an inhibitor of P450 and UGT enzymes 
in pooled human liver microsomes (HLM) 
Enzyme Substrate (concentration) 
Inhibition with 10 μM Desloratadine (% activity remaining) 
Direct 
inhibition 
(Zero-min 
Preincubation) 
TDI 
(30 min 
preincubation 
−NADPH) 
MDI 
(30 min 
preincubation 
+NADPH) 
Barecki et 
al., 2001a 
CYP1A2 
Phenacetin 
(40 μM) 
96.3 80.3 93.2 110b 
CYP2B6 
Bupropion 
(50 μM) 
51.8 59.5 59.6 
ND 
CYP2C8 
Paclitaxel 
(5 μM) 
98.9 117 100 
CYP2C9 
Diclofenac 
(6 μM) 
94.1 103 106 106 
CYP2C19 
S-Mephenytoin 
(40 μM) 
89.3 91.9 87.2 112 
CYP2D6 
Dextromethorphan 
(7.5 μM) 
68.4 67.0 78.1 86.3 
CYP3A4/5 
Midazolam 
(3 μM) 
55.7 56.1 55.0  84.0
c, 
80.0d 
UGT1A1 17β-Estradiol 
(9 μM) 
89.7 
Not applicable 
UGT1A3 
CDCAe 
(20 μM) 
92.1 
UGT1A4 
Trifluoperazine 
(12 μM) 
88.3 
UGT1A6 
1-Naphthol 
(1 μM) 
94.4 
UGT1A9 
Propofol 
(20 μM) 
103 
UGT2B7 
Morphine 
(400 μM) 
91.2 
UGT2B10 
Levomedetomidine 
(7 μM) 
21.6 
UGT2B15 
Oxazepam 
(50 μM) 
92.4 
UGT2B17 
Testosterone 
(5 μM) 
75.7 
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a Only direct inhibition (0 min preincubation) was evaluated. 
b Substrate used was 7-exthoxyresorufin 
c Substrate used was dextromethorphan 
d Substrate used was testosterone 
CDCA: chenodeoxycholic acid; NA: not applicable; ND: no data  
253 
 
6.2. Assessment of desloratadine as an inhibitor of CYP2C8 in 
human hepatocytes. 
As shown in the preceding section (Figure 6.2 and Table 6.1), desloratadine did not inhibit 
CYP2C8. This enzyme does not metabolize desloratadine but it does metabolize 
desloratadine N-glucuronide. Unfortunately, this N-glucuronide is too unstable to perform 
direct tests of its inhibitory potential. Therefore, desloratadine was evaluated as an 
inhibitor of CYP2C8 in CHH, which can convert desloratadine to its N-glucuronide. In this 
assay, desloratadine (0.1−100 µM) was incubated with CHH (0.5 million cells/mL) for up 
to 2 h, after which the activity of CYP2C8 was measured with paclitaxel (10 µM) and 
amodiaquine (10 µM), as described in Chapter 2. As shown in Figure 6.3 and Table 6.1, 
desloratadine was not a direct or time-dependent inhibitor of CYP2C8 in CHH (IC50 values 
>100 μM). 
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Figure 6.3. Evaluation of desloratadine as an inhibitor of CYP2C8 activity toward 
amodiaquine (left) and paclitaxel (right) in cryopreserved human hepatocytes 
As described in Chapter 2, the inhibition of CYP2C8, as measured by amodiaquine N-
dealkylation (left panel) and paclitaxel 6α-hydroxylation (right panel), was performed with 
0.1, 0.3, 1, 3, 10, 30, and 100 μM desloratadine in cryopreserved human hepatocytes 
(0.5 million cells/mL). Desloratadine was preincubated with CHH for 0, 30 and 120 min, 
after which CYP2C8 activity was measured with a 10-min incubation with amodiaquine 
(10 µM) or 30-min incubation time with paclitaxel (10 µM). 
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6.3. Assessment of desloratadine as an inhibitor of nine UGT 
enzymes. 
Desloratadine was evaluated as an inhibitor of nine UGT enzymes in HLM (≤0.1 mg/mL) 
as described in Table 2.4 and Chapter 2. As shown in Table 6.1 and Figure 6.4, 
desloratadine (10 μM) caused no inhibition (<15%) of UGT1A1, UGT1A3, UGT1A4, 
UGT1A6, UGT1A9, UGT2B7, or UGT2B15 and caused weak inhibition of UGT2B17 
(24%). In contrast, UGT2B10 activity, as measured by levomedetomidine N-
glucuronidation, was strongly inhibited (78%) by desloratadine. The UGT2B10 inhibition 
assay was repeated with a wide range of concentrations of desloratadine (0.1-100 µM), 
which established that desloratadine inhibited UGT2B10 with an IC50 of 1.6 μM, as shown 
in Figure 6.5. 
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Figure 6.4. Evaluation of desloratadine (10 µM) as an inhibitor of UGT enzymes in 
human liver microsomes 
The UGT inhibition potential of desloratadine (10 μM) was assessed in HLM (≤ 0.1 
mg/mL) with UDP-GlcUA and the UGT-selective substrates identified in the figure (at a 
final concentration approximately equal to its Km). The incubation time was 5 or 10 min.  
Experimental details are described in Chapter 2. 
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Figure 6.5. IC50 determination of the UGT2B10 inhibition potential by desloratadine 
in HLM 
Desloratadine (0.1, 0.3, 1, 3, 10, 30, and 100 μM) was evaluated as an inhibitor of 
UGT2B10 (levomedetomidine N-glucuronidation) in HLM (0.1 mg/mL). The substrate 
concentration was 7 µM and the incubation time was 10 min, as described in Chapter 2. 
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6.4. Further characterization of the UGT enzymes involved in 3-
hydroxydesloratadine formation. 
I previously identified recombinant UGT2B10 as the only UGT enzyme capable of 
supporting the CYP2C8-dependent formation of 3-hydroxydesloratadine in Chapter 5. 
However, this assessment was based on studies with a panel of recombinant UGT 
enzymes (each of which was co-incubated with recombinant CYP2C8). Although these 
studies implicated UGT2B10 in the formation of 3-hydroxydesloratadine they do not 
exclude the possibility that HLM contain other UGT enzymes that contribute to this 
reaction. UGT2B10 is one of two enzymes renowned for its ability to form N-glucuronides; 
the other is UGT1A4 (Parkinson et al., 2013). To evaluate the role of UGT2B10 and 
UGT1A4 in the formation of 3-hydroxydesloratadine, inhibitors either UGT1A4 
(hecogenin; 100 μM) or UGT2B10 (nicotine; 500 μM) were added separately or in 
combination to HLM (0.1 mg/mL) in the presence of NADPH and UDP-GlcUA, followed 
by assessment of 3-hydroxdesloratadine formation and/or measurement of UGT1A4 
activity (trifluoperazine N-glucuronidation) and UGT2B10 activity (levomedetomidine N-
glucuronidation), as described in Chapter 2. As shown in Figure 6.6, trifluoperazine N-
glucuronidation was inhibited only by the UGT1A4 inhibitor hecogenin whereas 
levomedetomidine N-glucuronidation was inhibited only by the UGT2B10 inhibitor 
nicotine. When NADPH- and UDP-GlcUA-fortified HLM were incubated with 10 μM 
desloratadine, hecogenin did not inhibit 3-hydroxydesloratadine formation whereas 
nicotine and a combination of hecogenin and nicotine caused moderate inhibition of 45% 
and 35% respectively. When the concentration of desloratadine was lowered to 1 μM, 
complete inhibition of 3-hydroxydesloratadine formation was observed with nicotine and 
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hecogenin + nicotine, whereas hecogenin caused no inhibition of 3-hydroxydesloratadine 
formation. These results suggest that UGT2B10 is the only UGT enzyme in HLM capable 
of catalyzing the N-glucuronidation of desloratadine.  
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Figure 6.6. The effect of the UGT1A4 inhibitor hecogenin and the UGT2B10 inhibitor 
nicotine on the formation of 3-hydroxydesloratadine by NADPH- and UDP-GlcUA-
fortified human liver microsomes (HLM) 
Inhibitors of UGT1A4 (hecogenin; 100 μM) and UGT2B10 (nicotine; 500 μM) or the 
combination of both were examined for their ability to inhibit the conversion of 
desloratadine (1 and 10 µM) to 3-hydroxydesloratadine by human liver microsomes (0.1 
mg/mL) supplemented with NADPH and UDP-GlcUA. The activity of UGT1A4 and 
UGT2B10 were measured as trifluoperazine N-glucuronidation and levomedetomidine N-
glucuronidation, respectively. Experimental details are described in Chapter 2. 
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DISCUSSION 
Desloratadine (marketed as Clarinex® in the US and Aerius® in Europe) received FDA 
approval in 2001 for the treatment of allergic rhinitis and chronic idiopathic urticaria (Geha 
and Meltzer, 2001; Henz, 2001). The major human circulating metabolite of desloratadine 
is 3-hydroxydesloratadine, a metabolite whose enzymology remained a mystery for over 
20 years due, in large part, to the inability of conventional in vitro test systems, such as 
subcellular fractions, to form 3-hydroxydesloratadine (Ghosal et al., 2009). As described 
in Chapters 4 and 5, I demonstrated that CHH are capable of forming 3-
hydroxydesloratadine, with a Km of 1.6 μM. Studies with P450 inhibitors in CHH and 
comparisons of the sample-to-sample variation in 3-hydroxydesloratadine formation with 
the variation in P450 activities in CHH (correlation analysis) implicated CYP2C8 in the 
conversion of desloratadine to 3-hydroxydesloratadine (Chapter 5). These findings in 
CHH made the inability of HLM to form 3-desloratadine all the more puzzling because 
HLM contain functional CYP2C8. Furthermore, recombinant CYP2C8 was also incapable 
of converting desloratadine to 3-hydroxydesloratadine despite catalyzing high rates of 
metabolism of substrates like paclitaxel and amodiaquine. The seemingly paradoxical 
findings were resolved with the discovery that the substrate for CYP2C8 is not 
desloratadine itself but its N-glucuronide, as shown in Figure 6.1. When individual 
recombinant UGT enzymes were co-incubated with recombinant CYP2C8, it was found 
that UGT2B10 was the only UGT enzyme capable of supporting the CYP2C8-dependent 
conversion of desloratadine to 3-hydroxydesloratadine (Chapter 5). 
The studies in Chapter 5 advanced our understanding of the victim potential of 
desloratadine. Based on these studies, it is now known, for example, that drugs that alter 
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the activity of UGT2B10 and CYP2C8 are factors that likely impact the disposition of 
desloratadine. Furthermore, genetic polymorphisms (loss-of-function allelic variants) of 
UGT2B10 and/or CYP2C8 are candidates for explaining why a small percentage of 
human subjects are poor metabolizers of desloratadine (Prenner et al., 2006). 
In the present study, I examined the perpetrator potential of desloratadine based on its 
ability to inhibit P450 and UGT enzymes in HLM. The direct but not time- or metabolism-
dependent P450 inhibition potential of desloratadine was previously evaluated by Barecki 
and colleagues (2001). Since this study was published, subsequent regulatory guidelines 
expanded the panel of CYP enzymes recommended for testing (CYP2B6 and CYP2C8 
were added) and they recommended an evaluation of both reversible and irreversible 
inhibition of P450 enzymes (FDA, 2012; EMA, 2013). Inhibition of CYP2B6 or CYP2C8 is 
the basis for certain clinically relevant DDIs, such as the mechanism-based inactivation 
of CYP2B6 by clopidogrel and ticlopidine leading to clinical interactions with bupropion, 
efavirenz and ketamine (Richter et al., 2004; Turpeinen et al., 2005; Peltoniemi et al., 
2011; Jiang et al., 2013). Likewise, the mechanism-based inactivation of CYP2C8 by 
gemfibrozil glucuronide or clopidogrel glucuronide leads to a clinical interaction with 
cerivastatin that resulted in the withdrawal of cerivastatin from the market (Backman et 
al., 2002; Ogilvie et al., 2006; Tornio et al., 2014).  
In the present study, the inhibition of seven P450 enzymes, namely CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, was evaluated with a single 
concentration of desloratadine (10 μM; approximately 10 times Cmax) at low HLM 
concentrations (≤ 0.1 mg/mL) with a short probe-substrate incubation time (5 min) and 
included an assessment of reversible inhibition (no preincubation, time-dependent 
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inhibition (30-min pre-incubation of desloratadine and HLM without NADPH) and 
metabolism-dependent inhibition (30-min pre-incubation of desloratadine and HLM with 
NADPH). There was no evidence that desloratadine caused significant time- or 
metabolism-dependent inhibition of any of the CYP enzymes examined, but it did cause 
reversible inhibition of certain enzymes. Consistent with the data reported by Barecki and 
colleagues (2001), the results of this study (Figure 6.2 and Table 6.1) showed that 
desloratadine is not an inhibitor of CYP1A2, CYP2C9, and CYP2C19; but is a moderate 
inhibitor of CYP2D6 and CYP3A4/5 The slightly greater degree of CYP2D6 and CYP3A4 
inhibition observed in the current study (32% and 44%, respectively) compared with the 
Barecki study (14% and 16-20%, respectively) can reasonably be differences in 
experimental design. Barecki et al. (2001) used relatively high protein concentrations (up 
to 10 times those used in the current study), which would have lowered the unbound 
concentration of desloratadine to a greater extent. In addition to inhibiting CYP2D6 and 
CYP3A4/5, desloratadine also inhibited CYP2B6 (~48%).   
The ability of desloratadine to inhibit CYP2C8 was evaluated in HLM and CHH. 
Hepatocytes were used to evaluate the possibility that CYP2C8 could be inhibited by 
desloratadine N-glucuronide. No inhibition of CYP2C8 was observed in either HLM or 
CHH (Table 6.1, Figure 6.2 and Figure 6.3). These results are consistent with a clinical 
report demonstrating no effect of desloratadine on serum levels of the CYP2C8 substrate 
montelukast (Cingi et al., 2013). Few clinical studies have been performed to evaluate 
desloratadine as an inhibitor of CYP2D6 or CYP3A4. Desloratadine does not affect the 
pharmacokinetics of fluoxetine or azithromycin to a clinically significant extent (Gupta et 
al., 2001; Gupta et al., 2004). The previously reported requirement of UDP-GlcUA in 
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3-hydroxydesloratadine formation led us to investigate the perpetrator potential of 
desloratadine towards UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7 
UGT2B10, UGT2B15 and UGT2B17. Desloratadine was identified as a potent and 
selective inhibitor of UGT2B10 (Figure 6.4), consistent with its involvement in 
3-hydroxydesloratadine formation. Desloratadine inhibited UGT2B10 with an IC50 of 1.6 
μM (Figure 6.5), which is comparable to the reported clinical plasma Cmax value of 1.3 μM 
(Schering-Plough, 2001). 
In accordance with regulatory guidelines (FDA, 2012), the potential clinical relevance of 
P450 inhibition in vitro can be evaluated based on the [I]/Ki ratio, (where [I] is the total 
unbound plasma Cmax concentration and Ki is the unbound inhibition constant) and is used 
for in vitro to in vivo extrapolation (IVIVE) to predicted the fold change in AUC of a victim 
drug (where AUC with inhibitor/AUC without inhibitor = 1 + [I]/Ki) (Ito et al., 1998). When 
the substrate concentration is equal to Km, the Ki value can be estimated from the IC50 
value using the Cheng-Prusoff equation, where Ki = IC50/2 for competitive inhibition 
(Cheng and Prusoff, 1973; Haupt et al., 2011). This same approach has also been applied 
for the prediction of UGT mediated DDIs (Williams et al., 2004; Miners et al., 2010g). The 
fuinc for desloratadine would be 0.84 based on a logP value of 4 (from www.drugbank.ca) 
using the equation from Hallifax et al., (2006). Using this approach, the unbound Ki value 
is 0.67 μM therefore desloratadine is predicted to cause a 2.9-fold increase in the plasma 
AUC of a drug that is cleared exclusively by UGT2B10. To my knowledge, there is no 
known drug exclusively cleared through UGT2B10. Many drugs that are substrates of 
UGT enzymes are commonly cleared through other pathways, and many substrates of 
UGT2B10 are also N-glucuronidated by UGT1A4. Nevertheless, the discovery that 
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desloratadine is a selective UGT2B10 inhibitor is important for in vitro UGT reaction 
phenotyping studies; it can be used as a chemical inhibitor to determine the fraction of a 
drug metabolized through UGT2B10. 
Both UGT1A4 and UGT2B10 are well known for their ability to N-glucuronidate drugs 
such as amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, 
tamoxifen, ketoconazole and midazolam (Kato et al., 2013). In Chapter 5, I determined 
that recombinant UGT2B10 was the only UGT enzyme capable of supporting the 
CYP2C8-dependent conversion of desloratadine. This finding does not establish that 
UGT2B10 is the only enzyme in HLM capable of supporting this reaction. It is possible, 
for example, that in a more complete test system such as HLM, UGT1A4 may play a role 
in addition to UGT2B10. To evaluate this possibility, I performed a chemical inhibition 
study using the UGT1A4 inhibitor hecogenin and the UGT2B10 inhibitor nicotine (alone 
or in combination) with HLM (supplemented with both UDP-GlcUA and NADPH) and 
examined the formation of 3-hydroxydesloratadine as well as the activity UGT1A4 (with 
trifluoperazine) and UGT2B10 (with levomedetomidine) (Figure 6.6). The formation of 3-
hydroxydesloratadine was inhibited by the CYP2B10 inhibitor nicotine but not by the 
UGT1A4 inhibitor hecogenin, confirming that UGT2B10 is solely responsible for the 
formation of 3-hydroxydesloratadine, consistent with the results of my previous study with 
recombinant enzyme results (Kazmi et al., 2015). 
Desloratadine N-glucuronide is so unstable that efforts to detect its formation by LC-
MS/MS were unsuccessful. In an effort to find evidence for desloratadine glucuronidation, 
I attempted to use an indirect measure of glucuronidation by measuring formation of UDP, 
a byproduct of UGT reactions, as shown in Figure 6.1. Unfortunately, I was unsuccessful 
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in developing an LC-MS/MS method for UDP. I also attempted to measure desloratadine 
glucuronidation indirectly by incubating desloratadine (as well as the UGT2B10 substrate 
levomedetomidine) for up to 4 hours with HLM or rUGT2B10 + rUGT1A6 and a low 
concentration of UDP-GlcUA (30 μM) followed by the addition of an excess (500 μM) of 
1-naphthol (a UGT1A6 substrate that is rapidly glucuronidated) for 10 min to consume 
any remaining UDP-GlcUA. The amount of 1-naphthol glucuronide should have provided 
an indirect measure of the amount of UDP-GlcUA remaining; however, there was no 
discernible difference between control (no drug), desloratadine or levomedetomidine 
incubations. 
In conclusion, desloratadine was identified as a potent and selective inhibitor of 
UGT2B10, the enzyme implicated in the N-glucuronidation of desloratadine. 
Desloratadine was a weak reversible inhibitor P450 enzymes and showed no significant 
time- or metabolism-dependent inhibition of any of the CYP enzymes examined. Because 
of the instability of desloratadine N-glucuronide, desloratadine is unsuitable as a probe 
substrate for UGT2B10. However, as an inhibitor of UGT2B10, desloratadine can be used 
as part of standard in vitro chemical inhibition studies for the reaction phenotyping of UGT 
substrates, allowing for the determination of fractional metabolism by UGT2B10. These 
findings contribute to our understanding of the role of UGT enzymes in drug clearance 
and provide greater insight into the potential for desloratadine mediated DDIs. 
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7.1. Summary and overall conclusions 
Before I was born, the metabolism of debrisoquine and the duration of its hypotensive 
effect in humans were shown to be under the control of a single recessive gene, which 
was subsequently identified as CYP2D6 (Mahgoub et al., 1977; Idle et al., 1978). In 1990 
Monahan et al. published the first paper describing elevated levels of terfenadine and 
torsade de pointes (a risk factor for ventricular arrhythmia) following the coadministration 
of terfenadine with the CYP3A4/5 inhibitor ketoconazole (Monahan et al., 1990). Since 
these seminal findings, the activity of all P450 enzymes involved in drug metabolism have 
been shown to vary enormously from one individual to the next due to intrinsic factors, 
such as genetic polymorphisms (as in the case of CYP2D6) or extrinsic factors, such as 
concomitant drug therapy (as in the case of CYP3A4/5). Accordingly, identifying the drug-
metabolizing enzymes and drug transporters that determine the disposition of a drug 
candidate is indispensable to the drug development process; one that is required by 
regulatory agencies such as the FDA and EMA to ensure the safety and well-being of 
patients. Over the last 50 years, there have been considerable advances in the in vitro 
test systems used to assess drug disposition, from the early days of animal liver 
microsomal samples to the current availability of large pools (n=200) of human liver 
microsomes (HLM), large pools (n=50 or 100) of cryopreserved human hepatocytes 
(CHH) and recombinant enzymes, as well as the identification of enzyme-specific 
substrates and inhibitors that can be used in vitro and, in many cases, in vivo. The large 
pools of HLM and CHH eliminate the large sample-to-sample in enzyme activity that 
complicated early studies of in vitro drug metabolism, although this wide variation is the 
basis for the technique known as correlation analysis, which is one of the so-called 
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reaction phenotyping methods for identifying which CYP enzyme is primarily responsible 
for metabolizing a drug candidate. These current in vitro test systems are important 
mainstays for the assessment of drug disposition and the data generated with these 
assays is widely used by pharmaceutical companies and regulatory agencies to make 
risk assessments of new drug candidates.  
Although considerable advances have been made with the quality of HLM and CHH, 
certain key differences remain that are inherent to each test system. CHH for instance 
are an intact cellular test system with the ability to perform Phase I and Phase II 
metabolism with a full complement of enzymatic cofactors, as well as transport processes 
of drugs (such as drug uptake). HLM on the other hand are isolated endoplasmic 
reticulum and their ability to metabolize drugs is not restricted by drug permeability, 
although the range of metabolic reactions that can be assessed is limited (typically P450, 
FMO, UGT and carboxylesterase) and requires the addition of exogenous cofactor. 
Regardless of the advantages or limitations of each system, both in vitro test systems are 
widely employed by the pharmaceutical industry for the in vitro to in vivo extrapolation 
(IVIVE) of drug metabolic clearance, which plays an important role in the process of 
identifying drug candidates with favorable pharmacokinetic properties, such as low dose 
and once-a-day dosing. As described in previous chapters (Chapter 1, 3 and 4), both 
HLM and CHH generally underpredict the in vivo clearance of drugs (Chiba et al., 2009); 
however, this underprediction is much greater in CHH with high intrinsic clearance drugs 
(CLint) than in HLM (Lu et al., 2006; Hallifax et al., 2010). The case of midazolam, a high 
CLint substrate of CYP3A4/5, is of particular importance because midazolam is widely 
used as an in vitro and in vivo CYP3A4/5 probe in the assessment of drug-drug 
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interactions (DDIs). Therefore, the initial focus of my dissertation research was to 
determine the mechanism by which midazolam clearance is restricted in hepatocytes 
compared with microsomes. Other investigators had proposed that midazolam clearance 
is restricted in CHH by permeability or cofactor availability (Lu et al., 2006; Foster et al., 
2011). However the results presented in Chapter 3 demonstrated that neither membrane 
permeability nor intracellular cofactor availability was a likely explanation for the system-
dependent clearance of midazolam, based on the following observations: 
1. Permeabilizing CHH by sonication or the pore-forming agent saponin did not 
increase the rate of midazolam metabolism even when the permeabilized 
hepatocytes were supplemented with NADPH; 
2. The rate of uptake of midazolam by CHH greatly exceeded the rate of metabolism 
of midazolam; 
3. Microsomes isolated from the pooled CHH had comparable CYP3A4/5 activity 
towards midazolam as microsomes prepared directly from human liver (indicating 
the pooled CHH used in these studies did not contain abnormally low CYP3A4/5 
activity). 
In an effort to determine if the system-dependent clearance midazolam was unique or a 
property of other CYP3A4/5 substrates with similar physicochemical properties, the 
clearance of alfentanil, nifedipine and verapamil was assessed in HLM and CHH. System-
dependent clearance was observed with these other CYP3A4/5 substrates, although 
when estimates of hepatic clearance based on in vitro clearance were compared with 
experimentally determined values of blood clearance in vivo the difference was much less 
than that of midazolam (~2-fold for alfentanil, nifedipine and verapamil versus 5-fold for 
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midazolam). These results suggested that the underprediction of midazolam clearance 
was more pronounced than that of other substrates of CYP3A4/5. 
Having established in Chapter 3 that a factor other than permeability or cofactor 
availability is responsible for the system-dependent clearance of midazolam, I examined 
the impact of in vitro incubation conditions on P450 activity, namely the ionic strength of 
the incubation buffer and the effect of cell culture media. These studies are described in 
Chapter 4. There was precedent for this investigation, as previous researchers had shown 
that P450 reactions were in some cases highly dependent on buffer ionic strength 
(Gemzik et al., 1990; Yamazaki et al., 1997; Maenpaa et al., 1998). The effects of cell 
culture media on the clearance of substrates was a novel aspect of this research as I 
sought to identify a cell culture medium capable of increasing midazolam clearance in 
CHH to that of HLM. The results showed that in HLM, P450 activities generally peaked at 
50 mM phosphate buffer, with the exceptions of CYP3A4/5 and CYP2E1 where the 
enzymatic activities were found to increase with increasing buffer ionic strength. However, 
in HLM in the presence of cell culture media, namely, Waymouth’s, MCM+ and DMEM, 
the metabolism of midazolam (CYP3A4/5) and chlorzoxazone (CYP2E1) were markedly 
reduced. This finding was interesting because CYP3A4/5 and CYP2E1 share other 
properties that distinguish them for other P450 enzymes; for example, CYP3A4, CYP3A5 
and CYP2E1 form oligomers (homodimers through hexamers) and their activities are 
stimulated by cytochrome b5 (even heme-depleted cytochrome b5) (Parkinson et al., 
2013; Davydov et al., 2015). The effects of cell culture media on midazolam clearance in 
CHH had a similar but less pronounced effect to that of HLM. Another interesting finding 
was that the reduction of midazolam clearance by certain cell culture media in both HLM 
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and CHH was not observed to the same extent as other substrates of CYP3A4/5. When 
the kinetics of midazolam metabolism were assessed in HLM, both MCM+ and Williams’ 
E medium caused a marked increase in Km compared to 50 mM phosphate buffer, 
suggesting the presence of inhibitory substances in these media. Complete versions and 
salt-only versions of each medium were examined for their effects on CYP3A4/5 activity 
in HLM towards different substrates. Midazolam metabolism was increased in the salt-
only media, lending further evidence for the presence of an inhibitory substance in the 
cell culture media examined. The effects of the salt-only media varied from one CYP3A4/5 
substrate to the other, with little or no changes observed for some substrates and inverse 
changes (relative to midazolam) observed for others. This suggests that the inhibitory 
effect of cell culture media is relatively specific to midazolam metabolism. This was an 
unexpected finding because CYP3A4/5 is known to contain two overlapping substrate 
binding pockets, a so-called benzodiazepine-binding site and a steroid-binding site 
(Parkinson et al., 2013), and many of the substrates evaluated in this study are 
considered, like midazolam, to bind to the benzodiazepine binding site (such as 
nifedipine, alfentanil and verapamil). The effect of an inhibitor on midazolam metabolism 
would therefore be expected to have a similar effect on the metabolism of other substrates 
of the same binding site, an effect that was not observed in my research.  
Overall, I was unable to find a cell culture media that increased midazolam metabolism in 
CHH; however, my findings have implications on the conduct of in vitro metabolism 
studies. First, many researchers use buffers of varying ionic strength (typically up to 100 
mM phosphate) in studies with HLM. The studies described in Chapter 4 suggest that 50 
mM phosphate is the optimum concentration because it supports maximal activity of most 
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P450 activities and, although submaximal for CYP3A4/5, it accurately predicts the in vivo 
clearance of CYP3A4/5 drugs like midazolam, alfentanil, nifedipine and verapamil. 
Second, Williams’ E medium was found to support CYP3A4/5 activity in CHH to similar 
levels as KHB medium (the medium used in Chapter 3). This is important, because KHB 
medium is not suitable for prolonged incubations of CHH; however, Williams’ E is suitable, 
suggesting that Williams’ E medium should be used for long-term metabolism studies in 
CHH, such as the hepatocyte relay-method for measuring the half-life of metabolically 
stable drugs described by Di et al., (2012, 2013). Even modest changes in the activity of 
CYP3A4/5 can have profound effects on the metabolism of low clearance drugs over long 
term incubations, and having a medium that maintains CYP3A4/5 activities over time is 
beneficial. 
The focus of my dissertation research shifted when attempting to find a substrate of 
CYP3A4/5 with the same system-dependent clearance characteristics as midazolam. I 
tested loratadine, which is metabolized primarily by CYP3A4/5 to desloratadine, in CHH 
with varying cell culture media and found that loratadine metabolism resembled the other 
CYP3A4/5 substrates that were examined. However, the metabolite 
3-hydroxydesloratadine was also detected in these incubations, which was unexpected 
because no prior in vitro test system or non-clinical species had been shown to support 
its formation (Ramanathan et al., 2006; Ghosal et al., 2009). 3-Hydroxydesloratadine is 
the major circulating human metabolite of desloratadine, and the enzymology of its 
formation, prior to this study, was unknown, despite a post-marketing commitment 
imposed by the FDA on the manufacturer, Schering-Plough (Schering-Plough, 2001). 
This finding was also interesting from the perspective of system-dependent clearance, 
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because the metabolism of desloratadine to 3-hydroxydesloratadine was found to occur 
only in CHH, and not HLM, suggesting that desloratadine was a drug metabolized more 
readily in CHH than HLM; a finding opposite to that of midazolam.  
The studies outlined in Chapter 5 were designed to identify the enzyme or enzymes 
responsible for forming 3-hydroxdesloratadine. Using a panel of CYP-selective inhibitors, 
I was able to determine that CYP2C8 was involved in the formation of 
3-hydroxydesloratadine in CHH. This finding was unusual for two reasons.  First, CYP2C8 
activity is well represented in HLM, and therefore HLM should be capable of forming 
3-hydroxydesloratadine when in fact they are not. Second, desloratadine is a basic drug 
and CYP2C8 tends to metabolize acidic drugs. This led me to investigate what factors 
were promoting 3-hydroxydesloratadine formation in CHH and conversely preventing its 
formation in HLM. When CHH were sonicated or permeabilized with saponin, they lost 
the ability to form 3-hydroxydesloratadine even when supplemented with NADPH. 
However, when sonicated/saponin-treated hepatocytes were supplemented with both 
NADPH (to support P450 activity) and UDP-GlcUA (to support UGT activity) their ability 
to form 3-hydroxydesloratadine was partially restored. This suggested glucuronidation of 
desloratadine was involved in the formation of 3-hydroxydesloratadine by CYP2C8. This 
possibility was confirmed when I demonstrated that recombinant CYP2C8 could form 
3-hydroxydesloratadine when co-incubated with recombinant UGT2B10. Only 
recombinant UGT2B10 supported the CYP2C8-dependent formation of 
3-hydroxydesloratadine. This finding was consistent with the known properties of 
UGT2B10 and CYP2C8. The only glucuronidation reaction that can occur with 
desloratadine is N-glucuronidation (which could occur at one of two nitrogen atoms in 
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desloratadine). Interestingly, UGT2B10 is one of the few human UGT enzymes capable 
of catalyzing the N-glucuronidation of drugs (the other notable enzyme is UGT1A4). Once 
converted to an N-glucuronide, desloratadine is transformed into a large acidic compound 
and, as such, the type of substrate typically metabolized by CYP2C8 (Parkinson et al., 
2013). When the sample-to-sample variation in 3-hydroxydesloratadine formation by 
CHH was examined, a high correlation was observed was observed with both CYP2C8 
and UGT2B10 activity. Unfortunately, the N-glucuronide of desloratadine was too 
unstable to characterize by mass spectrometry. Nevertheless, the results presented in 
Chapter 5 strongly suggest that desloratadine N-glucuronide is an obligatory intermediate 
in the conversion of desloratadine to 3-hydroxydesloratadine. 
Having solved the enzymology of 3-hydroxydesloratadine formation in Chapter 5, the 
studies in Chapter 6 examined the perpetrator potential of desloratadine; i.e., its ability to 
cause DDIs by inhibiting P450 or UGT enzymes in vitro. Desloratadine was found to be 
a selective inhibitor of UGT2B10, consistent with the role of this UGT in the formation of 
3-hydroxydesloratadine. Further characterization of the formation of 
3-hydroxydesloratadine in NADPH- and UDP-GlcUA-fortified HLM with selective 
inhibitors of UGT2B10 and UGT1A4 confirmed that indeed UGT2B10 is the solely 
responsible for supporting the CYP2C8-dependent formation of 3-hydroxydesloratadine. 
Desloratadine was a weak inhibitor of certain P450 enzymes in HLM (namely, CYP2B6, 
CYP2D6 and CYP3A4) but, based on criteria proposed by the FDA, the inhibition was too 
weak to be clinically significant. Desloratadine did not inhibit CYP2C8 in HLM or CHH, 
suggesting that desloratadine will not cause clinically significant inhibition of CYP2C8. 
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The research presented in Chapter 5 and Chapter 6 solved the mystery surrounding the 
enzymology of formation of 3-hydroxydesloratadine. Given that a segment of the 
population are poor metabolizers (PMs) of desloratadine with greatly reduced 
3-hydroxydesloratadine formation (Prenner et al., 2006), the research presented in this 
dissertation now provides a pathway for the investigation of the genetic basis of the PM 
phenotype. Based on my findings, I anticipate that the FDA label for desloratadine will 
likely be changed to indicate the enzymology of 3-hydroxydesloratadine formation. 
Furthermore, there are limited selective in vitro chemical inhibitors for use in reaction 
phenotyping studies of UGT enzymes with new drug candidates (Miners et al., 2010a). 
The identification of desloratadine as a selective inhibitor of UGT2B10 serves to advance 
this field of research. In the future, desloratadine can be used in vitro studies to delineate 
the contribution of UGT1A4 and UGT2B10 to the N-glucuronidation of new drug 
candidates. 
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7.2. Future directions 
The research outlined in this dissertation did establish that the system-dependent 
clearance of midazolam, which is much greater in HLM than CHH, was more pronounced 
than that of other CYP3A4/5 substrates. Although I was unable to find a cell culture 
medium that increased the metabolism of midazolam in CHH to compensate for the 
system-dependent difference, I did establish that other incubation conditions, such as 
buffer ionic strength, can play a role in midazolam clearance. In the future, the following 
four studies might help to explain the system-dependent clearance of midazolam. First, 
cryopreserved rat and human hepatocytes could be compared with freshly isolated rat 
and human hepatocytes for their ability to metabolize midazolam. A comparison of 
midazolam clearance in rat liver microsomes and freshly isolated rat hepatocytes 
revealed no system-dependent clearance (Jones and Houston, 2004). This raises the 
possibility that the process of cryopreservation impairs midazolam clearance by human 
hepatocytes. In itself, this finding would not establish the mechanism underlying the 
system-dependent clearance of midazolam but it would identify the issue as an in vitro 
artifact. 
Second, a wide variety of media (more than the five examined in my dissertation) could 
be screened in the hope of identifying a medium that supported much higher rates of 
midazolam clearance by CHH.  
Third, endogenous factors could be investigated as a cause of the underprediction of 
midazolam clearance by CHH. It is possible, for example, that high concentrations of 
ammonia in CHH impede the metabolic clearance of midazolam. In 1998, Maenpaa et al. 
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identified ammonia present in glucose 6-phosphate dehydrogenase solutions (used as a 
component of the NADPH-generating system) inhibits the metabolism of midazolam by 
HLM (Maenpaa et al., 1998). Ammonia is formed during the metabolism of amino acids 
(which are present in certain cell culture media at super-physiological concentrations). 
The intracellular concentration of ammonia in hepatocytes can reach millimolar levels 
through pH partitioning (Remesy et al., 1986). Therefore, in CHH, it is possible that 
ammonia is acting as an endogenous inhibitor of midazolam clearance. To assess this, it 
would be interesting to add ammonium chloride (at hepatocyte concentrations) to HLM 
and evaluate midazolam metabolism under those conditions. However, the research in 
Chapter 3 may argue against ammonia as an inhibitor, because when CHH were 
sonicated or treated with saponin, any endogenous ammonia should have been released 
from the hepatocytes and diluted approximately 100 fold in the incubation matrix (at 1 
million cells/mL hepatocytes are roughly 1% of the incubation volume). No changes in 
midazolam metabolism were observed in permeabilized CHH, Nevertheless, evaluating 
of ammonia content of CHH (and freshly isolated hepatocytes) and evaluating the effects 
of ammonium chloride on midazolam clearance in CHH may be interesting avenues to 
pursue in the future. 
Fourth, while suspended CHH are often used for metabolic clearance determinations, 
there are other hepatocyte based models used for other applications. These include 
hepatocyte co-culture systems, 3D-hepatocyte systems such as spheroids, and 
microfluidic systems that include media flow (Godoy et al., 2013). These models offer 
improvements in hepatocyte longevity and function, and it would be interesting to 
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determine if midazolam clearance in these hepatocyte models is improved over 
suspended CHH. 
With respect to the studies on desloratadine metabolism, indirect evidence was presented 
that desloratadine N-glucuronide is an obligatory intermediate in the formation of 3-
hydroxydesloratadine by CYP2C8. The evidence was necessarily indirect because 
desloratadine N-glucuronide was too unstable to characterize by mass spectrometry. 
Accordingly, no experiments with synthetic desloratadine N-glucuronide were attempted. 
However, two studies could be conducted in the future to ascertain which of the two 
possible N-glucuronides of desloratadine is metabolized by CYP2C8 to 3-
hydroxydesloratadine. First, an attempt could be made to synthesize both N-glucuronides 
(the tertiary N-glucuronide formed by glucuronidation of the piperidine ring and the 
quaternary ammonium glucuronide formed by glucuronidation of the pyridine ring). If one 
of these N-glucuronides is stable and one is not, the former can be evaluated as a 
substrate for CYP2C8 and, if no 3-hydroxydesloratadine is formed, then the latter can be 
assumed to be the unstable N-glucuronide that is metabolized by CYP2C8 to 3-
hydroxydesloratadine. A second approach is to synthesize the 4 analogs of desloratadine 
shown in Figure 7.1. Analogs 1A and 2A lack the piperidine and pyridine nitrogen atom, 
respectively. I predict that CHH will convert only one of these analogs to a 3-hydroxylated 
metabolite, which will identify the site of N-glucuronidation. The analogs 1B and 2B are 
desloratadine derivatives containing a stable cyclohexyl-carboxylic acid moiety (a 
glucuronide mimetic). I predict that only one of these will be metabolized by recombinant 
CYP2C8 (or HLM) to a 3-hydroxy metabolite. Both approaches will potentially provide 
additional support for the role of N-glucuronidation in the formation of 3-
280 
 
hydroxydesloratadine and will provisionally identify which of the two possible N-
glucuronides of desloratadine is formed by UGT2B10. 
  
281 
 
 
Figure 7.1. Analogs of desloratadine to investigate the site of N-glucuronidation 
that supports the CYP2C8-dependent formation of 3-hydroxydesloratadine 
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Only a limited number of clinical DDI studies have been conducted with desloratadine 
either as the victim or perpetrator drug. Studies in Chapter 6 predicted that desloratadine 
will not cause clinically relevant inhibition of any of the major drug-metabolizing P450 
enzymes in HLM. Although desloratadine caused weak inhibition of CYP2D6 and 
CYP3A4, clinical studies established that desloratadine does not inhibit these enzymes 
in the clinic (reviewed in Chapter 6). In the future, it would be of interest to ascertain 
whether, as predicted, desloratadine does not cause clinically relevant inhibition of the 
metabolism of a sensitive in vivo probe substrate of CYP2C8, such as repaglinide. If, in 
the future, a drug is identified whose clearance is largely dependent on metabolism by 
UGT2B10, it would be interest to investigate whether desloratadine can inhibit its 
metabolism in a clinical DDI study. However, it was recently shown that UGT2B10 
genotype plays a key role in nicotine N-glucuronidation (Berg et al., 2010). Therefore, it 
would be interesting in the future to evaluate whether desloratadine can lower blood and 
urinary levels of nicotine N-glucuronide in cigarette smokers. 
Based on the research in this dissertation, a clinical interaction study of desloratadine 
with a strong inhibitor of UGT2B10 or CYP2C8 would provide in vivo confirmation of my 
in vitro findings. While no clinically significant UGT2B10 inhibitors have been identified, 
gemfibrozil and clopidogrel (through conversion to their acyl glucuronide) are clinically 
significant, irreversible inhibition of CYP2C8 (Backman et al., 2002; Ogilvie et al., 2006; 
Tornio et al., 2014). Therefore, in the future, it would be interesting to evaluate the 
pharmacokinetics of desloratadine in healthy subjects before and after treatment with 
gemfibrozil (to inhibit CYP2C8). I predict that gemfibrozil will inhibit the metabolic 
clearance and increase systemic exposure (plasma AUC) of desloratadine.  
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Poor metabolizers of desloratadine have been identified, as described in Chapter 5. The 
studies described in my dissertation suggest the PM phenotype is due to genetic 
polymorphisms (loss-of-function alleles) of CYP2C8 and/or UGT2B10. This prediction 
could be tested in vitro and in vivo. In the future, it would be interesting to genotype a 
wide panel of CHH from individual donors to determine their CYP2C8 and UGT2B10 
allele status and examine the effects of these allelic variants on the conversion of 
desloratadine to 3-hydroxydesloratadine. A similar study could be conducted in 
individuals who, on the basis of prior genotyping analysis, could be categorized as poor 
metabolizers with respect to CYP2C8 or UGT2B10. For example, it would be interesting 
to evaluate the pharmacokinetics of desloratadine in those individuals identified as poor 
metabolizers of nicotine N-glucuronidation and shown to have loss-of-function alleles of 
UGT2B10. Likewise, it would interesting to evaluate the pharmacokinetics of 
desloratadine in individuals previously identified as poor metabolizers of repaglinide due 
to loss-of-function alleles of CYP2C8. Alternatively, the pharmacokinetics desloratadine 
could be assessed in a large population to identify poor metabolizers who could then be 
genotyped for CYP2C8 and UGT2B10. Such studies would establish whether, as 
predicted based on my dissertation research, genetic polymorphisms of CYP2C8 and 
UGT2B10 are the basis for poor metabolizers of desloratadine. 
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7.3. Final thoughts 
Despite over 50 years of research on P450 enzymes since their discovery by Omura and 
Sato (1964), it is astonishing that we are still learning more about the fundamental 
properties of these enzymes. The research presented in this dissertation helps our 
understanding of the clearance of different drugs by P450 under various in vitro conditions 
and adds further perspective on the curious case of the system-dependent clearance of 
midazolam. The ultimate goal of the pharmaceutical industry is to have predictive in vitro 
models to expedite drug development and ultimately ensure patient safety. My 
dissertation research furthers our advancement towards that goal, as we attempted to 
gain a mechanistic understanding of the system-dependent clearance of midazolam, the 
most commonly used CYP3A4/5 probe in in vitro studies.  
My successful characterization of the enzymology of desloratadine metabolism to 
3-hydroxydesloratadine has a direct impact on the users of loratadine and desloratadine, 
as this research can now be used to update the labels of these drugs and provide a 
foundation for the investigation of the desloratadine poor metabolizer phenotype. The 
research in this dissertation also provides pharmaceutical researchers with a better 
understanding of nuances of the currently and widely used in vitro systems and provides 
recommendations for in vitro incubation conditions as well as a new selective UGT2B10 
inhibitor to use in drug metabolism studies. 
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